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Cancer is one of the major health problems worldwide, counting thousands of new cases 
and deaths annually. The current modalities for cancer treatment include surgery, 
chemotherapy, radiotherapy and immunotherapy. However, occasionally some of these 
modalities cannot be used due to the stage of the tumor or have insufficient effect in tumor 
regression, whereby new therapy strategies are needed. The application of nanotechnology in 
cancer treatment opened the opportunity to develop new strategies, and drug delivery systems 
(DDS) can be found among them. The use of DDS has been reported in several studies as a 
promising approach for delivering drugs to the place of action and reduce the drawbacks of 
conventional drug administration. To develop these systems, biocompatible and non-toxic 
materials are needed, where the selected drug can be loaded. Among the several materials 
that could be used for DDS preparation, are zeolites. 
The main objective of this work was the development of effective DDS based on zeolites to 
be used in breast and colorectal cancer treatment. Thus, several structures and their potential 
as carriers were investigated, as well as the mechanisms underlying zeolite internalization, 
exploring surface functionalization on zeolite toxicity and uptake by human cells and exploring 
the use of zeolites as magnetic resonance imaging agents. 
The potential of the use of the anti-inflammatory drug salicylic acid, for breast cancer 
treatment, loaded into silica microporous and mesoporous structures, was assessed. It was 
observed that mesoporous structures had higher drug loading capacity than microporous 
structures. In terms of cytotoxicity, only DDS prepared with mesoporous structures were able 
to decrease cell growth. Overall, the results indicated the potential of salicylic acid for cancer 
treatment when loaded into mesoporous structures, but not when loaded into microporous 
structures. So, in order to study the potential of the microporous structures as host for DDS, 
an anticancer drug was used. 
Then, three different zeolites (NaY, NaA and ZSM5) and one titanosilicate (ETS-10) were 
investigated as carriers for the anticancer drug 5-fluorouracil (5-FU) in order to select the most 
promising zeolite structures for further studies. The results showed the biocompatibility of 
these microporous structures since they were not toxic to colon or breast cancer cells. In 
addition, loading 5-FU in these structures led to potentiation of 5-FU and allowed the selection 
of two zeolites, NaY and LTL for the next studies. 
To finalize the exploration of the potential of zeolite for DDS preparation, DDS were 
prepared, and their in vitro and in vivo efficacy were assessed. Results of the in vitro studies 
confirmed the potential of the DDS prepared with NaY and LTL (Zeo L) for breast, colorectal 
and melanoma cancers treatment since there was a significant inhibition of cell growth when 




However, in vivo studies using the chick embryo chorioallantoic membrane as model (CAM) 
revealed that DDS induced a reduction in tumor perimeter for breast cancer cells, while no 
reduction was detected for colon tumors, under the used concentration of DDS.  
Zeolite NaY magnetization revealed its potential as magnetic resonance imaging agent, 
opening new opportunities to prepare hybrid systems combining the encapsulating and 
delivery properties of the zeolites and the magnetic properties of biocompatible magnetite 
nanoparticles. 
Considering the scarce studies on the internalization mechanisms of zeolite nanoparticles, 
the endocytic mechanisms involved in their internalization by human cells were explored. The 
results showed that zeolite internalization is likely mediated by caveolin-dependent 
endocytosis and it is also dependent on microtubule polymerization pathways. In these studies, 
the uptake of zeolite nanoparticles was assessed in the same cell lines. It was found that 
cancer cells internalize higher amounts of zeolite nanoparticles and at a faster rate than normal 
cells. The effect of zeolite surface functionalization plays also an important role in the cellular 
uptake. Based on the observations from these studies, it was possible to observe that 
positively-charged zeolite nanoparticles present higher uptake rates than negatively-charged 
zeolite nanoparticles. 
This work provides a valuable contribution to the use of zeolites as carriers for DDS 
preparation and presents novel evidences about the biological mechanisms enrolled in the 
uptake of zeolite nanoparticles by human cells. Thus, the work performed in this thesis is not 
an end of a research project, but an important contribution to a better design of DDS based on 




















O cancro constitui um dos maiores problemas de saúde no mundo, contando anualmente 
com milhares de novos casos e mortes. As atuais abordagens de tratamento do cancro 
incluem cirurgia, quimioterapia, radioterapia e imunoterapia. Contudo, por vezes algumas não 
podem ser utilizadas devido à fase avançada do tumor ou por apresentarem pouco efeito na 
regressão do mesmo, pelo que são necessárias novas abordagens terapêuticas. A aplicação 
da nanotecnologia no tratamento do cancro, abriu a oportunidade de desenvolver novas 
estratégias, contando-se entre estas os sistemas de libertação de fármacos. Vários estudos 
têm reportado o uso destes sistemas como uma abordagem promissora para a entrega de 
fármacos no local de ação e na redução dos efeitos secundários associados aos sistemas de 
administração convencionais. Para o desenvolvimento de sistemas de libertação de fármacos, 
são necessários materiais biocompatíveis e não tóxicos onde o fármaco possa ser inserido. 
Entre o grande número de materiais que podem ser usados para a preparação destes 
sistemas, encontram-se os zeólitos. 
O principal objetivo deste trabalho foi desenvolver sistemas de libertação de fármacos 
baseados em zeólitos para o tratamento do cancro colorretal e da mama. Assim, foram 
exploradas várias estruturas e avaliado o seu potencial como transportadores de fármacos, 
bem como os mecanismos subjacentes à internalização das partículas de zeólitos por células 
humanas tumorais. Foi também avaliado o efeito da funcionalização da superfície na 
toxicidade e internalização das nanopartículas nas células e explorado o uso de zeólitos como 
agentes para imagem de ressonância magnética (MRI). 
Foi avaliado o potencial do uso do anti-inflamatório ácido salicílico para o tratamento do 
cancro da mama quando encapsulado em estruturas de sílica micro- e mesoporosas. 
Observou-se que as estruturas mesoporosas apresentavam maior capacidade de 
encapsulamento do fármaco do que as estruturas microporosas. Em termos de citotoxicidade, 
apenas os sistemas de libertação de fármacos preparados com estruturas mesoporosas foram 
capazes de reduzir o crescimento celular. No geral, os resultados indicaram o potencial do 
ácido salicílico para o tratamento do cancro quando encapsulado em estruturas mesoporosas, 
mas não quando encapsulado em estruturas microporosas. Assim, para estudar o potencial 
do uso das estruturas microporosas como material para a preparação de sistemas de 
libertação, foi utilizado um fármaco antineoplásico. Neste contexto, três zeólitos diferentes 
(NaY, NaA e ZSM5) e um titanosilicato (ETS-10) foram explorados como suportes para o 
fármaco antineoplásico 5-fluorouracilo (5-FU), de forma a selecionar as estruturas mais 
promissoras para os estudos seguintes. Os resultados demonstraram que estes materiais são 
biocompatíveis, uma vez que não se revelaram tóxicos para células do cancro colorretal e 




do seu efeito. Este estudo permitiu a seleção de duas estruturas zeolíticas, NaY e LTL, para 
os estudos subsequentes. 
Para finalizar a exploração do potencial dos zeólitos para a preparação de sistemas de 
libertação de fármacos, foram preparados sistemas usando os zeólitos NaY e L, e a sua 
eficácia in vitro e in vivo foi avaliada. Os resultados dos estudos in vitro confirmaram o 
potencial dos sistemas de libertação preparados com os zeólitos NaY e LTL (Zeo L) no 
tratamento do cancro da mama, colorretal e melanoma, uma vez que se verificou uma inibição 
significativa do crescimento celular quando as células foram tratadas com os sistemas. 
Verificou-se ainda uma potenciação do 5-FU quando comparado com o fármaco livre. 
Contudo, os estudos in vivo usando o modelo membrana corioalantóide de embrião de galinha 
(CAM), mostraram que, na concentração usada, os DDS induziram a redução dos tumores da 
linha Hs 578T, mas não dos tumores da linha RKO. 
A magnetização do zeólito NaY revelou o seu potencial como agente para MRI, abrindo 
novas oportunidades para a preparação de sistemas híbridos que combinem as propriedades 
de encapsulação e libertação dos zeólitos e, as propriedades das nanopartículas magnéticas. 
Uma vez que há poucos estudos sobre os mecanismos de internalização das 
nanopartículas de zeólitos, foram também estudados os mecanismos envolvidos na sua 
internalização em células humanas. Os resultados mostraram que a internalização dos 
zeólitos é principalmente mediada pela endocitose dependente da caveolina, sendo também 
dependente das vias envolvidas na polimerização dos microtúbulos. Nestes estudos, 
verificou-se ainda a internalização dos zeólitos em células humanas e observou-se que as 
células cancerígenas internalizam maior quantidade de zeólito a uma taxa mais rápida do que 
as células normais. Concluiu-se também que o efeito da funcionalização da superfície dos 
zeólitos desempenha um papel importante na internalização celular. Os resultados obtidos 
mostraram que nanopartículas de zeólitos positivamente carregadas têm maior capacidade 
de internalização do que partículas negativamente carregadas. 
Em suma, este trabalho fornece uma contribuição importante sobre o uso de zeólitos para 
a preparação de sistemas de libertação controlada de fármacos e apresenta novas evidências 
sobre os mecanismos biológicos envolvidos na internalização dos zeólitos em células 
humanas. Assim, o trabalho desenvolvido nesta tese poderá contribuir para o 
desenvolvimento de melhores sistemas de libertação de fármacos baseados em estruturas 
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RESEARCH MOTIVATION AND THESIS OUTLINE 
Developing drug delivery systems (DDS) for cancer treatment using nanomaterials as 
carriers is an important and developing area of research. A great effort has been put into this 
area, though there is still a need to further optimize the current DDS in order to develop more 
efficient systems. 
Motivated by that, the ultimate goal of the work developed in this thesis is the development 
of efficient DDS based on zeolites structures to be used in the cancer context using breast and 
colorectal cancer cells as models. However, to achieve this goal, many steps had to be 
performed, namely: 1) evaluation, selection and synthesis of different porous structures to be 
used as nanocarriers for the encapsulation of drugs used in the treatment of breast and 
colorectal cancer; 2) assessment of the efficacy of DDS based on zeolite using in vitro and in 
vivo models; 3) exploration of the use of zeolites as hybrid materials to be used in magnetic 
resonance imaging (MRI) or hyperthermia treatments; 4) elucidating the internalization 
mechanisms associated with zeolite particles uptake by cells; 5) functionalization of the surface 
of zeolites to enhance their internalization and 5) assess the cytotoxicity of the materials in 
vitro. 
 
This thesis is organized in five chapters, as follows: 
 
Chapter 1: This introductory chapter aims to present a general overview about the 
necessary concepts to understand the work of this thesis. 
 
Chapter 2: Exploration of zeolite structures as nanocarriers for encapsulated drugs for 
cancer treatment.  
This chapter is composed by three subchapters: 
 
Subchapter 2.1 consists in the use of salicylic acid (SA) encapsulated in porous materials 
as DDS for cancer treatment. In this chapter micro and mesoporous structures were selected 
as hosts for DDS using SA as drug model in breast and colon cancer cell lines, in order to 
investigate if the use of this anti-inflammatory drug loaded into zeolites is a promising strategy 
for cancer therapy. 
 
Subchapter 2.2 is dedicated to the assessment of the most promising porous structures as 
DDS using 5-fluorouracil (5-FU) as anticancer drug. 5-FU, chemotherapeutic drug used for the 




identify which structure is more promising. From this study, the zeolite structures NaY and LTL 
were selected for the following studies. 
 
Subchapter 2.3 reports the preparation of DDS and assessment of their effect using in vitro 
and in vivo models. For this study, the chick embryo chorioallantoic membrane (CAM) was 
used as in vivo model, which allows to study tumor growth and angiogenesis. 
 
Chapter 3 covers the exploration of the potential of the zeolite NaY as a hybrid material for 
MRI use and host for DDS. In the previous chapter, the potential of zeolites to be use as 
carriers to delivery drugs was already reported. This chapter goes deeper into the use of zeolite 
NaY and demonstrates the potential of this zeolite to be used as MRI agent. 
 
Chapter 4: Characterization of the mechanisms involved in the uptake of zeolite 
nanocarriers by human cells. 
This chapter is composed by two subchapters:  
 
Subchapter 4.1 characterizes the biological mechanisms involved in the uptake of zeolite 
nanoparticles by cancer and normal human cells. In this chapter pharmacological inhibitors 
were used to investigate the endocytic pathways involved in zeolite internalization and the 
uptake of zeolite by human cells was also verified. The results suggested that the 
internalization of zeolite L is mediated by caveolin-dependent process. 
 
Subchapter 4.2 goes deeper into the internalization mechanisms of zeolite L and describes 
the effect of the surface functionalization in the cellular uptake. This subchapter validates the 
studies performed in subchapter 4.1, using for this purpose six pharmacological inhibitors. The 
effect of zeolite L surface functionalization on cellular uptake was also studied using 
microscopy techniques to achieve this purpose. 
 
Finally, chapter 5 summarizes and integrates the main conclusions withdrawn from this 
work. Also, some suggestions for future work are presented. 
 
The work developed in this thesis was carried out at the School of Sciences, Chemistry 
Department and School of Medicine, Life and Health Sciences Research Institute (ICVS), 
University of Minho, Braga, Portugal, and at the Institut de Science et d’Ingénierie 
Supramoléculaire (ISIS), University of Strasbourg, Strasbourg, France and at the International 
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The objective of this chapter is to focus on the general considerations about the preparation 
and applications of drug delivery systems (DDS) based on porous materials for the treatment 
of cancer, as this thesis has been outlined. 
There are many porous materials used in the preparation of DDS, which present several 
advantages comparing with the conventional administration of drugs and allow to enhance the 
efficiency of disease treatment and to improve the quality of life of the patient. In the different 
porous materials described, zeolite aluminosilicates are good candidates to pursue these 
challenges since their inner and outer surfaces allow modifications. They are very attractive as 
nanocarriers because they are commercially available or can be synthesized easily, their 
surface allows modification and their size is tunable. Moreover, zeolites are essentially 
nontoxic, biocompatible, lack immunogenicity and their multifunctional potential, among 
others, make them highly attractive in many aspects of medicine. A description of the 
mechanisms of internalization of the particles and living cells is also presented, with a 
description of the different pathways involved, with a special focus on endocytosis. The factors 
influencing endocytosis are also reviewed, as well as the tools to identify the endocytic 
pathways involved in the endocytosis of nanoparticles. All these features, in combination with 
the ability of the zeolites to enter cells by endocytic pathways, naturally make them good 










































1.1.1. FACTS ABOUT CANCER  
Cancer results from a breakdown of the regulatory mechanisms that govern normal cell 
behavior, resulting in uncontrolled cell growth and division, invading adjacent normal tissues 
and organs and eventually spreading throughout the body.1,2 Abnormal proliferation can occur 
in any of the different cells in the body, and this is the reason why there are more than a 
hundred different types of cancer, which can have different behaviors and response to 
treatment. This abnormal growth results in a mass of cells, called tumor that may be either 
benign or malignant.1 A benign tumor is confined to its original site and does not invade the 
normal tissue nor spreads to distant body sites. In turn, a malignant tumor is capable of 
spreading throughout the body via the circulatory or lymphatic systems, originating metastasis 
and invading surrounding normal tissues.3 
Cancer is one of the leading causes of morbidity and death worldwide, counting 
approximately 14 million new cases in 2012 and 8.8 million deaths in 2015.4 Bearing in mind 
the remarkable progress in medicine, with better ways of prevention, detection and treatment 
of cancer over the last decades, why is there still such a high number of new cases? In our 
day-to-day life, we are exposed to hazardous substances that are able to cause cancer, such 
as, radiation, chemicals and viruses. These agents are called carcinogens and can damage 
the DNA and induce mutations. Some examples are: the ultraviolet radiation, responsible for 
skin cancer; tobacco smoke, which is a major cause of lung cancer, as well as being involved 
in cancers of the oral cavity, pharynx, larynx, esophagus and others; aflatoxin, a food 
contaminant which can cause liver cancer; and human papilloma virus (HPV), responsible 
agent for cervical cancer.5–7 Other carcinogens, called tumor promoters, can contribute to 
cancer development by stimulating cell proliferation rather than by inducing mutations. Tumor 
promoter forms principally benign tumors that could progress into cancer by multiple genetic 
changes. Important tumor promoters are hormones, especially estrogens. When the cells of 
the endometrium are exposed to excess of estrogen, it significantly increases the probability 
of a woman to develop endometrial cancer.5 Beyond these factors, others can contribute to 
the development of cancer, for instance ageing since the incidence of cancer rises dramatically 
with age, the use of alcohol and unhealthy diet. Recently scientists concluded that the 
consumption of red and processed meat likely can have a carcinogenic effect.8–10 
Cancer cells can be characterized by the following “hallmarks” of cancer proposed by 
Hanahan and Weinberg11 (Figure 1.1): Sustaining proliferative signaling. Cancer cells are 
capable of sustaining chronic proliferation by producing growth signals that stimulate their own 
proliferation, leading to continuous autostimulation of cell division (autocrine growth 




stimulation) and by having overactive signal receptors;12 Evading growth suppressors. 
Growth suppressors are important to stop cell growth and proliferation; however, cancer cells 
can interrupt or ignore these factors as a result of mutations or alterations in tumor suppressor 
genes; Activating invasion and metastasis. Cancer cells lose the function of cell adhesion 
molecules, which contribute to their capacity to metastasize, spreading throughout the body 
and interfering with the function of normal tissues and organs; Enabling replicative 
immortality. After DNA damage, normal cells normally undergo apoptosis. In turn, cancer cells 
fail this mechanism, which contributes substantially to tumor development. In addition to 
evading apoptosis, cancer cells generally acquire the capacity for unlimited replication as a 
result of expression of telomerase, which is required to maintain the ends of eukaryotic 
chromosomes (telomeres);5 Inducing angiogenesis. Cancer cells are able to stimulate the 
formation of new blood vessels (angiogenesis), to supply the tumor with oxygen and adequate 
nutrients for its growth. These new vessels are formed as response to growth factors secreted 
by cancer cells and are important not only in supporting the tumor growth, but also in 
metastasis; Resisting cell death. Contrary to what happens with normal cells that die by 
apoptosis when becoming old or damaged, cancer cells avoid this mechanism of cell death 
and continue to accumulate in the body.11 
 
 
Figure 1.1: The six Hallmarks of Cancer.11 
 
Despite the six hallmarks of cancer, nowadays there are two additional hallmarks suggested, 
involved in the pathogenesis of some and perhaps all cancers. The first one is related to the 
capability of cancer cells to modify and reprogram their cellular metabolism, allowing a better 
neoplastic proliferation. The second one refers to the capability of cancer cells to evade the 
immunological system, especially T and B lymphocytes, macrophages and natural killer cells.11 
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1.1.2.  BREAST AND COLORECTAL CANCER 
There are more than 100 types of cancer, however lung, breast, prostate and colorectal 
constitute over half of the overall incidence in Europe.13,14 Despite a significant increase in lung 
cancer incidence in women in recent years (12% of all female cancers) as a result of tobacco 
epidemics, breast cancer is still the most common invasive tumor in women worldwide and the 
most frequent cause of death in women, which covers 25% of all cancer types.15–18 Almost 
362.000 new cases of breast cancer are diagnosed annually in Europe and was responsible 
for 92.000 deaths in 2012.19 Whereas breast cancer incidence rates are still increasing in most 
of the European countries, mortality rates have been decreasing, as a result of earlier 
diagnosis and improved therapies.17,20 
Breast cancer is a heterogeneous disease and can be divided into different subtypes related 
with human epidermal growth factor receptor 2 (HER2/ERBB2), expression of estrogen and 
progesterone receptor (ER and PR) and Ki67 protein. This cancer could be classified as 
luminal A, luminal B, HER2-positive, basal-like, normal-like and triple negative breast cancer 
(TNBC) (Table 1.1).21,22 Breast cancer controlled by ERs and PR hormonal receptors has the 
best prognosis and its treatment is based on hormonal therapy. HER2 is a membrane receptor 
involved in cell proliferation signal transduction and breast cancer related with this receptor is 
very often sensitive to treatment with anti-HER2 therapies, such as humanized monoclonal 
antibodies or specific inhibitors. Ki67 is a proliferation protein marker that can be detected in 
proliferating cells by immunohistochemistry, Ki67 labelling index (Ki67LI). Ki67LI corresponds 
to the percentage of invasive cancer cell nuclei positive for Ki67 immunostaining, over the total 
invasive cancer cell nuclei present in a histological sample.23 According to Ki67 index, tumors 
can be classified as low, intermediate, and highly proliferating for Ki67LI of ≤15%, 16%–30%, 
and >30%, respectively.24 Ki67 can be used to classify a tumor as luminal A or B, allowing to 
find the best treatments. Tumors with high Ki67 expression (>15%) have a poor prognosis.25,26 
In turn, TNBC constitutes about 15-20% of all breast cancers. ERs and PRs receptors are 
absent in this type of cancer and HER2 has low expression or is absent. TNBC has a poor 
prognosis and has high propensity to exacerbate, being more common in young women.27,28 
In Table 1.1, it is possible to observe the breast cancer molecular subtypes and their main 
treatments. Luminal B tumors are positive for ER/PR receptors and can be positive or negative 
for HER2, and the patients with these tumors have worse prognosis than those with luminal A 
tumors.29 
 




Table 1.1: The different subtypes of breast cancer, their main treatments and cell lines representative of each 
subtype.25  
Subtype EP/PR HER2 Ki67 Treatment Cell lines 
Luminal A +/+ - < 15% Antihormonal MCF-7, T47D 
Luminal B +/+ -/+ > 15% Antihormonal BT474 
HER2-
type 
-/- +  Anti-HER2 SkBr3, AU565 
TNBC -/- -/- > 15% Chemotherapy Hs 578T, MDA-MB231 
 
Colorectal cancer is the third most common cancer in men with 746.000 cases, representing 
10.0% of the total cancers and the second in women with 614.000 cases, representing 9.2% 
of the total worldwide.30,31 Every year, 345.000 new cases are diagnosed and 152.000 deaths 
are registered in both genders in Europe,19,30,32 being the most frequently diagnosed cancer 
and second common cause of cancer related death.33 The high incidence of this type of cancer 
could be related to various risk factors such as lack of physical activity, obesity, a diet low in 
fruits and vegetables, higher consumption of red and processed meat and smoking.32,34–36 A 
large proportion of this cancer is associated with environmental factors, since only 20% of the 
colorectal cancer cases have a hereditary cause; and some are associated with very defined 
syndromes, namely familial adenomatous polyposis or Lynch syndrome (hereditary 
nonpolyposis colorectal cancer (HNPCC)).37,38 Most colorectal cancers originate from the 
sigmoid colon or rectum and normally start to appear as benign polyps higher than one 
centimeter. Polyps with more than two centimeters can suffer from malignant alterations and 
polyps smaller than five millimeters rarely suffer from those alterations.39 
The options for colorectal cancer treatment include surgery, chemotherapy and radiation. 
Recently, new therapies have been developed to target specific signaling pathways involved 
in colorectal carcinogenesis, such as epidermal growth factor receptor (EGFR) signaling and 
angiogenesis, called targeted therapy.40 Targeted therapy then acts by different ways, the anti-
angiogenesis therapy which blocks the process of making new blood vessels by blocking the 
VEGF signaling pathway and consequently the tumors do not get the nutrients and oxygen 
that they need to grow;41 and EGFR inhibition where EGFR is blocked, preventing colorectal 
cancer cell proliferation.42 
 
1.1.3.  CANCER TREATMENTS 
There are several types of cancer treatment such as surgery, radiotherapy, chemotherapy, 
immunotherapy, hyperthermia and others.43,44 The kind of treatment depends on the type of 
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cancer and the stage of development at the time of diagnosis. In radiotherapy, tissues are 
exposed to ionizing radiation to induce DNA damage in malignant cells, cause apoptosis and 
thus shrink tumors and its impact depends on the sensitivity of the tumor to radiation.45–47 This 
treatment is used as an adjuvant in chemotherapy in about 60% of all cancers, however this 
could have impact on healthy tissues.47,48 In immunotherapy, some parts of a person’s immune 
system are used to fight the cancer.49,50 For this purpose, the immune system could be 
stimulated to attack cancer cells or could be given immune system components, such as 
proteins prepared from the immune system of the patient.51 Dendritic cells are also used in 
immunotherapy as they can initiate strong and long-lived tumor-specific T- cell responses.52,53 
Hyperthermia treatment could be used as thermal sensitizer or thermal ablator.54 It consists in 
increasing the temperature of a region of the tumor to 40-43 °C and is used as adjuvant of 
other cancer treatments such as chemotherapy and radiotherapy.43,55,56   
When cancer is in early stage, surgery is normally the first option, since it is associated with 
high levels of success in terms of remission and cure, as it aims to remove 100% of the 
malignant cells.47 However, many times when cancer is detected, it is already in advanced 
stage and, in these cases, beyond surgery other treatments, such as chemotherapy, are 
required.57 Chemotherapy is needed in 70-80% of cancer patients, becoming one of the most 
commonly used treatments. This treatment prevents the proliferation of cancer cells, tumor 
recurrence and metastasis and consequently prolongs patient life time.58,59 Despite its wide 
use, traditional chemotherapy is limited and has numerous short-term side effects, such as 
nausea and vomiting, hair loss, fatigue and bone marrow suppression, because chemotherapy 
affects not only cancer cells but also healthy cells of rapidly proliferation60–62 and long-term 
side effects, such as cardiovascular diseases and infections.63,64 
 
1.1.4.  DRUGS USED IN CHEMOTHERAPY TREATMENTS 
There are many drugs used in chemotherapy and they can be divided into classic 
chemotherapeutic drugs and targeted therapeutic drugs.  
The most commonly used drugs in breast cancer treatments are paclitaxel (PTX), docetaxel 
(DCX), doxorubicin (DOX), 5-fluorouracil (5-FU), disulfiram (DSF) and camptothecin (CPT) 
which are classified as classic chemotherapeutic drugs and tamoxifen and torimefene which 
are classified as targeted chemotherapeutic drugs.65–67 Tamoxifen and toremifene are 
selective estrogen receptor modulators (SERM) recommended for treatment of 
premenopausal women with hormone-sensitive (ER) disease and for the treatment of hormone 
receptor positive breast cancer, respectively.67,68 
Some drugs approved for colorectal cancer treatment are irinotecan hydrochloride, 
oxaliplatin, capecitabine, 5-fluorouracil (5-FU) which are classified as classic 




chemotherapeutic drugs and bevacizumab (Avastin®) which was the first anti-angiogenic 
monoclonal antibody approved by the American Food and Drug Administration (FDA),69,70 
cetuximab, panitumumab and ramucirumab which are classified as targeted 
chemotherapeutic drugs.40,71–73 Cetuximab and panitumumab exert their effect on EGFR and 
ramucirumab inhibits VEGF and VEGF receptor.74 
 
5-FU (Figure 1.2), a low molecular weight drug, was the first chemotherapeutic drug and it 
was discovered in 1957 by Charles Heidelberger.59,75 This drug is used for the treatment of 
various types of solid cancers, including breast and colorectal cancers.76,77  
 
 
Figure 1.2: Chemical structure and molecular dimensions of 5-fluorouracil (left) and pyrimidine ring (right). The 
fluorine atom of 5-FU replaces the hydrogen at the 5-position of the pyrimidine ring. Adapted from.78–80 
 
5-FU is an uracil analogue because it has a fluorine atom in carbon-5 position of the 
pyrimidine ring, instead of a hydrogen and thus to exert its cytotoxic effects, it needs cell uptake 
and conversion to its active forms.81 The drug is quickly metabolized after its administration 
and originates different fluoronucleotides which have antineoplastic properties since it 
interferes with nucleic acid synthesis, retarding cancer cells growth.82,83 5-FU mechanism of 
action is associated with thymidylate syntase (TS) inhibition by fluoro-deoxyuridine 
monophosphate (FdUMP) and its incorporation into DNA and RNA.81,84 After entering cells, 5-
FU is incorporated into DNA when it is converted to 5′-fluoro-2′deoxyuridine-5′-trifosfato 
(FdUTP) and into RNA when it is converted to 5-fluorouridine-5′-triphosphate (FUTP). 5-FU 
can be metabolized by two metabolic pathways: i) the catabolic way, which inactivates the 80% 
of the drug in the liver, originating 5-fluoro-5,6-dihydro-uracil (5-FUH2) as metabolite; ii) the 
anabolic way, which originates active metabolites responsible for the cytotoxic effect of 5-FU 
on tumor cells, 5-fluorouridine-5’-monophosphate (FUMP), 5-fluorouridine (5-FUrd), 5-fluoro-
2’-deoxyuridine (5- FdUrd) and their derivatives (Figures 1.3 and 1.4).82 




Figure 1.3: The catabolic and anabolic pathways of 5-flurouracil in human cells. Abbreviations: 5-FU, 5-
fluorouracil; 5-FUH2, 5-fluoro-5,6-dihydro-uracil; 5-FUrd, 5-fluorouridine; 5-FdUrd, 5-fluoro-2’-deoxyuridine; FUMP, 
5-fluorouridine-5’-monophosphate. Adapted from.82  
 
 
Figure 1.4: Intracellular anabolism of 5-fluorouracil (5-FU). All of the compounds are represented in neutral form. 
LV (leucovorin) and OXO (potassium oxonate) are biochemical modulators of 5-FU. Abbreviations: 5-FUrd: 5-
fluorouridine; PRPP: 5′-phosphoribosyl-1-pyrophosphate; 5-FUMP: 5-fluorouridine-5 -monophosphate; 5-FUDP: 5-
fluorouridine-5’-diphosphate; 5-FUTP: 5-fluorouridine-5’-triphosphate; 5-FUDP-sugars: 5-FU-nucleotide sugars; 5-
FdUrd: 5-fluoro-2’-deoxyuridine; 5-FdUMP: 5-fluoro-2’-deoxyuridine-5’-monophosphate; 5-FdUDP: 5-fluoro-2’-
deoxyuridine-5’-diphosphate; 5-FdUTP: 5-fluoro-2’-deoxyuridine-5’-triphosphate; dUMP: 2’-deoxyuridine-5’-
monophosphate; dTMP: thymidine-5’-monophosphate.83 




5-FU has an erratic oral bioavailability, whereby this drug is administered intravenously. This 
drug has a short half-life (t1/2) (5 to 20 min), whereby cells are exposed to its active metabolites 
for a short time.83 Thus, it was necessary to develop different approaches to administer the 
drug and keep its concentration in the blood stream for longer periods of time and enhance 5-
FU effect,83 such as the combination ftorafur (tetrahydrofuranyl-5-fluorouracil, tegafur, FT) and 
uracil.59,85 5-Fluorouracil can also be associated to leucovorin and methotrexate to enhance its 
anticancer effect.76 
The use of 5-FU is limited by its side-effects which includes diarrhea, myelosuppression and 
thrombophlebitis of peripheral veins, as well as cardiotoxicity.59,86 For these reasons, 
researchers have been looking for strategies that allow an oral administration of 5-FU and at 
the same time reduce its systemic side-effects.87 One approach reports the use of 
capecitabine, one 5-fluorouracil oral pro-drug that is capable to cross the gastrointestinal 
barrier by remaining intact and then after three steps it is converted into 5-FU by the action of 
carboxylesterase and cytidine deaminase, which converts capecitabine into 5′-deoxy-5-
fluorouridine (5′DFUR) in the liver, and finally 5’DFUR by the action of thymidine 
phosphorylase, an enzyme with higher activity in tumor than in normal tissues, is converted to 
5-FU.76,83 Unfortunately, this drug also presents important side effects such as 
cardiotoxicity.86,88 One promising approach is the encapsulation of 5-FU into nanocarriers.  
Anirudhan et al. developed a novel drug delivery system with 3-methacryloxypropyl 
trimethoxy silane coated magnetic nanoparticles polymerized with glycidylmethacrylate-
grafted- maleated cyclodextrin for controlled release of 5-FU.89 Faria et al.90 developed a hybrid 
material using TiO2 nanotubes coated with semiconductors zinc sulfide quantum dots 
(TiO2/ZnS) and loaded it with 5-FU. The cytotoxic effect of TiO2/ZnS was tested in Chinese 
Hamster Ovary cells (CHO K1), revealing no signs of toxicity against mammalian cells and the 
release studies showed that these nanotubes could provide desirable release kinetics and 
controllable release time for 5-FU, proving its usefulness as drug-releasing materials in cancer 
therapy.90 In 2014, Patel et al.91  loaded 5-FU into solid lipid nanoparticles (SLNs) and the 
anticancer effect of 5-FU loaded SLNs was assessed in Caco-2 cell line, revealing that the 
effect in cell viability is concentration-dependent. The authors verified a potentiation of 5-FU 
anticancer activity when loaded in SLNs compared to pure 5-FU.91  
 
Another approach that has been studied is the combination of more than one cancer 
therapeutic agent and, in this way, it is an attempt to prevent mutation and resistance. Using 
two or more chemotherapeutic drugs the probability of killing more cancer cells rises since 
cancer cells are attacked by multiple drugs that disrupt different stages of the cell reproduction 
cycle. Combined chemotherapy has taken the following principles into account: using drugs 
with activity as single agents, avoiding the overlapping of drug toxicities, no cross-drug 
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resistance, different mechanisms of action, targeting different cell cycle phases and generating 
anticancer synergy.92,93 The development of nanomedicine has also created the opportunity to 
load different drugs into nanocarriers and overcome some problems encountered by free drug 
combination therapies. There are several ways to deliver multiple drugs using nanocarriers: 
one drug in its free form and another one loaded into a nanocarrier (free drug+nano), or both 
drugs loaded into different nanocarriers (nano+nano), or both drugs loaded into the same 
nanocarrier (co-encapsulation) (Figure 1.5).92 
 
 
Figure 1.5: Different approaches of combined chemotherapy using nanocarriers.92 
 
Co-encapsulation of synergistic drug combinations presents many benefits as it has been 
demonstrated by different studies.94–99 For instance, Anitha et al.98 evaluated the combinatorial 
effects of curcumin/5-fluorouracil loaded into thiolated chitosan nanoparticles (CRC-TCS-
NPs/5-FU-TCS-NPs) in vitro using colon cancer cells (HT29) and in vivo by the analysis of 
pharmacokinetics and biodistribution of CRC-TCS-NPs/5-FU-TCS-NPs in a mouse model. 
Using in vitro studies, they proved that the combinatorial anticancer effects enhance 2.5 to 3-
fold the anticancer effects and pharmacokinetic studies confirmed the improved plasma 
concentrations of 5-FU and curcumin loaded into thiolated chitosan nanoparticles up to 72 h, 
unlike bare curcumin and 5-FU.98 Tardi et al. combined irinotecan and cisplatin, loaded them 
into liposomes and evaluated the effect in vitro and in vivo, revealing that irinotecan/cisplatin 
7:1 molar ratio had superior antitumor activity when encapsulated in liposomes compared with 
the free-drug cocktail.99 
 
In the recent years, there has been an increasing number of studies showing a correlation 
between the use anti-inflammatory drugs and reduced incidence of cancer. Non-steroidal anti-
inflammatory drugs (NSAIDs) are used by their anti-inflammatory, antipyretic and analgesic 
effects, and aspirin is also effective in both the primary and secondary prevention of 
cardiovascular diseases.100 There is reliable data which correlate the use of NSAIDs in 
prevention of colorectal and breast cancers. NSAIDs exert their effect by inhibition of 




cyclooxygenases (COXs), thus inhibiting the conversion of arachidonic acid into thromboxanes 
and prostaglandins.100 COX-1 is expressed in platelets and the gastric mucosa and COX-2 is 
expressed mainly in the human brain and kidneys and in many sites during inflammation, 
wound-healing and cancer.100,101 COX-2 overexpression stimulates angiogenesis in tumors, 
being the most frequent anti-inflammatory/anticancer target.102 Anti-inflammatory drugs inhibit 
COX-2 expression, which make them effective as chemo-preventive agents if the clinical 
benefits compensate the toxic effects.103 Despite the numerous studies showing the promising 
activity of NSAIDs in the prevention and treatment of cancer, only treatment with aspirin 
combines the benefit of protection against cardiovascular disease with the potential to reduce 
the risk of some types of cancer.104–110 
 
1.2. NANOMATERIALS AS CARRIERS FOR DRUG DELIVERY SYSTEMS 
In the last years, the use of nanocarriers to improve drug delivery has been a flourishing 
strategy for cancer treatment. An ideal nanocarrier should have high drug loading capacity, be 
biocompatible and/or biodegradable and should deliver the drug on a specific site to avoid 
normal cells and tissues.111,112 Nanocarriers are used as hosts to develop drug delivery 
systems (DDS). DDS enable to overcome many of the limitations common to 
chemotherapeutic agents.57 When a drug is administered in the conventional way, it can have 
more limited effectiveness, lack of selectivity and poor biodistribution. When a drug is loaded 
into a nanocarrier (originating a DDS), it can be delivered on the target place, minimizing the 
undesirable side effects on healthy tissues, the drug is protected from rapid degradation or 
clearance and the drug concentration increases in the target tissues.113 These features clearly 
demonstrate the utmost importance of DDS in order to increase drug efficacy while decreasing 
their side effects and, in this way, overcome the present limitations of cancer therapy.114 The 
release of the drug from nanocarriers occurs by one or more mechanisms, such as diffusion, 
desorption of the drug bound to the surface, matrix erosion, diffusion through the capsule shell 
and a combined erosion-diffusion process.115  
There are several carriers that could be used to load drugs (Figure 1.6), including polymeric 
nanoparticles,116–118 liposomes,52,119 dendrimers,120–122 nanoemulsions,123–125 mesoporous 
silica nanoparticles,126–128 magnetic nanoparticles (MNPs),129–131 and zeolites.132–134 The 
current research results will focus on some of them. 
 




Figure 1.6: Established therapeutic nanocarriers in preclinical development.135 
 
1.2.1. POLYMERIC NANOPARTICLES 
Polymeric nanoparticles (PNPs) are based on polymers and have a good potential as 
DDS.136 After the creation of the first DDS based in polyglycolic acid, polymers have been 
gaining application as DDS since this material allows the preparation of efficient systems for 
drug delivery.137–139 These nanoparticles can be obtained by two methods: dispersion of the 
preformed polymers and polymerization of monomers.137 In the dispersion of the preformed 
polymers, nanoparticles can be prepared by several methods, such as solvent evaporation, 
salting-out, dialysis and supercritical fluid technology.137,140 In polymerization of monomers, 
various techniques are used, for instance, surfactant-free emulsion, micro-emulsion, mini-
emulsion and interfacial polymerization.140 Normally, PNPs are nanospheres or nanocapsules. 
When hydrophobic compounds are encapsulated into a polymeric matrix, the structures are 
called nanospheres, while compounds, independently of their physicochemical properties, are 
encapsulated into an aqueous or oily liquid core, the structures are named as nanocapsules 
(Figure 1.7).141 PNPs are prepared with biodegradable polymers, which allow their use for 
biomedical applications since these polymers do not accumulate in the body and are non-
toxic.141 
It is possible to find many examples of the use of PNPs in the literature for the preparation 
of DDS. The works of Chaves et al.142 show that clofazimine (CLZ) loaded in PLGA 
nanoparticles (NPs-CLZ) reduce its toxicity. The effect of NPs-CLZ was assessed on intestinal 
cells, Caco-2 and HT29-MTX, revealing that NPs-CLZ show no toxicity to cells compared to 




free CLZ solutions.142 Han et al.143 prepared poly(lactic-co-glycolic acid) nanoparticles with 
phospholipid shell and covered with polydopamine that allowed the conjugation of TAT peptide 
on the surface. They found that the nanoparticles modified with amidated TAT peptide (NLpT-
CA and NPpT-CA) avoided interactions with LS174T colon cancer cells and J774A.1 
macrophages at pH 7.4 but restored the ability to interact with LS174T cells at pH 6.5, 
delivering paclitaxel efficiently to the cells following a brief contact time.143 
 
 
Figure 1.7: Schematic representation of a nanocapsule and a nanosphere.144 
 
1.2.2. DENDRIMERS 
Dendrimers are polymeric molecules composed of a high number of branches that derive 
outward from a central core and surface groups, providing versatile building blocks (Figure 
1.8).145,146 Dendrimers are relatively easy to prepare, water soluble and have a high number of 
peripheral groups to functionalize, which make them appropriate to be used in different 
biomedical applications and to be administered by many routes, such as oral, transdermal 
diffusion and intravenous.147,148 
There are many studies about the use of dendrimers for biomedical applications. For 
example, Han et al.149 developed a DDS based on a polysaccharide-modified dendrimer 
responsive to the tumor microenvironment. The results showed that this strategy enhanced 
drug penetration and improved therapeutic efficacy.149 Lee et al.150 used a biodegradable 
dendrimer loaded with doxorubicin and evaluated its effect in mice bearing C-26 colon 
carcinomas. The results revealed that after 72 h of exposure, doxorubicin loaded into the 
dendrimer was more than ten times less toxic than free doxorubicin.150 Liu et al.151 synthetized 
a multifunctional delivery system combining DOX and pORF-hTRAIL to accumulate in brain 
glioma and to kill cancer cells, inducing apoptosis with lower side effects. The results showed 
a synergistic growth inhibition in U87MG cells.151 




Figure 1.8: Structure of a dendrimer.145 
 
1.2.3. LIPOSOMES 
Liposomes are spherical vesicles most often constituted of phospholipids, comprising at 
least one lipid bilayer like a cellular membrane which surrounds an aqueous solution core 
(Figure 1.9).152 Due to their features, liposomes can load hydrophilic or hydrophobic drugs in 
the core or in the bilayer, respectively, and their vesicles can vary from 25 nm to 2.5 μm in 
diameter.152,153 Due to their properties, liposomes are good candidates for the delivery of drugs 
to cells and they can also be functionalized with different ligands.154 Liposomes were the first 
nanocarriers approved by the American FDA for anticancer treatment (Doxils), where 
liposomes were loaded with doxorubicin.155 
Jiang et al.156 reported a dual-functional liposome system which comprised extracellular pH 
response and mitochondrial targeting properties in order to increase drug accumulation in 
mitochondria and consequently contribute to kill drug-resistant cancer cells by apoptosis. The 
results demonstrated that these dual-functional liposomes had great efficacy in A549 cells and 
A549/Taxol cells and in drug-resistant lung cancer A549/Taxol cells xenografted onto nude 
mice, resulting in 86.7% of tumor growth inhibition.156 Alshaer et al.157 conjugated onto 
PEGylated liposomes surface a 2′-F-pyrimidine-containing RNA aptamer (Apt1), previously 
selected for CD44. The results demonstrated higher sensitivity and selectivity for Apt1 
conjugated with liposomes compared to maleimide-functionalized liposomes, which show that 
Apt1 conjugated with liposomes is a promising specific DDS.157 Liu et al. created a pH-
responsive molecule (i.e., malachite green carbinol base (MG)) and liposome conjugated with 
HER-2 antibody for the co-delivery of doxorubicin (DOX) and verapamil (VER) to suppress 
drug resistance in HER-2 positive breast cancer.158 
 





Figure 1.9: Structure of a liposome. A) Representation of structural and design considerations for drug delivery 
using liposomes. Liposomes can be designed with polyethylene glycol (PEG) being a passive target and with 
different cargos ligands such as antibodies, peptides, proteins, carbohydrates, and also drug loaded being active 
targets. B) The usual classification system of vesicle size and lamellarity: vesicles with diameters less than 100 nm 
are classified as small unilamellar vesicles (SUV); vesicles with diameters between 100 and 1000 nm are classified 
as large unilamellar vesicles (LUV); vesicles larger than 1 µm are classified as giant unilamellar vesicles (GUV); 
vesicles with many layers are classified as multilamellar and  vesicles encapsulating smaller vesicles cells are 
classified as multivesicular.153 
 
1.2.4. MESOPOROUS SILICA NANOPARTICLES 
Mesoporous silica nanoparticles (MSNs) are amorphous inorganic nanoparticles comprising 
silicon dioxide units and pores not greater than 2 nm.159 This material has large specific surface 
area and pore volume, a controllable particle size and a good biocompatibility, which makes it 
widely studied for several applications, including the use as carrier for drug delivery (Figure 
1.10).160,161 MSNs are more stable to degradation and mechanical stress than liposomes or 
dendrimers due to the strong Si-O bond.162 
Freitas et al. prepared a system based on MCM-41 to be used in controlled drug delivery 
and imaging for cancer treatments.163 Maggini et al. prepared redox responsive mesoporous 
organo-silica nanoparticles for targeted drug delivery and proved that these particles have a 
higher cytotoxic effect on glioma C6 cells than non-breakable particles.164 Also, Kotcherlakota 
et al. loaded the anticancer drug curcumin in mesoporous silica materials to be used in cancer 
treatment, showing that curcumin loaded into MSNs revealed higher cytotoxicity to cancer cells 
and cellular uptake compared to pristine curcumin.165 
 




Figure 1.10: Representation of mesoporous silica nanoparticles and their cargo loading possibilities.166 
 
1.2.5. MAGNETIC NANOPARTICLES 
In the last decade, magnetic nanoparticles (MNPs) have gained attention as very promising 
candidates for biomedical applications (Figure 1.11). MNPs are biocompatible and can be used 
in different applications such as magnetic resonance imaging (MRI), drug delivery and 
hyperthermia.167–169 In hyperthermia, MNPs can be injected into the tumor region and a 
magnetic field is applied. The generated heat increases the tumor tissue temperature to around 
42-45 °C which will kill cancer cells, whereas the healthy cells will survive because they are 
stronger tolerant to thermal heating.170,171 
MNPs nanoparticles could be conjugated with other materials, creating hybrid materials that 
can conjugate the features of both. In the literature, it is possible to find some examples of the 
conjugation of MNPs with other materials. Wan et al. created a hybrid material conjugating 
nanohydroxyapatite and magnetic nanoparticles to be used as nanocarrier for controlled 
delivery of 5-fluorouracil.172 Wang et al. developed a material composed by hydroxypropyl 
methyl cellulose (HPMC), polyvinyl alcohol (PVA) and magnetic nanoparticles for magnetic 
hyperthermia ablation of tumors.173 
 





Figure 1.11: Structure of a magnetic nanoparticle and the possibilities for modification.174 
 
1.2.6. ZEOLITES 
Zeolites are crystalline aluminosilicates comprising silicon (Si), aluminum (Al), oxygen (O) 
and water molecules, characterized by three dimensional channels and cavities whose 
dimensions are comparable with small organic molecules.175–177 Their framework is assembled 
by TO4 tetrahedra where T is silicon or aluminum atoms bridged by oxygen, originating SiO4 
and AlO4-.178 The negative charge of the zeolite generated by the substitution of Si4+ by Al3+ in 
the tetrahedra, could be neutralized by cationic exchange with H+, Na+ or K+. However, theses 
cations could be replaced by other transition metal ions since they are very mobile.179 
The way the tetrahedra are linked to each other originates a wide variety of different 
structures, more than 200, which are listed by the International Zeolite Association (IZA).180 
For example, zeolite NaY belongs to the faujasite family (FAU) and has a tridimensional 
structure with pores of 0.73 nm (Figure 1.12A).180 The basic structural units of zeolite NaY are 
sodalite cages (or β cages) with an internal diameter of 0.62 nm that are linked by hexagonal 
prisms to form a spherical supercage with 1.18 nm of diameter.181,182 Zeolite L belongs to Linde 
Type L family (LTL), presents unidimensional channels which are linked by cancrinite cages 
and hexagonal prisms, forming a cylindrical crystal shape and it has 0.71 nm pores (Figure 
1.12B).183 Zeolite L nanocrystals are easy to synthesize, to functionalize and presents a 
defined and controlled morphology and porosity.184 
 




Figure 1.12: Zeolite structures of A) NaY185 and B) L.186 
 
Comparing with other nanocarriers, zeolites have the advantage of being used for 
biomedical applications since they are relatively cost-effective, biocompatible, present low 
toxicity, are stable at pH variations, can load small drug molecules and it is possible to tune 
zeolite properties by changing the SiO2/Al2O3 ratio, the commutable cation and the surface 
functional groups.187,188 It is possible to find numerous examples of the use of zeolites in 
biomedical applications in the literature, including drug delivery,80,189–192 radiotherapy,193 
wound-healing,194 imaging,195 which demonstrate the versatility of these structures. 
 
1.3. TOOLS TO DETERMINE ENDOCYTIC PATHWAYS 
Understanding the interaction between particles and living cells is crucial for assessments if 
a material is available to reach a desired intracellular compartment and if it is deemed suitable 
for theranostic use.196 There are some established approaches to determine the endocytic 
pathways involved in the endocytosis of nanoparticles: using pharmacological inhibitors, 
molecular inhibition and co-localization studies.197,198 
 
1.3.1. PHARMACOLOGICAL INHIBITORS 
Pharmacological inhibitors can block specific endocytic pathways and can be used to study 
the pathway responsible for cellular uptake of nanoparticles. There are many inhibitors to be 
used in these studies like chlorpromazine, filipin, dynasore, nystatin, genistein, nocodazole, 
LY94002 and others.198 These inhibitors block specific pathways: chlorpromazine is used to 
block clathrin-dependent endocytosis,199,200 filipin and nystatin block caveolae-mediated 
endocytosis by interacting with cholesterol,201–204 dynasore is a GTPase inhibitor that rapidly 
and reversibly inhibits dynamin activity, preventing endocytosis,205,206 genistein impedes 
caveolae-dependent endocytosis by inhibiting several tyrosine kinases,207,208 nocodazole is a 
microtubule-depolymerizing agent inhibiting microtubule dependent pathways,209,210 and 
LY294002 inhibits micropinocytosis209 (Table 1.2). When assays with pharmacological 




inhibitors are performed, the concentration and incubation times of the inhibitors need to be 
optimized to avoid cytotoxic side effects to cells used in the assays.197,198 These studies have 
some disadvantages since one inhibitor could interfere with different pathways at the same 
time.211 
 
Table 1.2: Effect of pharmacological inhibitors used to study endocytosis. 
Affected mechanism Inhibitor(s) Action 
Clathrin-dependent 
endocytosis 























1.3.2. MOLECULAR INHIBITION 
The use of mutated proteins can be used to block endocytic mechanisms at the protein 
level.197,198 For this purpose, mutated proteins like DN-Eps15, DN-dyn2, Dn-Rab5, are 
introduced in cells and they will interfere with the function of their endogenous analogues and 
consequently blocks the endocytic mechanism for which the protein is required.198 With this 
approach, it is possible to bind a fluorescent protein to a mutated protein, allowing microscopic 
observation and selection of the transfected cells, which represent an advantage of this 
approach.198 Though, this method presents some disadvantages like higher concentration of 
mutated protein compared to the normal endogenous protein, which can originate lower-affinity 
interactions not detected in cells missing such mutated proteins.197 It is also possible to use 
siRNA to downregulate crucial endocytic proteins.198 However, this approach also has some 
considerations that should be taken in account: knockdown of proteins could take 2-5 days, 
which could lead to cellular changes, resulting in observations not relevant for the target 
protein;197 since protein downregulation does not occur in the same way in all cells, it is 
complicated to perform a quantitative analysis;198 to introduce the siRNA in cells, transfection 
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agents need to be used, which can cause cellular stress and consequently affect the endocytic 
profile.198 
 
1.3.3. FLUORESCENCE LOCALIZATION OF NANOPARTICLES 
The cellular uptake and transport of nanoparticles could also be studied using fluorescent 
nanoparticles and confocal microscopy. By confocal microscopy it is possible to evaluate the 
intracellular localization of nanoparticles and if the endosomes are labelled after the 
internalization, enabling to obtain information about the endocytic mechanism under study.198 
However, for the confocal experiments, it is necessary to fix and permeabilize the cells, which 
can originate some artefacts. Moreover, sometimes it is difficult to conclude if the nanoparticles 
are inside or just bound to the cell surface.197 However, this limitation could be solved using 
electron microscopies: scanning electron microscopy (SEM), atomic force microscopy (AFM) 
and transmission electron microscopy (TEM). SEM and AFM could be used to investigate the 
initial phase of the endocytic events since these techniques allow the surface visualization of 
cells and have a maximum resolution of 1 nm and 30 nm for the lateral resolution and up to 
0.1 nm for the vertical resolution, respectively.198 TEM could be used to examine the 
localization of nanoparticles inside the cells since this technique allows the observation of 
ultrathin sections of cells.198 In the work of Cacchioli et al., on in vitro cytocompatibility of 
SiC/SiO2 core-shell nanowires, SEM and TEM were used to investigate the cellular 
internalization of SiC/SiO2 nanowires.212 Havrdova et al. used field emission scanning electron 
microscopy (FE-SEM) to detect nanoparticles inside human mesenchymal stem cells 
(hMSCs).167 
 
1.4. MECHANISMS OF INTERNALIZATION 
When the materials interact with cells, their internalization can occur by different pathways: 
energy-independent or non-endocytic and endocytic pathways (Figure 1.13). These pathways 
can be determined by several factors, namely the cell type and the physicochemical properties 
of particles like size, shape and surface charge.213,214 Some studies demonstrated that the size 
of particles can influence the internalization pathways and showed that smaller particles are 
taken up more rapidly than larger ones.215,216 The shape of the nanoparticles also has influence 
on the internalization process since particles presenting a good aspect ratio, the ratio of length 
to width of a particle, are the fastest internalized.217,218 Gratton et al. found that HeLa cells 
internalized 4 times faster high-aspect-ratio particles (diameter (d) = 150 nm and height (h) = 
450 nm) than low-aspect-ratio particles (d = 200 nm and h = 200 nm).215 The surface charge 
influences the internalization of nanoparticles since their charge will interact with the surface 




charge of the cell membrane. It seems to be a pattern that shows that positively charged 
particles are endocytosed more efficiently than negatively charged particles.197,219 Another 
factor that influences nanoparticles internalization is the cell type. Cells could have different 
proteins involved in the internalization which will determine the endocytic pathway responsible 




Figure 1.13: Schematic representation of the different cellular uptake pathways in mammal cells. The processes 
represented on the top are related to endocytic pathways. The processes represented at the bottom right side are 
related to direct penetration. 1) Phagocytosis; 2) Macropinocytosis; 3) Clathrin-dependent endocytosis; 4) Caveolin-
dependent endocytosis; and 5) Clathrin and caveolin-independent endocytosis. Adapted from.220,221 
 
1.4.1.  DIRECT PENETRATION 
Direct penetration is a non-endocytic pathway and nanoparticles enter the cells via energy-
independent pathways. There are different mechanisms involved in the internalization of 
nanoparticles by this pathway, such as pore formation, micelle formation, the carpet-like model 
and the membrane thinning model.222,223 The inverted micelle model occurs as a result of 
electrostatic interactions between cationic particles and negatively charged phospholipids of 
the cell membrane, which results in the destabilization of the membrane and the formation of 
an invagination. A reorganization of adjacent lipids occurs and leads to the formation of an 
inverted micelle that encloses nanoparticles in a hydrophilic core. In the pore formation model, 
transient pores are created in the cell membrane, leading to the cellular internalization of 
particles. In the carpet model, there is a transient disruption of the cellular membrane, which 
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contributes to the cellular uptake.211,222–224 Normally, direct penetration is associated with the 
internalization of cell penetrating peptides.204,225–227  
 
1.4.2.  ENDOCYTIC PATHWAYS 
1.4.2.1.  ENDOCYTOSIS  
A nanoparticle can interact with the cell membrane and enter the cell by endocytosis. In the 
endocytosis process the nanoparticles are engulfed by the cellular membrane forming the 
endosomes. The endosomes transport the nanoparticles for different specialized vesicular 
structures and consequently the nanoparticles are distributed in different destinations. When 
the nanoparticles deliver their compounds to the cells, they are recycled to the extracellular 
milieu or carried across the cells.228 This is the most common way for internalization of 
nanoparticles and it is divided into phagocytosis and pinocytosis (Figure 1.14). Phagocytosis 
refers to the uptake of large particles and it is specific of phagocytic cells such as 
macrophages.228,229 Pinocytosis refers to the uptake of fluids and solutes and is present in all 
types of cells. Pinocytosis is divided in clathrin-mediated endocytosis, caveolae-mediated 




Figure 1.14: Classification of endocytosis based on endocytosis proteins that are involved in the initial entry of 









In the clathrin-dependent endocytosis that occurs in mammalian cells, the nanoparticles 
interact with receptors of the cellular membrane which is polymerized on the cytosolic side by 
different adaptor and accessory proteins.218,231 The nanoparticles are internalized and form 
clathrin-coated pits (CCPs) and subsequently clathrin-coated vesicles (CCVs).219,232 The 
formation of CCPs occurs in the initial phase of clathrin-mediated endocytosis, consisting in 
transmembrane receptors and clathrin, a triskelion-shaped scaffold protein and the 
heterotetrameric protein AP-2.233,234 The formation of CCVs is dependent of several accessory 
proteins and it proceeds through five stages: initiation, cargo selection, coat assembly, scission 
and uncoating.233,235 GTPase activity of dynamin pinches off the vesicles with nanoparticles 
and CCVs are formed. Then, these CCVs move inside the cells through actin activity and then 
are released in the cytosol.219,235 The uptake of low-density lipoproteins and transferrin is 
mediated by this pathway.234 Ng et al.236 investigated the mechanism of uptake for gold 
nanoparticles in MRC5 lung fibroblasts and Chang liver cells. Cells treated with concanavalin 
A and chlorpromazine demonstrated a significant decrease of nanoparticle uptake by cells, 
implying that the uptake of these nanoparticles was facilitated by clathrin-mediated 
endocytosis.236 Oh et al.237 prepared different sized LDH nanoparticles with narrow size 
distribution by modulating the crystal growth rate and labelled each layered double hydroxides 
(LDHs) particles with a fluorophore. The cellular uptake rate of LDHs by human osteosarcoma 
(MNNG/HOS) cells was found to be highly dependent on the particle size (50 > 200 > 100 > 
350 nm), in which those ranging of 50 to 200 nm were selectively internalized into cells through 
clathrin-mediated endocytosis with enhanced permeability and retention.237 Forte et al.238 
evaluated the endocytic mechanism involved in the internalization of 44 nm (NP44) and 100 
nm (NP100) unmodified polystyrene nanoparticles (PS-NPs) into gastric adenocarcinoma 
(AGS) cells. They proved that NP44 accumulate rapidly and more efficiently compared to 
NP100 in the cytoplasm of AGS; both PS-NPs showed an energy-dependent mechanism of 
internalization and a clathrin-mediated endocytosis pathway.238 
 
Caveolin-dependent endocytosis 
Caveolin-dependent endocytosis is dependent on the protein caveolin. Three isoforms of 
caveolin are known in mammalian cells: caveolin-1 and -2 are present in endothelial cells, 
fibroblasts and adipocytes and caveolin-3 is specific to muscle.219,228 In this way, membrane 
invaginations are formed with size of around 50-100 nm, caveolae, mediated by caveolin-
1.231,232,239,240 The nanoparticles bind to the cell surface and move along the membrane to 
caveolae vesicles where they are kept through receptor-ligand interactions.232 The caveolae 
vesicles are pinched off from cellular membrane by the GTPase dynamin, originating the 
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cytosolic caveolar vesicle.232 Nanomaterials with carrier compounds sensitive to enzymatic 
action should be designed to use this pathway since this enables to escape from lysosomal 
enzymes.232,241 Cao et al.242 loaded the anticancer drug doxorubicin in four arm star-shaped 
poly(ɛ-caprolactone)-b-poly((N,N-diethylaminoethyl methacrylate)-r-(N-(3-sulfopropyl)-N-
methacryloxyethy-N,N-diethylammoniumbetain)) (4sPCLDEAS) micelles and tracked their 
endocytosis in HeLa cancer cells. The results demonstrated that caveolae-dependent endocytosis 
was the main pathway for the internalization of 4sPCLDEAS micelles.242 Wang et al.243 
explored the uptake of bovine serum albumin (BSA)-coated nanoparticles of different sizes (40 
and 100 nm) in endothelial cell monolayers. They observed that BSA-coated nanoparticles 
were internalized via caveolae-dependent endocytosis and only nanoparticles smaller than 
caveolae were internalized. The results also demonstrated that the transport of 40 nm particles 
was 2-fold greater than that of 100 nm ones.243 
 
Macropinocytosis 
Macropinocytosis occurs in almost all the cells with few exceptions, such as brain 
microvessel endothelial cells which is one of the clathrin-independent endocytosis.219,232 This 
route is a fluid-phase endocytosis since it internalizes large amounts of plasma membrane and 
extracellular medium, leading to the formation of macropinosomes which are fused membrane 
protrusions generally bigger than 1 µm and sometimes bigger than 5 µm.240,244,245 
Macropinosomes are larger than the clathrin-coated vesicles, which provides the cells a way 
to internalize large amounts of solute and membrane.246 Macropinocytic vesicles undergo a 
maturation process, shrink and move toward the lysosomes, acquiring and losing various 
endocytic protein markers during this process.246 Wadia et al. showed that TAT-fusion proteins 
are rapidly internalized in cells by lipid raft-dependent macropinocytosis.247 In another study, 
Khalil et al.248 investigated the internalization mechanism associated with liposomes modified 
with different densities of the octaarginine (R8) peptide. They observed that liposomes 
modified with high R8 density were taken up mainly by macropinocytosis, whereas those 
modified with low R8 density were internalized via clathrin-mediated endocytosis.248 
 
Phagocytosis 
Phagocytosis occurs predominantly in specialized cells of the immune system: 
macrophages, monocytes, neutrophils and dendritic cells.245 It is a receptor-mediated process 
and removes particles larger than 500 nm. Phagocytosis comprises three different steps: (1) 
recognition of the particle by opsonization in the bloodstream; (2) adhesion of the opsonized 
particles onto the cell membrane and (3) ingestion of the particles by cells (Figure 1.15). 




Particles are recognized by opsonins (opsonization process), including G or M 
immunoglobolins (Ig), as well as complement fragments (C3, C4 and C5), in addition to other 
blood serum proteins like fibronectin, laminin or C-reactive protein.232,245,249 In the opsonization 
process, opsonins tag the stranger nanoparticles and send a signal to macrophages. Then, 
the opsonized particles bind to the macrophage surface via specific receptor-ligand 
interactions like Fc receptor or complement receptor (CR) that can attach respectively to the 
constant fragment of Ig or complement molecules adsorbed at the particle.232,250 Receptor 
ligation initiates a signaling cascade, which leads to actin rearrangement, formation of 
pseudopodia that zipper up around the particles and engulf them, forming the phagosome. The 
phagosome is matured through numerous fission and fusion events, the cargo fused with late 
endosomes and ultimately with lysosomes originating phagolysosomes.228,232,245 The number 
of these consecutive events is dependent on the physicochemical properties of the ingested 
particles, typically persists from 30 minutes to several hours.245,251 
 
 
Figure 1.15: The steps of phagocytosis: 1) Particles undergo recognition in the bloodstream through 
opsonization i.e. adsorption of proteins (immunoglubulins (Ig) G and M, complement components (C3, C4, C5); 
blood serum proteins (including laminin, fibronectin, etc.); 2) Opsonized particles attach onto the cell membrane 
through receptors present on the cell surface of a phagocyte; 3) The particles are ingested into phagosomes and 
4) The phagosomes mature, fuse with lysosomes and become acidified, leading to the enzyme-rich 
phagolysosomes where the particles are prone to degradation.228 
 
Clathrin- and caveolin-independent endocytosis 
Recent investigations demonstrated that some endocytic pathways cannot be included into 
the previously described categories since many of them are clathrin- and caveolin-independent 
endocytosis. These pathways are classified as Arf-6-dependent, Cdc42-dependent and Rhoa-
dependent, depending on the type of protein that regulates the internalization.221,252,253. The 
involved endocytic apparatus might comprise clathrin-independent carriers (CLICs) or GPI-
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anchored protein-enriched early endosomal compartment (GEEC).254 However, studies about 
these pathways are still scarce and need further research. 
 
1.4.3.  PASSIVE TRANSPORT: ENHANCED PERMEABILITY AND RETENTION EFFECT 
The enhanced permeability and retention (EPR) effect consists in the accumulation of 
nanocarriers in the tumor as a result of their transport through the hyperpermeable tumor 
vasculature.70,255 The characteristic of leak vasculature allows the enhanced permeability of 
particles like proteins, liposomes, micelles and other soluble particles.70 The size of 
nanocarriers allows their extravasation and accumulation in the interstitial space of the tumors 
due to the incomplete lymphatic drainage system and the nanocarrier may stay retained in the 
tumor bed.256,257 To take advantage of the EPR effect, nanocarriers should be viable to stay in 
circulation for enough time to accumulate in the tumor, resist to blood stream aggregation and 
premature drug leakage and should avoid the reticuloendothelial system (RES) and renal 
filtration. To avoid being eliminated before their action, nanocarriers should be larger than 10 
nm, since particles smaller than 10 nm are subject to clearance by the kidney.258 This via is 
not sufficient to control the side effects of cytotoxic drugs and fully exploit the benefits of 
targeted delivery.114 
 
1.5. FACTORS INFLUENCING ENDOCYTIC PATHWAYS 
The size, shape and surface charge of the nanoparticles are the main factors that could 
influence endocytic pathways, as well as the cell type used. 
The size of the nanoparticles could influence the uptake by cells via either direct penetration 
through cellular membrane or by endocytosis. There are many studies that show the effect of 
nanoparticle size on the endocytic pathways used by cells. For example, Rejman et al. showed 
in their work that particles > 500 nm were internalized by a caveolin-mediated process while 
particles of 200 nm are internalized by a clathrin-mediated process.259 Suen and Chau 
demonstrated in their work that 50  and 120 nm folate-decorated nanoparticles were 
internalized via both clathrin- and caveolin-mediated endocytosis while the particles of 250 nm 
were internalized by caveolin-mediated endocytosis.260 Saw et al.261 investigated the effect of 
four sizes (30, 60, 80 and 100 nm) of cystine/citric acid-coated confeito-like gold nanoparticles 
(confeito-AuNPs) on cellular uptake. The results demonstrated that the smallest size of 
confeito-AuNPs (30 nm) have the highest cellular internalization rate via clathrin- and 
caveolae-mediated endocytosis. However, the other three sizes (60, 80 and 100 nm) use 
clathrin-mediated endocytosis for cellular uptake.261 




The shape of nanoparticles could affect the uptake rate and the biodistribution, the 
cytotoxicity and the internalization process. However, there is no consensus about which 
shape is more internalized. Some works demonstrated that rod-shaped NPs are faster and 
more internalized than that of the spherical nanoparticles.215,232 Conversely, other studies 
showed that the internalization of spherical nanoparticles is higher and faster than of those 
rod-shaped.262 Qiu et al. demonstrated the influence of the shape on the cellular uptake of 
Gold nanorods (Au NRs).263 Xie et al.264 synthesized three different shapes (stars, rods, and 
triangles) of methylpolyethylene glycol coated-anisotropic gold nanoparticles and investigated 
their internalization in RAW264.7 cells. They verified that star-shaped nanoparticles had the 
lowest internalization rate, followed by rod- and triangle-shaped nanoparticles which had the 
highest one and they also found that nanoparticles with different shapes tend to use different 
endocytic routes.264 
 
The efficiency and the pathways of cellular uptake of nanoparticles are highly dependent on 
their surface charge since there are many biomolecules with distinct charges in biological 
systems.265 
The cell membrane is negatively charged, which could affect the rate of internalization of the 
nanoparticles. The internalization of positively charged nanoparticles seems to be in favor 
compared with those negatively charged due to the electrostatic interactions between the 
negatively charged cellular membrane and the positively charged nanoparticles.266 In fact, in 
the literature it is possible to find several studies reporting that positively charged nanoparticles 
have higher rates of internalization than those negatively charged. Steinbach et al. modified 
the surface of nanoparticles with several different cell penetrating peptides with cationic 
regions and showed that the modified nanoparticles have greatest cell internalization than 
those unmodified.267 Bannunah et al.268 investigated the effect of surface charge on the 
interaction with Caco-2 monolayers as a model of the intestinal epithelium. They showed that 
the internalization and transport of positively charged nanoparticles are significantly affected 
in the presence of a clathrin pathway inhibitor (via chlorpromazine), by macropinocytosis 
inhibition (via 5-(N-ethyl-N-isopropyi)-amiloride) and under cholesterol depletion (via methyl-
β-cyclodextrin), but remained unaffected by the inhibition of lipid raft associated uptake 
(caveolae) by genistein.268 On the other hand, they observed that the internalization and 
transport of negatively charged nanoparticles is mostly reduced by inhibition of the lipid raft-
associated pathway (caveolae inhibition by genistein) and it was not significantly affected by 
the inhibition of clathrin pathway.268 
 
The information about how the cell type affects the cellular trafficking is still scarce. Further 
studies on the different endocytic pathways are needed since the distinct features between 
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cancer cells and normal cells could dictate the strategy to adopt for nanomaterials to reach the 
tumor and avoid effects on normal tissues.228 It is possible to find some studies in the literature 
that show that the cell type defined the internalization pathway, such as the study of Chung et 
al., which evaluated the effect of surface charge of mesoporous silica nanoparticles (MSNs) 
on cellular uptake and in vitro cytotoxicity using human mesenchymal stem cells (hMSCs) and 
3T3-L1 cells.269 Clathrin- and an actin-dependent endocytosis were involved in the 
internalization of unmodified MSNs in both cells since they were inhibited by phenylarsine 
oxide (PAO) and cytochalasin D (Cyt D).269  However, for strongly positive-charged MSNs, 
inhibitory effects were only observed for 3T3-L1 cells, which show that the MSNs uptake is cell 
type-dependent.269 Santos et al.270 used various pharmacological inhibitors in a range of 
representative human cell lines, including HeLa (cervical cancer), A549 (lung carcinoma) and 
1321N1 (brain astrocytoma) to study the uptake mechanisms of carboxylated polysterene 
nanoparticles of 40 and 200 nm. The results indicated that NP uptake in HeLa and 1321N1 
cells was strongly affected by actin depolymerisation, while A549 cells showed a stronger 
inhibition of NP uptake (in comparison to the other cell types), after microtubule disruption and 
treatment with genistein.270 A strong reduction of NP uptake was observed after 
chlorpromazine treatment only in the case of 1321N1 cells, suggesting that the same 
nanoparticles could use different endocytic pathways depending on the cell type.270  
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EXPLORATION OF ZEOLITE STRUCTURES AS NANOCARRIERS FOR 
ENCAPSULATED DRUGS FOR CANCER TREATMENT 
In this chapter all work about the use of microporous structures as nanocarriers for 
encapsulated drugs will be presented. This chapter represents an important part of this thesis, 
since it allowed the selection of the host porous structures and the drugs for further studies. 
The drug delivery systems (DDS) based on zeolites were defined and fully characterized. 
The first part, subchapter 2.1, includes the results of the study on the use of salicylic acid 
loaded into zeolite and mesoporous structures for breast cancer treatment. These studies 
allowed to define the zeolites as the best microporous structures for drug loading for cancer 
treatment. The selection of these frameworks was essential for obtain the best drug delivery 
systems.   
In the second part, subchapter 2.2 the results of the preparation of DDS with different 
microporous structures and their effect on colon and breast cancer cells will be presented. 
Finally, in the third part, the effect of three DDS in vitro using three different cell lines will be 









MICRO- AND MESOPOROUS STRUCTURES AS DRUG DELIVERY CARRIERS FOR 
SALICYLIC ACID1 
The potential of salicylic acid (SA) encapsulated in porous materials as drug delivery carriers 
for cancer treatment was studied. Different porous structures, the microporous zeolite NaY, 
and the mesoporous SBA-15 and MCM-41 were used as hosts for the anti-inflammatory drug. 
Characterization with different techniques (FTIR, UV/vis, TGA, 1H NMR, and 13C CPMAS 
NMR) demonstrated the successful loading of SA into the porous hosts. The mesoporous 
structures showed to be very efficient to encapsulate the SA molecule. The obtained drug 
delivery systems (DDS) accommodated 0.74 mmol (341 mg/gZEO) in NaY and 1.07 mmol (493 
mg/gZEO) to 1.23 mmol (566 mg/gZEO) for SBA-15 and MCM-41, respectively. Interactions 
between SA molecules and pore structures were identified. A fast and unrestricted liberation 
of SA at 10 min of the dissolution assay was achieved with 29.3, 46.6, and 50.1 μg mL-1 of SA 
from NaY, SBA-15, and MCM-41, respectively, in the in vitro drug release studies (PBS buffer 
pH 7.4, 37 °C). Kinetic modeling was used to determine the release patterns of the DDS. The 
porous structures and DDS were evaluated on Hs 578T and MDA-MB-468 breast cancer cell 
lines viability. The porous structures are nontoxic to cancer cells. Cell viability reduction was 
only observed after the release of SA from MCM- 41 followed by SBA-15 in both breast cancer 
cell lines (see graphical abstract below). 
 
 
                                               
1 N. Vilaça, F. Morais-Santos, A. F. Machado, A. Sirkecioʇlu, M. F. R. Pereira, M. Sardo, J. Rocha, 
P. Parpot, A. M. Fonseca, F. Baltazar and I. C. Neves, Micro- and mesoporous structures as drug 
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2.1.1.  INTRODUCTION 
Salicylic acid (SA) is a β-hydroxy acid, chemically classified as monohydroxy benzoic acid, 
commonly used to treat comedonal or noninflamed acne. SA is also the major metabolite and 
active component of aspirin (acetylsalicylic acid).1 Aspirin is recognized by its analgesic, anti-
inflammatory, and antipyretic effects.2 Several studies have proposed the use of anti-
inflammatory drugs as prevention and also as potential treatment of several types of cancer, 
including breast cancer.3–5 Recently, it has been suggested that the use of aspirin could reduce 
the development of different types of cancer such as pancreatic, breast, head, and neck 
cancer2,6–9 and can diminish the risk of developing colorectal cancer.1 
In spite of the emerging research toward the use of anti-inflammatory drugs in cancer 
therapy, few studies address their application in drug delivery systems.10,11 Arribo et al.10 
developed a new nanohydrogel system able to carry and deliver anti-inflammatory and 
anticancer drugs simultaneously, prednisolone and paclitaxel, respectively, and show their 
efficacy in different cancer cell lines. These systems are promising for applications in cancer 
treatment as combination therapy. 
Release of a drug in a preselected target cell requires a delivery carrier in which the drug is 
not distributed throughout the body in a nonspecific way, targeting the pharmacological site at 
concentrations with low cytotoxicity.12 The administration of most anti-inflammatory drugs in 
therapeutic doses can lead to development of gastrointestinal inflammation or ulcers.12 To 
circumvent these problems and have benefits for cancer therapy, encapsulation of anti-
inflammatory drugs into various drug carriers should help to achieve the desired goals.  
The structural properties and stability in biological environments of the porous structure 
make them very interesting as hosts for drug delivery.13–15 In our group we have already lead 
a detailed investigation on drug delivery systems (DDS) based on different zeolite structures 
with α-cyano-4-hydroxycinnamic acid or 5-fluorouracil and demonstrated their in vitro efficacy 
against colorectal carcinoma cells.16–18 In the present study, SA was loaded by diffusion in 
liquid phase in the void space of three different porous structures: one micro (NaY) and two 
mesoporous (MCM-41 and SBA-15) structures. Zeolite Y has a Faujasite (FAU)-type structure 
and is a crystalline microporous aluminosilicate based on sodalite cages joined by O bridges 
between the hexagonal faces which are arranged in a three-dimensional network. Supercages 
are 12-membered rings which are formed by the connection of sodalite cages in the framework 
with a diameter of 1.3 nm and an open diameter of 0.73 nm.19 In contrast with zeolite Y, MCM-
41 and SBA-15 are amorphous inorganic mesoporous silicas. Mesoporous silica materials 
possess high surface areas, tunable pore diameters, high pore volumes, and well-organized 
porosity, making them potential candidates for many applications.20,21 These materials differ in 
the pore diameters, thickness of the walls, and synthesis conditions.20 The mesoporous silica 






material MCM-41 has a unidimensional hexagonally ordered structure with straight channels. 
Large pore size materials, namely SBA-15, with pore sizes ranging between 0.2 and 30 nm 
are potential candidates for such biological applications due to their large range of pore 
dimensions in comparison to other mesoporous silica.22,23 In addition to their large pore sizes, 
SBA-15 materials possess higher hydrothermal stability because their pore walls are thicker 
than those of MCM-41 materials. Because of its attractive properties, SBA-15 has potential as 
DDS.24,25 
In the present study, NaY, MCM-41, and SBA-15 were chosen as hosts for loading an anti-
inflammatory drug in order to verify their potential viability for DDS in cancer therapy. For this 
purpose, SA was chosen as a drug model due to its small molecular size and short biological 
half-life. The DDS were characterized by a range of methods: FTIR, UV/vis, TGA, 1H NMR, 
and 13C solid-state CPMAS NMR. The effect of porous structures and of the DDS was 
evaluated on the viability of breast cancer cells (Hs 578T and MDA-MB-468). 
 
2.1.2.  EXPERIMENTAL  
2.1.2.1.  DRUG LOADING 
The microporous zeolite NaY (CBV100, Zeolyst International) and the mesoporous SBA-15 
and MCM-41 were used as hosts for the anti-inflammatory drug. The procedures used to 
synthesize the mesoporous structures, SBA-15 and MCM-41, were previously published.26 
The preparation of DDS was based on a previously established method.17,18 300 mg of each 
structure, previously dehydrated at 120 °C overnight in order to remove water from the pores, 
was added to a solution of 300 mg (2.17 mmol) of SA (Sigma-Aldrich, S5922) in 30 mL of 
acetone (Sigma-Aldrich, P.A.). The resulting suspensions at room temperature were stirred 
(300 rpm) for 48 h. Then, they were filtered off, and the DDS were dried in an oven at 60 °C 
for 12 h and stored in a desiccator. The pH of the suspensions was monitored during the DDS 
preparation. Throughout the work, the obtained DDS will be referred to as SA@porous, where 
porous represents the structure of the parent material used in DDS. 
 
2.1.2.2.  DRUG RELEASE STUDIES OF DDS 
Drug release from DDS was studied by UV/vis analysis at λ = 295 nm. The simulated body 
fluid was made using known amounts of sodium monobasic phosphate and sodium dibasic 
phosphate. Known amounts of the DDS were mixed (10 mg) in 50 mL of simulated body fluid 
at pH 7.4 and 37 °C, without stirring. 2 mL aliquots of DDS/ simulated body fluid were removed 
at regular intervals, and an equal amount of fresh simulated body fluid was added to keep 
constant the volume of the mixture (50 mL). The aliquots were filtered through a 0.20 µm filter 
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(Whatman) and analyzed by UV/vis. The amount of released SA was calculated using the 
equation previously described.19 Experiments were conducted in duplicate, and the values 
were averaged. The release studies were carried out for 6 h. 
 
2.1.2.3.  CHARACTERIZATION METHODS  
Textural characterization of the materials was based on the analysis of N2 adsorption 
isotherms, measured at -196 °C with a Nova 4200e (Quantachrome Instruments) equipment. 
Room temperature Fourier transform infrared (FTIR) spectra of the samples in KBr pellets 
were measured using a Bomem MB104 spectrometer in the range 4000-500 cm−1 by averaging 
32 scans at a maximum resolution of 8 cm−1.  
The magic-angle spinning nuclear magnetic resonance (MAS NMR) spectra were acquired 
on a Bruker Avance III 400 spectrometer operating at a B0 field of 9.4 T. All experiments were 
performed at room temperature, using a 4 mm double resonance MAS probe and a spinning 
rate of 12 kHz. The 1H and 13C Larmor frequency were 400.1 and 100.6 MHz, respectively. 13C 
chemical shifts are quoted in ppm from TMS and were referenced using glycine (C=O at 176.03 
ppm). 13C cross polarization MAS (CPMAS) spectra were recorded using a contact time of 2.0 
ms with 1H radio-frequency (RF) field strength of 90 kHz (50−100% RAMP-CP shape) and 
62.5 kHz for 13C. The 1H 90° pulse was set to 3.0 μs corresponding to RF field strength of 83 
kHz; a recycle delay of 5 s was employed. TPPM-15 decoupling was employed during the 
signal acquisition using a 6.75 μs pulse length for the basic TPPM pulse unit along the 1H 
channel, employing a 1H RF field strength of 70 kHz.  
1H NMR spectra were obtained on a Varian Unity Plus spectrometer at an operating 
frequency of 300 MHz using the solvent peak as internal reference at 25 °C, chemical shifts of 
protons being given in ppm using δH Me4Si = 0 ppm as reference.  
The release studies were carried out by Shimadzu UV/2501PC spectrophotometer using 
quartz cells at room temperature. The data were collected in the 600−200 nm range.  
The loadings of SA in the samples were determined by thermogravimetric analysis in a STA 
409 PC/4/H Luxx Netzsch thermal analyzer. The atmosphere used was high purity air (99.99% 
minimum purity) with a flow rate of 50 mL min-1. The sample holders used were crucibles of 
aluminum oxide, supplied by Netzsch. The samples were heated between 50 and 700 °C at 
10 °C min-1 to evaluate the thermal stability. 
 
2.1.2.4.  CELL CULTURE CONDITIONS AND CELL VIABILITY ASSAYS  
The human breast cancer cell lines Hs 578T and MDA-MB-468 were obtained from ATCC 
or from collections developed by Dr. Elena Moisseva (Cancer Biomarkers and Prevention 
Group, Departments of Biochemistry and Cancer Studies, University of Leicester, UK), Dr. 






Marc Mareel (Laboratory of Experimental Cancerology, Ghent University Hospital, Belgium), 
and Dr. Eric Lam (Imperial College School of Medicine, Hammersmith Hospital, London, UK). 
Cell lines were routinely cultured in DMEM (Dulbecco’s Modified Eagle Medium, Gibco), 
containing D-glucose (4.5 g L-1) (Invitrogen), supplemented with 10% of fetal bovine serum 
(FBS, Invitrogen) and 1% penicillin−streptomycin (Invitrogen), at 37 °C in a humidified 
atmosphere with 5% CO2. For the cellular viability assays, the DDS were prepared as stock 
suspensions of 1 mg mL-1 in culture medium without FBS. The suspensions dilutions were 
prepared from this stock also in DMEM without FBS, and the suspensions were submitted to 
ultrasonic dispersion for 2 min prior to use. The viability assay cells were plated in 96-well 
plates and allowed to adhere overnight in a complete DMEM medium before incubation with a 
culture medium without FBS containing the different parent materials and the DDS. The effect 
of DDS on total biomass was measured by the Sulforhodamine B assay (TOX-6, Sigma-
Aldrich), after 48 h of treatment, as previously described.18 All conditions were examined for 
statistical significance using Graph Pad Prism 5 Software two-tailed Student’s t test for mean 
comparison, the threshold for significance being P values ≤ 0.05. All assays were performed 
in triplicate at least two times. 
 
2.1.3.  RESULTS AND DISCUSSION 
2.1.3.1.  LOADING AND CHARACTERIZATION OF DDS 
Three different DDS were prepared with NaY (microporous) and MCM-41 and SBA-15 
(mesoporous), and their effects on the viability of two breast cancer cell lines were compared. 
The nitrogen adsorption-desorption isotherms results show the different capacity of the 
parent micro- and mesoporous structures to encapsulate the salicylic acid (SA). The 
equilibrium isotherms measured at -196 °C of NaY (a), MCM-41 (b), and SBA-15 (c) are 
illustrated in Figure 2.1.1. 
Textural properties obtained by N2 adsorption data for both mesoporous structures show 
that the isotherms are of type IV with a hysteresis loop-typical of solids with a mesoporous 
structure according to the IUPAC classification.27 The hysteresis loop is evident in SBA-15. 
The pore condensation typical of mesoporous materials was reflected in the adsorption 
isotherms, which present a characteristic sharp inflection at relative pressures lower than 0.35 
and 0.70 for MCM-41 and SBA-15, respectively. As expect, NaY exhibits a type I isotherm, 
which is typical of solids with a mesoporous structure.18,19 
 




Figure 2.1.1: Nitrogen adsorption-desorption isotherms of NaY (a), MCM-41 (b) and SBA-15 (c). 
 
The micropore volumes (Vmicro) and mesoporous surface areas (Smeso) were calculated by 
the t-method and the BET surface areas (SBET) by the BET equation. The difference calculated 
between the total pore volume for P/P0 = 0.987 (VP) and the micropore volume provide the 
mesopore volume (Vmeso). These values are summarized in Table 2.1.1. 
 
Table 2.1.1: Nitrogen adsorption-desorption isotherms of NaY (a), MCM-41 (b) and SBA-15 (c). 
Structure 
SBET ± 10 
(m2/g) 
Vmicroa ± 0.005 
(cm3/g) 
Sextb ± 5 
(m2/g) 
Vpc ± 0.005 
(cm3/g) 
Vmeso ± 0.005 
(cm3/g) 
NaY 792 0.340 19 0.378 0.038 
MCM-41 669 0 669 0.410 0.410 
SBA-15 494 0.041 399 0.660 0.619 
aMicropore volume obtained by the t-method. bArea different of micropores (area of mesopores + macropores) 
obtained by the t-method. cTotal pore volume for P/P0 = 0.987. 
 
Pore size distributions were obtained using the non-local density functional theory (NLDFT) 
kernel available in the Quantachrome package software developed for N2 adsorption at -196 
°C assuming silica materials with cylindrical pores. The results obtained are presented in 
Figure 2.1.2, where the different pore size distributions of the materials tested are evident: 






micropores with radius below 10 Å, mesopores with radius between 10 and 20 Å and between 
26 and 36 Å for NaY, MCM-41, and SBA-15, respectively. 
 
 
Figure 2.1.2: Pore size distribution obtained by DFT analysis.  
 
The SA was encapsulated into the host structures by adsorption in liquid phase. From our 
experience, the preparation method of the DDS used in this work does not affect the molecular 
integrity of the drug as well as the host structures.16–18 
The presence of SA in the solutions after loading in host structures was confirmed by 1H 
NMR spectroscopy. Data were obtained with the supernatant solution and compared with pure 
SA. The 1H NMR spectra of SA and the residue obtained from supernatant solution were 
recorded at 300 MHz in CDCl3. The carboxylic proton is shifted more downfield than the 
hydroxyl protons, 13.40 and 11.50 ppm, respectively. In the structure of the acid, the peaks of 
the aromatic protons present chemical shifts, H−H coupling constants, and splitting patterns 
as expected: C3−H (6.95, d, 3J = 7.7), C4−H (7.50, t, 3J = 7.5), C5−H (6.91, t, 3J = 7.4), C6−H 
(7.82, d, 3J = 7.7). These proton chemical shifts are the same observed for the SA pure 
molecule.28 1H NMR analysis confirms the integrity of the molecular structure of SA after 
loading in the host structures. 
Thermogravimetric analysis (TGA) was carried out to determine the loading of SA into the 
porous structures. All DDS present the same weight loss profile in the studied temperature 
range. TGA data of pure SA show two distinct weight changes around 170 and 280 °C, 
attributed to the onset of melting followed by decomposition of the SA molecule.19 In the case 
of DDS, the weight change is extended over the entire temperature range up to 700 °C. The 
weight loss up to 150 °C was also observed in all DDS, which can be attributed to the removal 
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of physisorbed water in the structures: 19 weight losses of 24.7, 9.0, and 10.7% are ascribed 
to SA@NaY, SA@MCM-41, and SA@SBA-15, respectively. The TGA curves for the parent 
micro- and mesoporous structures show the same weight loss profile around 120-140 °C. The 
other weight changes observed in DDS were similar to the ones of pure SA with weight losses 
of 50.1, 45.3, and 43.6% to SA@NaY, SA@MCM-41, and SA@SBA-15, respectively. The SA 
loadings calculated from the TGA data are provided in Table 2.1.2. 
 
Table 2.1.2: Loading of SA in the DDS determined by TGA. 
DDS SA (mmol)a SA (mmol)b Yield (%)c 
SA@NaY 2.17 0.74 34.1 
SA@MCM-41 2.17 1.23 56.7 
SA@SBA-15 2.17 1.07 49.3 
aInitial SA amount in the solution. bSA loading in host structure determined by TGA. cEncapsulation efficiency of 
SA in the host structures. 
 
The TGA data indicate that the highest SA loadings are achieved for the mesoporous 
structures, MCM-41, followed by SBA-15. As expected, the mesoporous structures are more 
efficient in the encapsulation of SA than the zeolite NaY. The reason for the difference of the 
loading between the three DDS might be related to the geometry of the porous structures. NaY 
possesses cavities interconnected by small pores (0.73 nm) which can accommodate lower 
amounts of SA molecules. In contrast, MCM-41 and SBA-15 have long cylindrical channels 
with large diameter (∼3 nm for MCM-41 and ∼7 nm for SBA-15 (see Figure 2.1.2)) in which 
small SA molecules can diffuse and accommodate easily. 
IR spectroscopic data display the evidence of the interaction between SA molecules and the 
porous structures. FTIR spectra of SA, DDS, and parent host structures are shown in parts (A) 
NaY, (B) MCM-41, and (C) SBA-15 of Figure 2.1.3. 
Figure 2.1.3c shows the characteristic vibrational modes of the drug molecule. A peak at 
1660 cm−1 is observed for pure SA and is attributed to the carboxyl acid (C=O) vibrational 
mode. Additional bands attributed to (C−C) stretching appear at 1578, 1444, 1325, 1295, 
1155, and 1030 cm−1. Also, a peak observed at 3238 cm−1 is assigned to  (O−H) vibrational 
mode from the hydroxyl group.29 







Figure 2.1.3: FTIR spectra of (a) porous structures, (b) SA@porous, and (c) SA molecule in (A) NaY, (B) MCM-
41, and (C) SBA-15. 
 
FTIR spectra of SA@porous (Figure 2.1.3b) are dominated by the strong bands assigned to 
the vibrational modes arising from the porous structures. In all parent structures, the bands at 
3500 and 1650 cm−1 attributed to the (O−H) stretching and the δ(O−H) deformation vibrations, 
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respectively, were observed and are due to the presence of physisorbed water. In the spectral 
region between 1250 and 500 cm−1, the bands corresponding to the lattice vibrations are 
depicted.17,28,29 In addition to these strong bands caused by the hosts, the FTIR spectra of DDS 
(Figure 2.1.3b) show bands in the 1600−1200 cm−1 region where the porous structures do not 
absorb and are thus attributed to the presence of the encapsulated drug molecule. In this 
region, at 1488, 1447, and 1381 cm−1, weaker bands attributed to SA phenyl group vibrations 
are observed. Furthermore, the principal vibrational bands of the host structures after drug 
encapsulation do no shift or broaden, further substantiating that the porous frameworks remain 
unchanged. The spectra of the DDS display the bands attributed to SA, with slight shifts 
indicating that SA is present and presents host−guest interactions with the porous frameworks. 
Figure 2.1.4 presents the 13C CPMAS NMR spectra of SA, SA@ MCM-41, and SA@SAB-
15. 
The characteristic peaks of the drug molecule with the resonances at δ13C = 175.8 (C7), 
161.9 (C2), 138.2 (C4), 132.8 (C6), 120.9 (C5), 118.1 (C3), and 111.7 ppm (C1) are depicted 
in the 13C NMR spectrum of SA.28 All observed peaks were assigned to the corresponding 13C 
moiety in SA, in accordance with previous studies.28 The peaks ascribed to C4, C6, C5, and 
C3 appear in the same spectral region in all spectra: SA and SA@porous, indicating the 
presence and the integrity of the drug inside the pores of the host. In contrast, the resonances 
due to the carbonyl carbon C7 do not appear in the CPMAS NMR spectra of the encapsulated 
drug systems (SA@MCM-41 and SA@SBA- 15). 
 
 
Figure 2.1.4: 13C CPMAS NMR spectra of SA, SA@MCM-41, and SA@SBA-15. The asterisk denotes the 
presence of CH3 peaks arising from acetone. 






The disappearance of the carbonyl carbon peaks was observed in similar work described 
by Larsen et al.30 These authors attributed the loss of the signal to the high mobility of the 
aspirin molecules in the MCM-41 structure, leading to a decreased efficiency of the CPMAS 
technique due to a decrease in the 13C−1H dipolar coupling.30 The interactions of the SA 
molecule with the host structures were evidenced by the shift observed in the phenyl ring 
carbon peaks for all DDS compared to the SA pure molecule. The differences between the 
spectra of the SA@porous systems and pure SA are attributed to drug interactions with the 
host structures, consistent with the FTIR analysis (see Figure 2.1.3).  
Despite the SA interactions with the parent host structures, the drug can be released out 
from the structures. The in vitro release studies were performed in simulated body fluid at pH 
7.4 and 37 °C to mimic the in vitro conditions of the breast cancer cell viability assays 
performed in this study. According to UV/vis analysis the SA molecule was not degraded. 




Figure 2.1.5: SA release from NaY, MCM-41, and SBA-15 at PBS pH 7.4 medium. 
 
In the first 15 min, there was an initial burst rate with ca. 50% release of SA observed for all 
DDS. As expected, the dissolution rate of SA released from the mesoporous carriers was 
approximately 1.5-1.6-fold faster than the dissolution rate of SA from the microporous carrier. 
The cumulative concentration of SA at typical sampling times of 15, 60, and 120 min were 34, 
51, and 61 μm mL-1 for NaY. Accordingly, the cumulative concentrations were 53, 79, and 90 
μm mL-1 for SBA-15 and 58, 88, and 100 μm mL-1 for MCM-41. The cumulative concentrations 
of SA from all DDS stabilize after 120 min until the end of the dissolution assay (360 min). The 
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total amount of SA released at the end of the assay was 68.4, 97, and 111 μg mL-1 for NaY, 
SBA-15, and MCM-41, respectively. 
The kinetics of the in vitro release of drugs from porous carrier materials is frequently 
described using the zero-order, Higuchi, Korsmeyer-Peppas, and Weibull models.18,31–33 The 
validation of the model to describe the release profile was determined by the best correlation 
coefficient taking into account the conditions of the application of the kinetic models.31 In our 
studies, the Korsmeyer-Peppas model fits the SA from the microporous carrier with R2 = 0.973, 
while the Higuchi model was the best to describe SA release from the mesoporous carriers 
(R2 = 0.944 and 0.940 for SBA-15 and MCM-41, respectively). These kinetic models describe 
the drug release mechanism by a process based on Fickian diffusion.31–33 These results 
indicate a clear influence of the pore size of the carriers on the diffusion behavior of the drug 
molecules. Nevertheless, also the nature of the drug is important when choosing the best 
kinetic model.18 
 
2.1.3.2.  DRUG BIOACTIVITY STUDIES  
The cytotoxicity studies were carried out in two different breast cancer cell lines, Hs 578T 
and MDA-MB-468. The drug bioactivity studies were performed by preparing three working 
DDS concentrations by diluting a stock suspension (1.0 mg mL-1) in culture medium. For better 
homogenization, all suspensions were submitted to ultrasonic dispersion for 2 min prior to use. 
The best results were achieved with 0.025 mg mL-1 of the DDS concentration which has 0.044 
mM of SA (4.4 × 10−5 mmol) for SA@NaY, 0.066 mM of SA (6.6 ×10−5 mmol) for SA@MCM-
41, and 0.079 mM of SA (7.9 × 10−5 mmol) for SA@SBA-15. 
 
 
Figure 2.1.6: Cell viability of breast cancer cell lines was measured by Sulforhodamine B assay after cell 
incubation with 0.025 mg mL-1 concentrations of DDS for 48 h. Values are expressed as mean ± S.E.M of at least 
two independent assays. **p < 0.01, ***p < 0.001 compared to control (0 mg mL-1 of DDS, considered as 100% of 
viability, dashed line). 






The ability of SA released from each DDS to affect cell viability is shown in Figure 2.1.6. 
SBA-15 and MCM-41 as hosts were able to decrease cell viability in both cell lines; however, 
the MDA-MB-468 cell line was more sensitive than Hs 578T, presenting a reduction of 30% 
(SA@SBA-15) and 50% (SA@MCM-41) comparing with the respective control (parent porous 
materials, dashed line). In the Hs 578T cell line the decrease in cell viability was approximately 
35% and 20% for SA@SBA-15 and SA@MCM-41, respectively. The DDS based on NaY 
zeolite did not show any effect on cell viability, remaining similar to the control. The large effect 
demonstrated by the DDS based on SBA-15 and MCM-41 is due to the enhanced ability in 
loading SA and a better encapsulation efficiency (Table 2.1.2). Also, the amount of released 
SA was much higher in these DDS (Figure 2.1.5), which makes them better DDS than NaY, 
presenting better results in the decrease of cell viability. 
Chronic inflammation has been associated with neoplasia, and anti-inflammatory drugs have 
potential as anticancer agents.34 The reduction of breast cancer cell viability by SA 
encapsulated in porous materials highlights their potential to support the activity of anti-
inflammatory drugs in cancer therapy. 
 
2.1.4.  CONCLUSIONS 
The SA molecule was successfully encapsulated into different porous materials and retains 
its molecular integrity. The parent structures after the encapsulation of the drug molecule do 
not show any structural modifications or loss of crystallinity. The mesoporous materials SBA-
15 and MCM-41 proved to be more efficient in loading SA than microporous zeolite NaY. The 
release rate of SA increases with increasing pore size for materials with pore diameters in the 
range 2.5-3.6 nm and follows a Higuchi model to describe the release of SA. The cytotoxicity 
studies show that the selected porous materials are nontoxic with regard to two different breast 
cancer cell lines: Hs 578T and MDA-MB-468. Only the DDS prepared with the mesoporous 
structures revealed a cell viability reduction in both breast cancer cell lines. These results 
indicate the potential of using SA encapsulated in porous structures for drug loading and 
delivery to cancer cells. However, further studies are necessary for a better understanding of 
the drug delivery process. 
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COMPARISON OF DIFFERENT SILICA MICROPOROUS STRUCTURES AS DRUG 
DELIVERY SYSTEMS FOR IN VITRO MODELS OF SOLID TUMORS2 
Several silica microporous structures have been studied for their potential as drug delivery 
systems (DDS) over the last years. However, systematic studies comparing host structures 
with different topologies and particle sizes, and toxicity studies to human cancer cells, are 
scarce. In the present work, 3D crystalline structures, three different zeolites (large, medium 
and small pore size) and one titanosilicate (large pore size) were used as hosts for loading 5-
fluorouracil (5-FU), an anticancer drug currently used to treat several malignant tumors. Here, 
we (i) compared the loading capacity and drug release profiles of the different hosts in 
simulated body fluid conditions, including host structure stability studies; (ii) established the 
kinetic parameters for the release of 5-FU and (iii) studied the effect of 5-FU encapsulation in 
the viability of human breast and colon cancer cells, with determination of the potentiation 
factor. The loading capacity and the release profile of the DDS were revealed to be dependent 
on the porous framework of the host structures. Decrease in pH to 2.0 (simulation of gastro-
intestinal fluid), showed stability of the host structures, with minimal leaching of Al3+ and no Ti4+ 
for long periods of time (up to 72 h). All DDS drug release profiles fitted the Weibull model. 
These silica microporous structures were revealed to be non-toxic to the cancer cells, while all 
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The development and selection of drug delivery systems (DDS) is a yield of vital importance 
in medicine and healthcare. The first commercial DDS was approved by FDA (U.S. Food and 
Drug Administration) in 1990, containing an antifungal drug, amphotericin B, and after that 
more than 10 DDS became commercially available.1  
An ideal DDS is a system that should improve drug bioavailability, prevent its premature 
degradation, also potentiating its effect. Importantly, the systems must maintain drug 
concentrations within their therapeutic window, by controlling the drug release rates, and target 
the pharmacological site at effective concentrations, but with low cytotoxicity.1,2  
In this context, inorganic nanomaterials have a range of structural and physical properties 
that are suitable for therapeutic delivery systems. The sizes, topologies, and surfaces of 
inorganic nanomaterials can be tailored to produce distinct interactions with both in vitro and 
in vivo biological systems.3 In this class of materials, silica-based structures, such as 
microporous crystalline titanosilicates and zeolites, mesoporous silica and amorphous or/and 
crystalline silica particles, are important materials with a wide range of applications. 
Thus, zeolites and titanosilicate materials are porous nanomaterials with many potential 
applications in the biomedical field. There are several examples of zeolite application reported 
in the literature, including for drug delivery4–6 and imaging.7–9 These examples show that 
different zeolite structures can be exchanged with cations, functionalized or loaded with drug 
molecules for specific biomedical applications.10 In the case of the microporous titanosilicate 
materials, recent studies show that these materials have potential as drug carriers, with low 
cytotoxicity.11–13 
The goal of this work is to study the potential of several silica microporous structures as 
hosts for 5-fluorouracil (5-FU) as drug delivery systems for in vitro models of colorectal and 
breast cancers. 5-FU is a pyrimidine analog antimetabolite, with a general spectrum of activity 
against solid tumors, such as breast, colorectal, liver and brain cancer, alone or in combination 
with other chemotherapeutic agents.14–16 Due to its structure, 5-FU interferes with nucleoside 
metabolism and can be incorporated into RNA and DNA, leading to cytotoxicity and tumor cell 
apoptosis, by inhibiting thymidylate synthase.14 There are several limitations to the use of 5-
FU, including its erratic oral bioavailability, with variable gastrointestinal absorption and rapid 
degradation, its short plasma half-life, development of resistance and important cytotoxicity to 
normal cells.15,17,18 Thus, preparation of DDS containing 5-FU could improve its oral 
bioavailability, preventing its premature degradation and decrease its side effects, increasing 
concentrations at the target cell site, with lower cytotoxicity for normal cells. 
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2.2.2.  EXPERIMENTAL  
2.2.2.1.  PREPARATION AND CHARACTERIZATION OF THE SILICA MICROPOROUS 
STRUCTURES AS HOST FOR THE DDS 
Several powder silica microporous structures: three zeolites, FAU (NaY, Si/Al = 2.83, CBV100, 
Zeolyst International); MFI ((NH4)ZSM5, Si/Al = 15.0, CBV 3024E, Zeolyst International) and 
Linde Type A (NaA, Si/Al = 1.24, BCR-705, Sigma-Aldrich), and one titanosilicate, Engelhard 
Titano Silicate (ETS-10) were used as host for preparing DDS with 5-fluoro-1H-pyrimidine-2,4-
dione usually 5-fluorouracil (5-FU, Sigma-Aldrich, 99%). ETS-10 was synthesized according 
to the procedure previously published.19 The pentasil structure was subjected to the treatments 
used before in order to obtain NaZSM5. NaZSM5 was prepared by ion exchange of NH4+ from 
(NH4)ZSM5 by Na+ with NaNO3 solution.20 Briefly, sample was prepared by exchanging 5 g of 
(NH4)ZSM5 with 125 mL (25 mL of solution per g zeolite) of 0.50 M NaNO3 solution in an 
Erlenmeyer flask with a stirrer at room temperature during 24 h. The suspension was separated 
by filtration, washed with deionized water and dried in an oven at 60 °C for 8 h. The same 
procedure was performed with a fresh 0.50 M NaNO3 solution. After the two ion exchange 
treatments, NaZSM5 was dried in an oven at 60 °C for 8 h and calcined at 500 °C during 8 h 
under a dry air stream.  
The morphology and the particle size of the hosts were carried out by scanning electron 
microscopy (SEM) (JOEL JSM-6010LV/Braga). Textural characterization of the hosts was 
based on the analysis of N2 adsorption isotherms, measured at -196 °C with a Nova 4200e 
(Quantachrome Instruments) equipment. 
 
2.2.2.2. DDS PREPARATION  
Before use, all powder silica microporous structures were dehydrated at 120 °C overnight in 
order to remove the water from the pores. All DDS were prepared by the established 
encapsulation method.4,21 So, 5-FU was encapsulated into the host structures by mixing 100 
mg of each host with a solution of 5-FU (130 mg, 0.99 mmol) in acetone (15 mL, Aldrich P.A.) 
as a solvent and was stirred for 48 h at room temperature. The suspensions were filtered off 
and dried in an oven at 60 °C for 24 h. Finally, the resulting DDS were stored in a desiccator. 
The pH of the suspensions was monitored during the DDS preparation. Throughout the 
manuscript, the obtained DDS were identified to as 5-FU@porous where porous represents 
the silica host structure used in DDS. 
The amount of loaded 5-FU was measured using thermogravimetric analysis (TGA) in a STA 
409 PC/4/H Luxx Netzsch thermal analyzer. The atmosphere used was high purity air (99.99% 
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minimum purity) with a low rate of 50 cm3 min-1. The sample holders used were crucibles of 
alumina oxide, supplied by Netzsch. The samples were heated between 50 and 700 °C at 10 
°C min-1 to evaluate the thermal stability. 
 
2.2.2.3.  DRUG RELEASE STUDIES OF 5-FU@POROUS AND STABILITY OF THE HOSTS 
STRUCTURES  
The drug release studies were performed according to the procedure describe elsewhere.4,22 
Briefly, the studies were carried out with 10 mg of DDS mixed in 50 mL of specific solutions in 
order to mimic body fluid conditions (BF) at different pHs and 37 °C: pH 7.4 obtained with a 
solution of Na2HPO4/NaH2PO4; pH 5.8 obtained with a solution of KH2PO4/NaOH and pH 2.0 
with a solution of KCl/HCl. The samples were stirred at ca. 60 rpm and 5 mL aliquots of DDS/BF 
solution were removed at regular intervals and an equal amount of fresh dissolution medium 
was added to keep the volume of the mixture constant (50 mL). Aliquots were filtered through 
a 0.20 µm filter (Whatman). Quantification of the release of 5-FU was carried out by UV/vis 
spectroscopy using a UV/vis Recording Spectrophotometer UV-2501PC from Shimadzu with 
software UVProbe 2.10. From the withdrawn aliquots, 0.5 mL were placed in quartz cuvette 
and added to 2.5 mL of each BF solution and the absorbance of 5-FU was monitored at 260 
nm. From the withdraw aliquots, 0.5 mL of this solution was placed in quartz cuvette and added 
with 2.5 mL of each BF solution and the absorbance of 5-FU was monitored at 260 nm. A 
calibration curve was constructed using solutions of 5-FU with concentrations from 0.0005 to 
0.1000 mg mL-1. The amount of released 5-FU was calculated using the equation previously 
described.4,23 Experiments were conducted in triplicate and the values were averaged. The 
release studies were carried out for 6 h. 
The stability of the host structures was evaluated by FTIR and XRD analyses. In these 
studies, 15 mL of pH 2.0 BF solution was added to 10 mg of NaY or ETS-10 during 72 h under 
stirring at room temperature. The suspensions were filtered off and dried in an oven at 60 °C 
for 24 h and stored in a desiccator. The pH of the suspensions was monitored during the assay. 
Room temperature Fourier Transform Infrared (FTIR) spectra of the parent structures in KBr 
pellets (2/100 mg) were measured using a ABB FTLA2000 spectrometer in the range 4000–
500 cm-1 by averaging 32 scans at a maximum resolution of 8 cm-1. Powder X-ray diffraction 
analysis (XRD) was carried out using a Philips Analytical X-ray model PW1710 BASED 
diffractometer system equipped with a Cu X-ray tube (selected wavelength λCuKa = 1.54056 
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2.2.2.4.  CELL VIABILITY STUDIES  
The cell viability studies were performed with two human colon cancer cell lines and one 
breast cancer cell line. The human breast cancer cell line, MDA-MB-468, was obtained from 
ATCC (American Type Culture Collection). The human colon cancer derived cell lines HCT-15 
and RKO were kindly provided by Dr Raquel Seruca (IPATIMUP, Porto, Portugal). HCT-15 
colon cancer cells were maintained in RPMI 1640 medium (Gibco), RKO colon cancer cells 
and MDA-MB-468 breast cancer cells were maintained in DMEM medium (Gibco). Both cell 
lines were supplemented with 10% (v/v) fetal bovine serum (FBS) (Gibco, Invitrogen, USA) 
and 1% (v/v) penicillin–streptomycin solution (P/S) (Invitrogen, USA) and incubated at 37 °C 
in a 5% CO2 humidified atmosphere. Cells were subcultured approximately every three days 
and maintained in a log-phase growth. 
Cell viability was assessed using the in vitro Toxicology Assay Kit. Sulforhodamine B (SRB) 
based (Sigma-Aldrich, St. Louis, MO, USA). HCT-15 (7500 cells per 100 mL per well), RKO 
(6000 cells per 100 mL per well) and MDA-MB-468 (10 000 cells per 100 mL per well) cells 
were seeded in 96-well plates and incubated at 37 °C in a 5% CO2 humidified atmosphere for 
24 h. In order to assess the effects of the parent structures, 5-FU and DDS used and cells 
were incubated with increasing concentrations of the systems in culture medium. Controls 
were performed with culture medium alone. After an incubation period of 48 h, the spent media 
were removed and the plate wells were washed with 1× phosphate-buffered solution, pH 7.4 
(PBS). After a fixation step with cold 10% trichloroacetic acid (TCA), cells were stained with 
0.4% SRB and the incorporated dye was solubilized with 10 mM of Tris. Absorbance was 
monitored with a microplate reader at 570 nm with a background absorbance of 655 nm. Cell 
viability was determined as percentage of viability: (OD experiment/OD control) × 100 (%). 
One-way ANOVA, followed by Dunnett post-test were used to perform cell viability assay 
statistical analysis. The previous tests and 50% growth inhibition (IC50) were determined using 
the Graphpad Prism 5® software. The level of significance in all the statistical analysis was set 
at ***p < 0.001 compared to host alone. All assays were performed in triplicate from three 
independent experiments. The results were expressed as mean value ± SD of the triplicate 
assays. 
 
2.2.3.  RESULTS AND DISCUSSION 
DDS were prepared using silica microporous structure hosts with different topologies and 
pore sizes, containing aluminum or titanium in the framework. 
The chosen 3D zeolites belong to the FAU (large pores), MFI (medium pores) and LTA 
(small pores) structures.24 ETS-10 is a 3D large pore structure with titanium in the framework.11 
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The hosts NaY (FAU) and NaA (LTA) were commercially available. However, the parent ETS-
10 structure was synthesized and the parent (NH4)ZSM5 (MFI) was modified in order to obtain 
HZSM5 and NaZSM5. The modifications in ZSM5 host were performed to study the pore 
aperture effect in the loading of 5-FU. NaY was already used in a previous publication to 
encapsulate 5-FU and it is used here for comparison with the remaining structures.4 
SEM and nitrogen adsorption analyses were performed for evaluating the average particle 
size and the surface area of the hosts, respectively. Figure 2.2.1 display the SEM micrographs 
of some silica microporous structures. The average of the particle size obeys the following 
sequence, larger particles (>100 nm): NaY 700 nm,4 ZSM5 880 nm, NaA 2700 nm and ETS-
10 with 2600 nm and smaller particles (<100 nm): LTL 80 nm.4 
 
 
Figure 2.2.1: SEM micrographs of (a) ZSM5, (b) ETS-10, (c) NaY e (d) NaA with same resolution. 
 
The nitrogen adsorption measurements show different surface areas for the zeolite hosts. 
The BET surface areas (SBET) was determined by the BET equation and the values obtained 
were: NaY 792 m2 g-1, LTL 566 m2 g-1, ZSM5 395 m2 g-1 and NaA 290 m2 g-1. 
The 5-FU release studies were carried out with all DDS at different pH media simulating 
blood and gastrointestinal body fluids,25 and the stability of the host structure at pH = 2.0 was 
studied with NaY and ETS-10. Besides, cell viability studies were performed on HCT-15 and 
RKO human colon cancer cells for all hosts and DDS. However, the viability on MDA-MB-468 
human breast cancer cell was tested only with the DDS based in NaY, ETS-10 (large pores) 
and compared with NaA (small pores). 
Table 2.2.1 shows the loading of 5-FU in the silica microporous structures obtained by 
thermogravimetric analysis. TGA profile results are similar for all DDS with two weight losses 
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observed; the first weight loss was related to the removal of physisorbed water of the host 
structure and the other one was attributed to the presence of 5-FU in the DDS.4 The presence 
of acetone was not detected by TGA analysis since the temperature used in the preparation 
of the DDS is sufficient to evaporate the solvent.26 It is evident that loading of 5-FU in the DDS 
is related to the porous framework of the hosts. The large pore structures, NaY and ETS-10, 
have higher 5-FU loading capacity than the remaining microporous structures. The medium 
pore structure HZSM5 presents intermediate 5-FU loading and the introduction of sodium in 
(NH4)ZSM5 by ion exchange, enhances a decrease in the loading of 5-FU with 6.8 mmol per 
ghost for NaZSM5, followed by the small pore structure NaA (3D) with 5.8 mmol per ghost. 
 
Table 2.2.1: Loading of 5-FU in DDS 
Host DDS RTheoa RExpa 
5-FU 
(mmol/ghost)b 
NaY 5-FU@NaY 1.30 0.98 7.5 
HZSM5 5-FU@HZSM5 1.30 0.97 7.4 
NaZSM5 5-FU@NaZSM5 1.30 0.89 6.8 
NaA 5-FU@NaA 1.30 0.75 5.8 
ETS-10 5-FU@ETS-10 1.30 0.99 7.6 
aRTheo and RExp. is the ratio of [5-FU]/[host] (wt/wt). b5-FU loading in host determined by TGA. 
 
In order to mimic the in vitro conditions of the cancer cell viability assays, 5-FU release 
studies from the silica microporous structures were performed in culture medium at different 
pH values and 37 °C, by UV/vis analysis. The release was recorded for 360 min, however the 
concentration remained constant after 60 min. 
These studies have been conducted at pH 7.4, 5.8 and 2.0 in order to simulate the blood, 
intestinal and stomach fluids, respectively.25 As expected, 5-FU can be easily released from 
the different microporous hosts due to its small size.4 As an example, the UV/vis spectra of 5-
FU release from 5-FU@NaY (Figure 2.2.2) and the release profiles versus time at pH 7.4 of 
the prepared DDS are shown in Figure 2.2.3. 
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Figure 2.2.2: UV/vis spectra of 5-FU release from 5-FU@NaY up to 60 min. 
 
The results from UV/vis spectra show that, after release from the DDS, 5-FU molecule 
maintain the characteristic wavelength of the drug (λ = 260 nm).27 All DDS release profiles 
show similar behavior, with almost complete release of the adsorbed 5-FU after 40 min, as a 
consequence of the rapid desorption of the drug. 
 
 
Figure 2.2.3: Release profiles of DDS obtained in BF solution at pH = 7.4 and 37 ºC, followed during 60 min. 
Release measurements were conducted in triplicate and the concentration values were averaged. 
 
The cumulative concentrations for all DDS stabilize after this time and display approximately 
the same value until the end of the dissolution assays (360 min). However, some differences 
were observed between ETS-10 and the zeolites. The release of 5-FU appears to be 
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dependent on the 5-FU loading capacity of the host. From the large pore 3D structures, ETS-
10 and NaY display the highest 5-FU release rates due to the higher amount of adsorbed drug, 
being ETS-10 release slightly faster (Table 2.2.1). The DDS based on NaA show the slowest 
rates compared to the large pore structures. The same behavior was observed for HZSM5 and 
NaZSM5, with the last one presenting the lowest release rates due to the introduction of 
sodium in the structure (Figure 2.2.4).  
 
 
Figure 2.2.4: Release profiles of 5-FU@HZSM5 and 5-FU@NaZSM5 obtained in BF solution at pH = 7.4 and 
37 ºC, followed during 60 min. Release measurements were conducted in triplicate and the concentration values 
were averaged. 
 
These results are in line with those reported in the literature, which show that silica materials 
are an important class of controlled release matrices. 
In the work of Larsen et al. the effect of different Si/Al ratio of Y zeolite as hosts for loading 
and release of 5-fluorouracil were studied and they observed a similar behavior.28 Also, the 
DDS based on mesoporous organo-silica nanoparticles with different drugs present the same 
profile of drug release29 and the mesoporous silica material SBA-15 was used to achieve 
immediate release of poorly soluble drug compounds such as itraconazole.30 However, the 
studies stated by Martens et al. show that the release of the antiseptic chlorhexidine, a large 
molecule with antibacterial activity, from amorphous microporous silica was fine-tuned by 
adapting particle size and pore diameter.31 Recently, our group also showed that the release 
of salicylic acid from mesoporous and microporous silica hosts is dependent of the pore size 
of the carriers.26 
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There are several mathematical kinetic models used to describe in vitro drug dissolution and 
drug release from particles.32–34 Weibull, first-order, Higuchi and Korsmeyer–Peppas are some 
of the major applied and best describing drug release models.32–34 The release profiles at pH 
7.4 were fitted to these models and the Weibull model shows the best fitting (Figure 2.2.5). In 
this kinetic model two parameters were determined, the shape (“b”) and scale (“a”) parameters. 
The “b” parameter describe the shape of the dissolution curve and the “a” parameter 
represents the time dependence of the system.32–34 These parameters obtained with this model 
are listed in Table 2.2.2. 
 
 
Figure 2.2.5: Release profiles of a) 5-FU@ETS-10, b) 5-FU@NaY, c) 5-FU@NaZSM5, d) 5-FU@HZSM5, e) 5-
FU@LTL and d) 5-FU@NaA in buffer solution at pH = 7.4 and 37 ºC. Release measurements were conducted in 
triplicate and the concentration values were averaged. The solid points and dotted lines show the Weibull model 
fits to the respective data sets with fit parameters listed in Table 2.2.2. 
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Table 2.2.2: Fitted kinetic parameters for the release of 5-FU from DDS according to the Weibull model 
DDS “b”a “a”a Rb 
5-FU@NaY 0.35 0.08 0.9986 
5-FU@HZSM5 0.21 0.49 0.9996 
5-FU@NaZSM5 0.26 0.65 0.9975 
5-FU@NaA 0.15 0.41 0.9699 
5-FU@ETS-10 0.40 0.16 0.9842 
a”b” is the shape parameter and “a” is the scale parameter of the Weibull model.32 bCorrelation coefficient. 
 
The “b” parameter calculated for all DDS seems to be dependent on the microporous 
structures of the hosts. The large pore structures, NaY and ETS-10, have the highest values 
with 0.35 and 0.40, respectively; followed by the medium pores with similar values and the 
small pores with 0.15. This parameter describes the shape of the curve as exponential (b = 1, 
case 1), sigmoid, S-shaped, (b > 1, case 2), or parabolic, with a higher initial slope and after 
that consistent with the exponential (b < 1, case 3).32–34 The obtained values are in accordance 
to case 3 where the release profiles of all DDS present in Figures 2.2.3 and 2.2.4 show this 
behavior. 
The effect of pH on drug release was also evaluated at pH 5.8 and 2.0. The lower pH medium 
is more likely to affect the stability of the DDS since 5-FU is a weak acid (pKa of 7.93) and the 
pH influences the interaction of the molecule with the surface.27 For these studies, all DDS 
were submitted to these different pH media, and Figure 2.2.6 shows the results obtained for 5-
FU@NaA, as an example. 
As expected from 5-FU structure, even at low pH, the 5-FU molecule is not degraded since, 
we did not observe any shift of the characteristic wavelength of the drug. The results show that 
the variation of pH does not affect the release of 5-FU in the pH range of 2.0 to 7.4. The effect 
of pH was also studied for evaluation of the stability of the host microporous structures since 
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Figure 2.2.6: Release profiles of 5-FU@NaA DDS obtained in different BF solutions at pH = 7.4, 5.8 and 2.0 
and 37 ºC, followed during 60 min. Release measurements were conducted in triplicate and the concentration 
values were averaged. (Inset) UV/vis spectra up to 60 min of the release of 5-FU from the DDS at pH = 2.0. 
 
For this study, the large pore structures NaY and ETS-10 were selected and tested at lower 
pH. Besides, we also aimed to check if there was any leaching of Al3+ from NaY or Ti4+ from 
ETS-10. These hosts were incubated to pH 2.0 BF solution for 72 h under stirring, at room 
temperature. After the filtration and drying steps, the resulting solids were analyzed by FTIR 
and XRD. Figure 2.2.7 displays the FTIR spectra obtained before and after NaY and ETS-10 
treatment, respectively. 
FTIR spectra obtained after treatment for both host structures show the fingerprint bands of 
the parent structures.35,36 Also, the principal vibrational bands of the host structures after 
treatment do not shift or broaden, which confirms that the pore frameworks remain unchanged. 
So, in all FTIR spectra, a very intense broad band at ca. 3500 cm-1 attributed to the hydroxyl 
groups, the (O–H) deformation band at 1650 cm-1 characteristic of the absorbed water and in 
the spectral region between 1250 and 500 cm-1, the bands corresponding to the lattice 
vibrations of the structures are observed.35,36 In the case of NaY zeolite, FTIR analysis allows 
to determine the framework Si/Al ratio using the characteristic band of the zeolite specific 
double ring vibration mode between 570-600 cm-1.37 From both spectra in Figure 2.2.7a, bands 
at 577.1 cm-1 and 577.7 cm-1 for NaY and NaY (pH = 2.0) were identified, respectively. From 
these values, the calculated framework Si/Al ratio was 2.66 for NaY and 2.71 for NaY (pH = 
2.0). The increase in Si/Al ratio observed is related to partial desalumination due to the contact 
of the zeolite structure with the lower pH solution.  
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Figure 2.2.7: FTIR spectra before and after treatment with pH = 2.0 BF solution of (a) NaY and (b) ETS-10, for 
72h. 
 
XRD analysis confirms these results. The powder X-ray diffraction patterns endorses that 
the crystalline structure of NaY or ETS-10 does not change after the treatment. In both XRD 
patterns after treatment, the characteristic Miller peaks corresponding to NaY or ETS-10 were 
observed indicating that the host structures are not severely affected by low pH (pH 2.0). Figure 
2.2.8 displays the XRD patterns of ETS-10 and ETS-10 at pH = 2.0. From Figure 2.2.8, the 
XRD patterns of both samples ETS-10 and ETS-10 (2.0) are similar and in good accordance 
with those reported in the literature.38,39 
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The relative crystallinity was estimated by the intensity of the characteristic diffraction peaks 
of the host structures after treatment, compared to the pattern of the parent structures, which 
was set to be 100% crystalline. The crystallinity obtained was 100% for ETS-10 (pH = 2.0) and 
85% for NaY (pH = 2.0). These results confirm that ETS-10 is not affected by pH 2.0 and NaY 
is slight affected by the treatment, which is in agreement with the FTIR results. 
 
 
Figure 2.2.8: XRD patterns before and after treatment with pH = 2.0 BF solutions of ETS-10 for 72 h. 
 
2.2.3.1.  CELL VIABILITY STUDIES 
Cell viability assays were performed with all parent silica microporous to compare their 
feasibility as host for DDS using different human cell lines, RKO and HCT-15 as colon cancer 
models and MDA-MB-468 as breast cancer model. These cell lines represent important human 
carcinomas and they were chosen as extrapolative models to test the potentiation of the 
chemotherapeutic agent 5-FU when encapsulated in the silica microporous structures. The 
large pore structures, NaY and ETS-10, and the corresponding DDS were used and compared 
with the small pore structure NaA in the viability study with the human cell line MDA-MB-468, 
as breast cancer model. 
The viability assays with microporous structures were optimized in our previous work.26 So, 
from a stock suspension (1.0 mg DDS per mL), sequential dilutions were made with free serum 
culture medium in order to get several working DDS concentrations (0.005 to 0.100 mg mL-1). 
The alterations in cell biomass were evaluated by the sulforhodamine B (SRB) method and 
were assessed after 48 h of incubation with DDS and the parent hosts. 
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The parent hosts did not induce reduction in cell viability in any of the cell lines studied. As 
an example, the ability of 5-FU released from 5-FU@ETS-10 and 5-FU@NaA to affect RKO 
cell viability is shown in Figure 2.2.9. The other DDS cell viability are shown in Figure 2.2.10. 
 
 
Figure 2.2.9: Effect of ETS-10 (a) and NaA (b) hosts and DDS systems on RKO colon carcinoma cell viability. 
RKO cells were incubated with hosts and different DDS concentrations for 48 h. Cell viability was measured by the 
SRB assay. Values are means ± SD of three independent experiments, each performed in triplicate. *p < 0.05, ***p 
< 0.001 compared to host alone. 
 
The hosts titanosilicate (ETS-10) and NaA do not show cytotoxicity to the colorectal cancer 
cell lines studied. The results are in accordance with what we have found for in the DDS 
prepared with different zeolite structures as hosts with the anticancer drugs α-cyano-4-
hydroxycinnamic acid (CHC) and 5-fluorouracil (5-FU), and we also studied their in vitro 
efficacy against colorectal carcinoma cells.4,26,40 These results are also in line with several 
toxicity studies which suggest that the internal surface of zeolites does not interact with the 
biological systems.41 However, the acidic surface characteristics could be also associated with 
some toxicity for specific cells. In fact, we showed that NaY zeolite induces toxicity in 
glioblastoma cells in all range of concentrations studied, but NaMOR zeolite did not show any 
toxicity to these cells. These results confirm that the zeolite toxicity is dependent on the cell 
type and the properties of the carrier structure. Also, in the same study, our results show that 
the DDS prepared with NaMOR are capable of reducing tumor size, using the in vivo chick 
chorioallantoic membrane (CAM) model.21 
From Figure 2.2.9, we can also see that there is an evident reduction in cell viability with 5-
FU containing DDS, compared to ETS-10 or NaA (controls), with increasing concentrations of 
5-FU in both DDS, for RKO cells. 
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Figure 2.2.10: Effect of HZSM5 a) and NaZSM5 b) hosts and DDS systems on RKO colon carcinoma cell 
viability. RKO cells were incubated with hosts and different DDS concentrations for 48 h. Cell viability was measured 
by the SRB assay. Values are means ± SD of three independent experiments, each performed in triplicate. *p < 
0.05, ***p < 0.001 compared to host alone. 
 
Table 2.2.3 shows the IC50 values for RKO and HCT-15 cell viability after treatment with the 
DDS systems, compared with the drug alone. 
 
Table 2.2.3: IC50 values for RKO and HCT-15 cell viability with 5-FU and DDS systems containing 5-FU. 
Cell line RKO HCT-15 
 IC50 (mM) Potentiation IC50 (mM) Potentiation 
5-FU 0.13 - 0.61 - 
5-FU@NaY 0.02 6.5 0.10 6.1 
5-FU@HZSM5 0.02 6.5 0.09 6.8 
5-FU@NaZSM5 0.08 1.6 0.20 3.1 
5-FU@NaA 0.11 1.2 0.11 5.5 
5-FU@ETS-10 0.02 6.5 0.12 5.1 
5-FU@LTLa4 0.03 4.3 0.31 1.9 
aLTL DDS results were from ref.4. 
 
It is clear from the results that there is a potentiation of the 5-FU when is encapsulated into 
the silica microporous structures in both colorectal cancer cell lines. This potentiation is 
dependent on the capacity of 5-FU loading, as well as on the porous framework of the hosts. 
For RKO cells, there is an increase in efficiency of the drug between 1.2 and 6.5-fold. The 
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highest potentiation (6.5-fold) was obtained with the 3D structures, (ETS-10 and NaY, large 
pores) and HZSM5 (medium pores) hosts, which correspond to 5-FU assay concentrations of 
0.02 mM. 
Concerning ZSM5 structure, the reduction in pore aperture in NaZSM5 decreases 5-FU 
potentiation in about 4-fold when compared to 5-FU@HZSM5. The lowest potentiation 
obtained was for NaA host (1.2-fold), which contains 0.11 mM of 5-FU. Likewise, treatment of 
HCT-15 cells with the encapsulated 5-FU resulted in a potentiation of the effect of the drug 
from 3.1 to 6.8-fold, corresponding to 5-FU assay concentrations of 0.20 and 0.09 mM, 
respectively. For this cell line, the 3D structures seem to favor the potentiation of the drug, 
rather than the loading of 5-FU in the hosts. 
The viability assays were also performed on MDA-MB-468 human breast cancer cells with 
the DDS based on NaY and ETS-10 (large pores) and compared with NaA (small pore). In 
addition, these hosts are not toxic for this cell line (Figure 2.2.11) and the DDS based in these 
hosts were very efficient in the decrease of the cell viability (Table 2.2.4). Importantly, inclusion 
of 5-FU in the DDS, increased substantially the sensitivity of the breast cancer cells to 5-FU, 
which are more resistant than the colon cancer cells. 
For MDA-MB-468 cells, the best DDS was obtained with ETS-10 with higher 5-FU loading. 
The potentiation obtained is double compared to the zeolite systems, which display the same 




Figure 2.2.11: Effect of ETS-10 a) and NaA b) hosts and DDS systems on MDA-MB-468 breast carcinoma cell 
viability. MDA-MB-468 cells were incubated with hosts and different DDS concentrations for 48 h. Cell viability was 
measured by the SRB assay. Values are means ± SD of three independent experiments, each performed in 
triplicate. *p < 0.05, ***p < 0.001 compared to host alone. 
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Table 2.2.4: IC50 values for MDA-MB-468 cell viability for 5-FU and DDS systems containing 5-FU. 
Cell line MDA-MB-468 
 IC50 (mM) Potentiation 
5-FU 3.80 - 
5-FU@NaY 0.38 10.0 
5-FU@NaA 0.37 10.2 
5-FU@ETS-10 0.19 19.9 
 
The potential of these host structures will depend on the design and delivery route to be 
used. While smaller particles (<100 nm, LTL zeolite) would be suitable for systemic 
administration, e.g. intra venous or inhalation delivery, larger particles (>100 nm, NaY, NaA 
and ZSM5 zeolites, and ETS-10) will have potential for topical delivery (Figure 2.2.1). Besides 
systemic treatment, 5-FU is also used topically for the treatment of non-melanoma skin cancer 
(e.g. superficial basal cell carcinoma) or even other skin pathological conditions such as actinic 
or solar keratosis.42,43 
 
2.2.4.  CONCLUSIONS 
The hosts selected for this work show potential to be used in the future design and 
development of DDS for biomedical applications. The silica microporous structures were 
selected due to the combination of non-cytotoxic effects to the cells, wide and accessible pore 
expected to be favorable for enhancement of the activity of 5-fuorouracil (5-FU). 5-FU was 
successfully loaded into the host structures and 5-FU loading was found to be highest in 3D 
large pores (NaY and ETS-10) followed by ZSM5 (3D, medium pore) and NaA (3D, small pore). 
All structures are not toxic to the colon and breast cancer cell lines studied and they preserved 
the integrity of 5-FU even at lower pH, before the contact with the cells. Moreover, 5-FU loaded 
into the host structures can be at least six times more effective in colon cancer cell death 
induction than the free 5-FU administered in vitro (5-FU@NaY and 5-FU@HZSM5 systems) 
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5-FU DRUG DELIVERY SYSTEMS BASED ON ZEOLITES FOR CANCER THERAPY: 
IN VITRO AND IN VIVO STUDIES3 
Zeolites have features that make them attractive as carriers for drug delivery systems (DDS). 
Herein, we loaded the anticancer drug 5-fluorouracil (5-FU) into two different zeolite structures, 
faujasite (FAU) and linde type L (LTL), to obtain DDS with different properties. The prepared 
DDS were tested in vitro using breast cancer (Hs 578T), colorectal carcinoma (RKO) and 
melanoma (A375) cell lines and in vivo using the chick embryo chorioallantoic membrane as 
model (CAM), which allows to study angiogenesis, and tumor growth. The results from the in 
vitro assays show that the prepared DDS were able to release the anticancer drug, significantly 
decreasing cell viability in all cell lines. In the in vivo CAM assay, there was a reduction in 
tumor perimeter for Hs 578T cells, while no reduction was detected for RKO tumors. Thus, 
after further optimization of the use of these DDS in vivo, they might prove to be promising in 







                                               
3 N. Vilaça, S. Granja, E. A. Prasetyanto, A. M. Fonseca, L. De Cola, F. Baltazar, I. C. Neves, 5-FU 
drug delivery systems based on zeolites for cancer therapy: in vitro and in vivo studies, submitted. 
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2.3.1.  INTRODUCTION 
Despite the recent advances and improvements in healthcare, cancer incidence has 
increased over the years, being the leading cause of death worldwide.1,2 In 2012, it affected 
8.2 million of people worldwide and it is estimated that in 2030 will lead to more than 13 million 
deaths per year, without discrimination between social economic state, gender or age.3,4 There 
are many factors that can contribute to the high number of new cases of cancer such as, life 
style, genetic predisposition, environmental factors, high-fat diet, smoking, and others.5–9 
In the midst of the different types of cancers,  breast cancer is the second most common 
cancer worldwide, and the most frequent in women10,11 and colorectal cancer is the third most 
common in men and the second in women in the world, with special occurrence in developed 
countries with an estimated 60% of all cases,12,13 In European Union (EU-28), there are 
193.000 new cases of colorectal cancer and 83.000 deaths in men and 152.000 new cases 
and 69.000 deaths in women. In turn, breast cancer had 362.000 new cases and was 
responsible for 92.000 of deaths in 2012.14 Because of that, scientists have been looking for 
new therapies that can reduce these numbers and contribute for a better quality of life of the 
patients.15 One of these strategies are the drug delivery systems (DDS). These systems have 
great advantages, comparing with the traditional routes of administration of drugs, namely, 
protecting normal tissues from the undesirable side effects of the drugs, delivery of the drugs 
on the tumor site, delivering drugs in controlled rates, enhancing the therapeutic index of 
drugs.16–19 
To assess the efficacy and toxicity of DDS, these are tested in in vitro models, since these 
provide a simple, safe and efficient way to evaluate DDS effects.20 However, in vitro models 
do not mimic the complexity of the tumor features, including the tumor environment and, 
sometimes, drugs that seem promising in vitro, fail in vivo.21 Because of that, it is important 
perform in vivo assays that can better simulate the features of the tumor.20 Among the different 
types of in vivo models, the chick embryo is a simple, rapid and low-cost model that allows the 
study of tumor growth, angiogenesis and metastasis. This model is capable to sustain grafted 
tissues and cells without species-specific restrictions since the lymphatic system of the chick 
is only fully developed at the later stages of incubation.22,23 The use of chick embryo as a in 
vivo model, which uses the chorioallantoic membrane (CAM), is a well-known experimental 
model suitable to evaluate the effect of the DDS.24,25 The CAM is a highly vascularized 
extraembryonic membrane, formed in the chicken egg26 by partial fusion of chorion and 
allantois at 3-5 days of embryo development.24,27 It is composed by three layers, the ectoderm, 
mesoderm and endoderm and contains extracellular matrix proteins which mimics the 
physiological cancer cell environment.28 The formed tumor on the CAM is exposed to the drugs 
or carriers to be studied and the perimeter of tumor and angiogenesis can be evaluated.29 




There are many studies using the CAM model to study the effect of drugs and materials on 
tumor development and angiogenesis.26,29–31 In this work, as continuation of your line of 
research, we prepared DDS using two different types of zeolite structures - hydrated 
aluminosilicate materials with a regular framework, which can entrap organic molecules on 
their pores32,33 – with different amounts of 5-fluorouracil (5-FU) a chemotherapeutic drug used 
in the treatment of several solid cancers: head and neck, pancreatic, colon, breast, skin cancer 
(basal cell and keratosis), and others.34 It is possible to find many studies in the literature 
reporting the assessment of in vitro efficacy of zeolites as DDS. However, to the best of our 
knowledge, the evaluation of the efficiency of DDS based in zeolites using in vivo models, is 
scarce.35 Understanding the behavior of these DDS in vivo is essential to improve their efficacy 
and to optimize concentration of these systems for in vivo applications. Hence, in order to 
explore the potential of these DDS for theranostic strategies, we compared the effects of DDS 
in in vitro models using breast, colorectal and melanoma cancer cell lines and in vivo CAM 
model for implanted breast and colorectal microtumors. 
 
2.3.2.  EXPERIMENTAL  
2.3.2.1.  MATERIALS  
All reagents and materials were used without any further purification. Zeolite NaY (CVB100, 
faujasite (FAU) structure) was obtained from Zeolyst International. Zeolite L, (Linde Type L 
(LTL) structure) was synthetized as previously described.36 5-fluorouracil (5-fluoro-1H-
pyrimidine-2,4-dione) was purchased from Sigma-Aldrich. 
 
2.3.2.2.  PREPARATION AND CHARACTERIZATION OF THE DRUG DELIVERY SYSTEMS  
Two different zeolite structures, faujasite, FAU (NaY) and Linde Type L, LTL (Zeo L), 
capable of hosting 5-FU, were used to prepare the DDS. The preparation of the DDS was 
performed previously described, with some modifications.37,38 Prior to the preparation of the 
DDS, the water in the zeolites pores was removed by dehydration at 120 °C during 12 h. 
Afterwards, solutions with different amounts of 5-FU (75 mg (0.577 mmol) designated by I and 
130 mg (0.999 mmol) by II) were dissolved in 10 mL of water, and 200 mg of NaY was added 
and mixed during 48 h at room temperature (RT). For Zeo L, 130 mg (0.999 mmol) of 5-FU 
dissolved in 10 mL of water was added to 200 mg of zeolite and it was also mixed during 48 h 
at RT. After, the solvent was evaporated at 65 °C by agitation 60 rpm, for all procedures. The 
obtained DDS was designated by 5-FU(I)@NaY and 5-FU(II)@NaY, where the subscript number 
refers to the number of moles of 5-FU used to prepare the DDS, 0.577 and 0.999 mmol, 
respectively, and 5-FU@Zeo L for the DDS prepared with zeolite LTL. 
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The prepared DDS were characterized by thermogravimetric analysis (TGA) and Fourier 
transform infrared (FTIR). TGA was performed to calculate the amount of drug loaded into the 
zeolitic structure. The conditions of the TGA analysis were described in.38 FTIR was carried 
out using 2 mg of sample mixed with 98 mg of KBr and the obtained pellets were measured 
with a AFT spectrometer between 4000-500 cm-1 by averaging 32 scans at a resolution of 4 
cm-1. 
 
2.3.2.3.  CELL LINES AND GROWTH CONDITIONS  
For the in vitro cellular viability assays three different model cell lines were used: Hs 578T 
of breast cancer, RKO of colorectal cancer and A375 of melanoma. Hs 578T cells and A375 
cells were obtained from ATCC and RKO was kindly provided by Dr. Raquel Seruca 
(IPATIMUP, Porto, Portugal). The three cell lines were maintained at 37 °C in 5% CO2 in DMEM 
medium (Gibco), supplemented with 10% fetal bovine serum (FBS) (Gibco, Invitrogen, USA) 
and 1% (v/v) penicillin–streptomycin solution (P/S) (Invitrogen, USA). 
 
2.3.2.4.  IN VITRO CELL VIABILITY ASSAYS 
Cell viability assays were performed as described before.37,38 Fleetingly, cells where plated 
in 96-well plates at density of 7000 cells per well for Hs 578T, 6000 cells per well for RKO and 
10000 cells per well for A375 and were left to adhere overnight. Stock suspensions of DDS 
and parent zeolites of 0.5 mg mL-1 were prepared in DMEM without FBS. From stock 
suspensions, diluted suspensions from 0.025 to 0.100 mg mL-1 were prepared, once again 
with DMEM without FBS. The resulting suspensions were sonicated for 2 min to avoid 
aggregates and get a better homogenization. Subsequently, the cell medium was removed 
from the wells and the cells were treated with the increasing solutions of DDS or zeolite for 48 
h. After this time, cell viability was quantified using the sulforhodamine B (SRB) assay37 and 
the obtained results were expressed as mean ± SD viable cells, comparing to the conditions 
with the parent zeolite. 
For IC50 determination cells were plated as described above, and the incubated with culture 
medium containing 0.01 - 10 mM of 5-FU for 48h. The effect of 5-FU was also measured by 
SRB assay. The IC50 values were calculated with Graphpad Prism 6® software, using a 









2.3.2.5.  CHICK CHORIOALLANTOIC MEMBRANE (CAM)  ASSAY  
This assay was performed to test the effect of the DDS in vivo on the tumor growth and 
angiogenesis. For this purpose, eggs were incubated at 37 °C (day 0), then, on day 3 of chick 
embryo development, a small window was made in the shell of the egg to detach the CAM 
membrane from the egg shell and eggs were incubated again at 37 °C. On day 9 of chick 
embryo development, 1×106 Hs 578T breast cancer cells and RKO colorectal cells were mixed 
with 10 µL of Matrigel to form a gel and graft the cells on top of the CAM, and incubated again 
at 37 °C. On day 13 of chick embryo development, the windows on the shell were opened and 
the formed tumor photographed in ovo, then 20 µL of the materials suspensions (0.5 mg mL-
1) to be tested were placed over the tumor and the shell window closed again. On 17 day of 
development, the eggs were opened and the tumors were photographed (in ovo). After that, 
the chick embryos were sacrificed at -80 °C for 10 min and the CAM membrane was removed 
from the egg and photographed (ex ovo). Tumors perimeters were measured using ImageJ at 
day 13 (corresponding day 0) and 17 (corresponding day 4). The results were expressed as 
mean perimeter ± SD of tumor growth for each group.  
The percentage of blood vessels density was measured in ImageJ using vessel analysis 
plugin.  
 
2.3.2.6.  IMMUNOHISTOCHEMISTRY  
The CAMs collected from the eggs were fixed in formalin and embedded in paraffin. The 
paraffin blocks were cut into thin sections from immunohistochemistry was performed for Ki-
67 (clone MIB-1, DAKO AP10243CM). Slides containing the paraffin sections of tumors, were 
deparaffinized and rehydrated and heat-induced for the antigen retrieval using a microwave 
oven during 15 min with 10 mM citrate buffer at pH 6.0. Endogenous peroxidases were 
inactivated using a 3% solution of hydrogen peroxide and UVblock (LabVision, Thermo 
Scientific) was added to the slides and incubated for 10 min. Incubation with the primary 
antibody (dilution 1:200) was done during 2 h at RT. After that, slides were washed twice with 
PBS for 5 min each and the secondary antibody (kit LabVision, Thermo Scientific) was 
incubated for 10 min at RT, and the slides washed again with PBS. Then, streptavidine 
peroxidase (kit LabVision, Thermo Scientific) was added for 10 min (RT), washed, and slides 
were incubated with the chromogen 3,3’-diamonobenzidine (DAB and Substrate System, 
Dako) for 10 min to allow the visualization of the immune reaction. After washing with PBS and 
water, the slides were counterstained with hematoxylin and analyzed under the light 
microscope. Cells presenting brown nuclear labeling were considered positive for Ki67 
staining. For Ki67 quantification tumor slides were observed under microscope (Olympus 
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BX61), and the areas stained for ki67 were photographed at 20× objective in five different 
fields. Then, negative and positive cells for Ki67 staining were counted and the percentage of 
Ki67 positive cells calculated based on the obtained data using the formula: (Ki67 positive 
cells/(Ki67 positive cells+Ki67 negative cells))×100.40,41  
 
2.3.2.7.  STATISTICAL ANALYSIS  
Differences between the in vitro cell viability assay results and the differences between Ki67 
positive cells and blood vessel density were analysed by one-way ANOVA, followed by 
Dunnett’s test. The differences between tumor perimeters, were assessed by two-way ANOVA 
with Sidak’s post-test. All results were analysed using GraphPad Prism 6® and are expressed 
as mean ± standard deviation (SD). Differences were considered statistically significant for *p 
< 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. 
 
2.3.3.  RESULTS AND DISCUSSION 
2.3.3.1.  PREPARATION AND CHARACTERIZATION OF DDS 
Preparation of DDS based on zeolite structures NaY and LTL for delivery 5-FU was based 
in our previous stablished protocols,32,37 using water as solvent in this work. The main 
advantage of this approach is related to the fact of water being non-toxic to cells and if some 
solvent stays entrapped into zeolite structures, it is guaranteed that the solvent will not cause 
toxicity to cells. 
The prepared DDS were characterized by means of FTIR and TGA (Figure 2.3.1). FTIR was 
used to prove the molecular interactions of 5-FU with the zeolite structures, the results are 
shown in Figure 2.3.1A and 2.3.1B. The spectra of Zeo L (Figure 2.3.1A-c) and NaY (Figure 
2.3.1B-d) show the characteristic framework bands of some groups such as: 3410 cm-1 for O-
H bond, between 1300-900 cm-1 for the asymmetric T-O-T stretching vibration, where T is Si 
or Al and at around 719 cm-1 related to the surface aluminium species, which are in according 
to the literature.42,43 The spectrum corresponding to the 5-fluorouracil, show bands at 2750-
3200 cm-1 characteristic of C-H and N-H bonds, a band for the imide at 1722 cm-1 assigned to 
the C double O bond, another one at 1374 cm-1 for C-N bond, and a peak at 1254 cm-1 related 
with the C-F stretching vibrations, according to the literature.44 Regarding the DDS spectra 
prepared with zeolite L (Figure 2.3.1A-b) and prepared with zeolite NaY (Figures 2.3.1B-b and 
2.3.1B-c), it is possible to observe the bands characteristic of the groups corresponding to both 
5-FU and zeolites. So, characteristics bands of O-H and Si-O-Si groups of the zeolites at 3410 
cm-1 and 1300-900 cm-1 respectively, are detected simultaneously. New bands at 3300-2800 
cm-1 for the C-H and N-H bonds, at 1731 cm-1 for the C=O and at 1259-1253 cm-1 for the C-F 




are observed. These bands are not observed in the zeolite spectra and they are characteristic 
of the 5-FU spectrum, confirming the presence of 5-FU on DDS which once again is in line 
with the literature.44 
Loading of 5-FU into the zeolites was determined by thermogravimetric analysis (TGA) 
(Figure 2.3.1C and Table 2.3.1). From the 5-FU TGA curve (Figure 2.3.1C-a), it can be seen 
that the drug molecule melts around 200 - 300 ºC and decomposes totally around 300 - 400 
ºC. The TGA curves for the zeolites (Figure 2.3.1C-c for Zeo L and 2.3.1C-f for NaY) shows 
weight loss around 50 - 150 ºC, which can be attributed to the removal of water from the zeolite. 
TGA curves for the DDS (Figure 2.3.1C-b for DDS prepared with Zeo L and Figures 2.3.1C-d 
and 2.3.1C-e for DDS prepared with NaY) show weight changes corresponding to the 5-FU 
and the zeolites, which are in accordance with Larsen et al.45  
As expected, DDS prepared with NaY obtained the highest loading of 5-FU (Table 2.3.1). 
For this zeolite, the loading of 5-FU was 0.46 mmol and 0.55 mmol for 5-FU(I)@NaY and 5-
FU(II)@NaY, respectively. From these results, it is also possible to verify that Zeo L has lower 
loading capacity than zeolite NaY. This can be related with structural features of the zeolites, 
Zeo L present mono-dimensional nanochannels and NaY have a tridimensional structure and 
facilitate the introduction of 5-FU in its channels.32,46  
 
 
Figure 2.3.1: DDS characterization: A) FTIR spectra of DDS prepared with zeolite LTL: a: 5-FU, b: 5-FU@Zeo 
L and c: Zeo L. B) FTIR spectra of DDS prepared with zeolite NaY: a: 5-FU, b: 5-FU(II)@NaY, c: 5-FU(I)@NaY and 
d: NaY. C) TGA curves of a: 5-FU, b: 5-FU@Zeo L, c: Zeo L, d: 5-FU(II)@NaY e: 5-FU(I)@NaY, and f: NaY.  
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Table 2.3.1: Loading of 5-FU in the DDS determined by TGA 
DDS 5-FU (mmoles)a 5-FU (mmoles)b 
5-FU(I)@NaY 0.58 0.46 
5-FU(II)@NaY 1.00 0.55 
5-FU@ Zeo L 1.00 0.42 
aInitial amount of 5-FU in the solution. b5-FU loading in zeolite structures determined by TGA. 
 
2.3.3.2  ASSESSMENT OF DRUG BIOACTIVITY  
Breast and colorectal cancer are the most common types of cancer worldwide.10,47 Despite 
of all advances in their treatment, they continue to cause high number of deaths every year. 
Because of that, it is important to look for new therapeutic approaches. In the current study, 
DDS based on zeolites were prepared to convey the chemotherapeutic agent 5-FU in different 
types of cancer models. In our previous work, we already reported the efficacy of DDS based 
on zeolite in colon, glioma and breast cancer.35,37,38 However, in the present study we 
performed various experiments in order to give further insights into the therapeutic effect of 5-
FU@zeolite on colorectal, breast and melanoma cancer in vitro and, importantly, the 
therapeutic effect on colorectal and breast cancer in vivo using the CAM model. 
Firstly, DDS were tested in vitro using for this purpose colorectal, breast and melanoma 
cancer cells. Then, in vivo studies using CAM model were carried out to determine whether 
the DDS are also effective in the reduction of 3D tumor size. Below we demonstrated our 
findings from these studies. 
 
Evaluation of DDS efficacy in vitro 
The main focus of this work was to evaluate the in vitro and in vivo efficacy of these DDS on 
breast and colorectal cancer.  
The in vitro cytotoxicity of NaY, 5-FU(I)@NaY, 5-FU(II)@NaY, Zeo L and 5-FU@Zeo L was 
assessed on breast (Hs 578T), colorectal (RKO) and melanoma (A375) cancer cells. Hs 578T 
cell line was chosen as a model of breast cancer which is representative of a triple-negative 
breast cancer (TNBC),11,48,49 RKO cells were chosen as model of colorectal cancer and A375 
was used as model of melanoma (skin cancer). 5-FU was chosen due its efficiency in the 
treatment of different types of cancers.50,51 
The effect of the parent zeolites and respective DDS on Hs 578T, RKO and A375 cell lines 
is shown in Figure 2.3.2. We exposed cells to parent zeolites and DDS in the range of 0.025 - 




0.100 mg mL-1 of concentrations. The incubation time was 48 h based on our previous studies 
showing that the highest reduction in cell viability was achieved at this time. The results 
demonstrated that NaY and Zeo L were nontoxic to any of the cell lines even for the highest 
tested concentrations. From our previous study, we know that the morphology and size of 
zeolite nanoparticles might play an important role in cell internalization. We showed that Zeo 
L (400 nm) is internalized faster than NaY (700 nm) by breast cancer cells.36 Sahu et al. 
demonstrated that SiO2 nanoparticles induced more toxicity than micron particles on L-132 
cells,52 as well as, Kihara et al. reported that nanozeolites with different sizes have different 
toxicity on HeLa cells.53 They also, reported that LTL zeolites (50 nm and 90 nm) were toxic 
for HeLa cells from 50 µg mL-1.53 However, our results demonstrate that there was no direct 
relation between the size of zeolite nanoparticles and their cytotoxicity, since both zeolites 
were nontoxic to the cells even in the highest concentrations tested. These results are in 
accordance to the reports by Deng and coworkers, where it was demonstrated that zinc oxide 
particles had the same toxicity on neural stem cell (NSC) independently of the size.54 Similar 
cytotoxicity of NaY and Zeo L observed in this work, might be related with the different cell 
lines used, which corroborate the premise that the cytotoxicity of the nanoparticles is 
dependent of the cell type where they are tested.55 Grund et al. have found that mitoxantrone-
loaded zeolite beta nanoparticles exhibit different cytotoxic activities depending the cell type 
and concentration.56 
The results of our study, demonstrate that treatment of the cells with all DDS resulted in a 
significant reduction of cell viability in a concentration-dependent manner (p < 0.05), compared 
to the parent zeolites (control group), with exception for 5-FU@Zeo L in Hs 578T cells at the 
lowest concentration (0.025 mg mL-1) (Figure 2.3.2). 5-FU(I)@NaY reduced Hs 578T cell 
viability in 10.5%, 61% for RKO and 76% for A375 cells in the highest DDS concentration 
(0.100 mg mL-1), compared to the same concentration of NaY. The highest concentration of 5-
FU(II)@NaY decreased cell viability in 16.6% for Hs 578T cells, 68.3% for RKO cells and 83.3% 
for A375 cells. In turn, 5-FU@Zeo L, reduced cell viability in 21% for Hs 578T cells, 75.4% for 
RKO cells and 70.1% for A375 cells. Also, at lower concentrations, a decrease in cell viability 
for all cell lines and all tested DDS was observed. Despite the inhibition of cell growth in all cell 
lines, it is clear that this inhibition is cell type-dependent since higher reduction is observed in 
RKO and A375 cell lines, than Hs 578T, denoting once again the importance of the cell type. 
 




Figure 2.3.2: Effect of Zeo L and 5-FU@Zeo L (a) and NaY and 5-FU(I)@NaY and 5-FU(II)@NaY (b) on Hs 578T 
breast cancer, RKO colon carcinoma and A375 melanoma cell viability. Cells were incubated with zeolites and 
different DDS concentrations for 48 h. Cell viability was measured by the SRB assay. Values are means ± SD of at 
least three independent experiments, each performed in triplicate. *p < 0.05, ***p < 0.001 and ****p < 0.0001 









The concentrations of 5-FU (mM) present in DDS suspensions used in in vitro drug 
bioactivity studies are shown in Table 2.3.2 and the IC50 values (for cell viability) for 5-FU and 
DDS are demonstrated in Table 2.3.3.  
 
Table 2.3.2: Final concentrations of 5-FU (mM) in the different DDS suspensions. 
 
The IC50 values for 5-FU(I)@NaY in Hs 578T cells are 5.55 mM, 0.05 mM for RKO and 0.09 
mM for A375, and for 5-FU(II)@NaY are 0.66 mM for Hs 578T, 0.06 mM for RKO and 0.08 mM 
for A375. The IC50 values of 5-FU@Zeo L are 1.99 mM for Hs 578T, 0.02 mM for RKO and 
0.09 mM for A375. Bearing in mind the 5-FU concentration in each DDS (Table 2.3.2) and 
comparing the IC50 values of free 5-FU with the DDS, a potentiation of 5-FU is observed when 
loaded into zeolite structures (Table 2.3.3). Despite the apparent lower effect of the DDS on 
Hs 578T cells, displaying higher IC50, the sensitivity of these cells to free 5-FU is much lower 
than for the other cells. Thus, the resulting potentiation is actually higher for Hs 578T cells than 
for RKO and A375. Data from literature demonstrate that the encapsulation of 5-FU into 
nanoparticles is a good approach to improve its efficacy and reduce toxicity.57–59 The presented 
results indicate that the prepared DDS have inhibitory effect on the tested cell lines and have 
a higher effect than the free 5-FU, thus demonstrating the potential of these systems for cancer 









DDS (mg mL-1) 0.500 (stock) 0.025 0.050 0.075 0.100 
5-FU(I)@NaY 
(mM 5-FU) 
0.88 0.04 0.09 0.13 0.18 
5-FU(II)@NaY 
(mM 5-FU) 
1.02 0.05 0.10 0.15 0.20 
5-FU@ Zeo L 
(mM 5-FU) 
0.83 0.04 0.08 0.12 0.17 
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Table 2.3.3: Viability IC50 values for 5-FU and DDS for Hs 578T, RKO and A375 cell lines. *For the calculation 
of 5-FU potentiation in Hs 578T cell line, was considered 10 mM as value of IC50 of free 5-FU. 
 
In vivo anti-tumor activity 
From the in vitro results, exposure to DDS appears to affect cell viability significantly. Thus, 
we evaluated the potential of these DDS in vivo using the chicken CAM assay. CAM is a simple 
and cost-effective model that allows the fast development of tumors when compared to 
mammal models.24 Several authors have been using this model for in vivo studies. Özcetin et 
al.26 used the CAM model to study the antiangiogenic effects of imatinib a tyrosine kinase 
inhibitor used in the treatment of myeloid leukemia60  while Katrancioglu et al.30 studied the 
antiangiogenic effects of an levosimendan, an inodilator used for the treatment of severe 
chronic heart failure.61 Also, the angiogenic and inflammatory effect of biomaterials was 
demonstrated by Valdes et al. and Zwadlo-Klarwasser et al. using CAM model.29,31 
In vivo CAM experiments were carried out using Hs 578T and RKO cells. At day 9 of embryo 
development, cells were mixed with Matrigel and placed onto the CAM membrane. After four 
days, the formed tumors were treated with 0.5 mg mL-1 suspensions of DDS and respective 
parent zeolites. Four days later, the effect of the materials on tumor growth was assessed. 
It was verified by Breslin et al. that the efficacy of docetaxel was reduced in 3D compared to 
2D cultures.62 Taking this finding in account, in our studies, we used higher concentrations of 
DDS for in vivo studies, since the in vivo drug response was expected to be different from the 
in vitro studies. It is known that the toxicity of the systems tested in the CAM could be evaluated 
in terms of embryo viability, inflammation and neovascularization of the CAM.63 Thus, from our 
observations during the time of the assay, it was possible to infer that the concentrations used 
were nontoxic to the chick embryos, as almost all of them were alive until the end of the 
treatment and no inflammation was observed in the CAM (Figures 2.3.3 to 2.3.6). 
Hs 578T cells formed smaller tumors than RKO cells, as can be observed in Figures 2.3.3 
and 2.3.4 for Hs 578T, and Figures 2.3.5 and 2.3.6 for RKO. The mean perimeter of Hs 578T 
tumors at day 0 (13-day-old of embryo) and day 4 (17-day-old of embryo) show differences 
between control, parent zeolites and DDS (Figures 2.3.3B and 2.3.4B). From Figures 2.3.3B 











5-FU > 10 - 0.13 - 0.17 - 
5-FU(I)@NaY 5.55 1.8 0.05 2.6 0.09 1.9 
5-FU(II)@NaY 0.60 16.7 0.06 2.2 0.08 2.1 
5-FU@Zeo L 1.99 5.0 0.02 6.5 0.09 1.9 




and 2.3.4B, as expected, is was observed that untreated tumors (control (CTR) and zeolite 
conditions) have grown between day 0 and day 4. In the case of the tumors treated with DDS, 
a difference was observed in the mean perimeter between day 0 and day 4, presenting a 
decrease in the mean tumor perimeter at day 4, however this difference is not significant when 
compared with control (p > 0.05).  
 
 
Figure 2.3.3: In vivo effect of NaY and DDS in Hs 578T tumor growth and angiogenesis. A) Representative 
photos of CAM assay in ovo (10× magnification) and ex ovo (10× magnification) at days 13 and 17 of development. 
B) Tumor perimeter at different conditions. The results are expressed as mean ± SD of tumor perimeter in day 0 
(13 days of development) of treatment and in day 4 (17 days of development) of treatment with zeolite and DDS 
(0.5 mg mL-1) (NaY group n=9, 5-FU(I)@NaY n=12, 5-FU(II)@NaY n=11) C) Blood vessel density around the tumors 
counted ex ovo using ImageJ. *p < 0.05 and ** p< 0.01. D) Representative pictures (400× magnification) of 
immunohistochemical analysis of Ki67 expression in tumors. E) Percentage of Ki67 positive cells of control 
compared with zeolite and DDS; data are the mean ± SD. *p < 0.01, ****p < 0.0001. 
 




Figure 2.3.4: In vivo effect of Zeo L and DDS in Hs 578T tumor growth and angiogenesis. A) Representative 
photos of CAM assay in ovo (10× magnification) and ex ovo (10× magnification) at days 13 and 17 of development. 
B) Tumor perimeter at different conditions. The results are expressed as mean ± SD of tumor perimeter in day 0 
(13 days of development) of treatment and in day 4 (17 days of development) of treatment with zeolite and DDS 
(0.5 mg mL-1) (Zeo L group n=11, and 5-FU@Zeo L group n=10). C) Blood vessel density around the tumors 
counted ex ovo using ImageJ. *p < 0.05 and **p < 0.01. D) Representative pictures (400× magnification) of 
immunohistochemical analysis of Ki67 expression in tumors. E) Percentage of Ki67 positive cells of control 
compared with DDS; data are expressed as mean ± SD. ***p < 0.001.  
 
In the case of RKO cells (Figures 2.3.5 and 2.3.6), the mean perimeter at day 0 is in the 
range of 12.8-14.1 mm and at day 4 is in the range of 14.7-16.9 mm (Figures 2.3.5B and 
2.3.6B). For this cell line, there was no apparent reduction in the tumor perimeter after 
treatment with DDS, even there is an increase in tumor perimeter in some of the conditions 
between day 0 to day 4 (Figures 2.3.5B and 2.3.6B). From these results, it is observed that 
there is some effect of the DDS on tumor perimeter only for Hs 578T cells, despite the small 
reduction observed. 
Regarding the blood vessel density in Hs 578T tumors compared with control (Figures 
2.3.3C and 2.3.4C), there is a significant decrease for both NaY and 5-FU(I)@NaY compared 




to control (untreated). In turn, for in RKO tumors (Figure 2.3.5C and 2.3.6C), there was no 
significant reduction in the density of blood vessels sorrounding the formed tumors upon 
exposure to the DDS. 
Bearing in mind the in vitro results, it was expected that the DDS would have some effect in 
in vivo tumor growth since there was a significant effect on cell viability in vitro. It is known, 
that in vitro assays are substantially different from the in vivo assays since 2D cell culture does 
not mimic the 3D tumor characteristics in a perfect way, such the interaction with stromal cells 
and vasculature.64 This could explain the differences found between in vitro and in vivo results. 
Ki67 is a cell proliferation marker that indicates the proliferation level of a tumor and its 
sensitivity to certain treatments.65 The results of the immunohistochemical analysis of Ki67 
expression could also explain the different findings for in vitro and in vivo results (Figures 
2.3.3D-E to 2.3.6D-E). Hs 578T cells have a low percentage of Ki67 positive cells, presenting 
36.4% in the NaY control group (n=10), 27.8% in 5-FU(I)@NaY group (n=11), 15.9% in 5-
FU(II)@NaY group (n=10), 32.2% in Zeo L control group (n=9) and 26.2% in 5-FU@Zeo L group 
(n=18) (Figures 2.3.3E and 2.3.4E). Comparing with control (only cells), treatment of the tumor 
with the DDS seems to not result in a significant reduction of Ki67 positive cells. However, 
when Ki67 positive cells were compared with the zeolite group, a significant reduction was 
observed (ANOVA, p < 0.01 for 5-FU(I)@NaY and p < 0.0001 for 5-FU(II)@NaY), demonstrating 
the effect of these DDS on the tumor cell proliferation. On the other hand, treatment with 5-
FU@Zeo L did not produce a significant reduction when compared with zeolite group (t-test, p 
> 0.05). The reduction in Ki67 positive cells between zeolite groups and DDS groups could 
explain the slight differences between the perimeter of Hs 578T tumors at day 0 and day 4 of 
treatment. 
In turn, RKO cells present higher percentage of Ki67 positive cells even in the groups treated 
with DDS: 73.7% in NaY control group (n=20), 79.3% in 5-FU(I)@NaY group (n=17), 66.4% in 
5-FU(II)@NaY group (n=18), 59.0% in Zeo L control group (n=20) and 63.4% in 5-FU@Zeo L 
group (n=15) (Figure 2.3.5E and 2.3.6E). Here, there was no reduction observed in the tumor 
perimeter (Figure 2.3.5B and 2.3.6B). Thus, the results show that RKO cells have higher 
proliferative activity than Hs 578T cells, with higher Ki67 index. The higher proliferative activity 
of RKO cells resulted in larger, and probably more dense tumors which might explain the lower 
response of these tumors to the treatment with DDS. Au et al. showed in their work that the 
penetration of drugs such as paclitaxel and doxorubicin in tumors, is dependent of the drug 
concentration and cell density, being higher in tumor with low cell density.66 
 
 




Figure 2.3.5: In vivo effect of NaY and DDS in RKO tumor growth and angiogenesis. A) Representative photos 
of CAM assay in ovo (10× magnification) and ex ovo (10× magnification) at days 13 and 17 of development. B) 
Tumor perimeter at different conditions. The results are expressed as mean ± SD of tumor perimeter in day 0 (13 
days of development) of treatment and in day 4 (17 days of development) of treatment with zeolites and DDS (0.5 
mg/mL) (CTR n=11, NaY n=10, 5-FU(I)@NaY n=10, 5-FU(II)@NaY n=13). C) Blood vessel density around the tumors 
counted ex ovo using ImageJ. *p < 0.05 and **p < 0.01. D) Representative pictures (400× magnification) of 
immunohistochemical analysis of Ki67 expression in tumors. E) Percentage of Ki67 positive cells of control 












Figure 2.3.6: In vivo effect of Zeo L and DDS in RKO tumor growth and angiogenesis. A) Representative photos 
of CAM assay in ovo (10× magnification) and ex ovo (10× magnification) at days 13 and 17 of development. B) 
Tumor perimeter at different conditions. The results are expressed as mean ± SD of tumor perimeter in day 0 (13 
days of development) of treatment and in day 4 (17 days of development) of treatment with zeolites and DDS (0.5 
mg mL-1) (CTR n=11, Zeo L n=11, and 5-FU@Zeo L group n=9). C) Blood vessel density around the tumors counted 
ex ovo using ImageJ. D) Representative pictures (400× magnification) of immunohistochemical analysis of Ki67 
expression in tumors. E) Percentage of Ki67 positive cells of control compared with DDS. Data are expressed as 
mean ± SD. *p < 0.05 and **p < 0.01. ***p < 0.001.  
 
The in vivo results are not totally in accordance with the in vitro results, since the effect of 
the DDS on cell viability in vitro was not confirmed in the in vivo model. In vitro studies 
demonstrated higher reduction in cell viability in RKO cells than in Hs 578T cells. However, in 
the in vivo studies some effect of the DDS on Hs 578T tumors was observed, but no effect in 
RKO tumors. This supports the knowledge that in vivo and in vitro systems are different and 
sometimes the results obtained in in vitro experiments are not confirmed in vivo.21 It is known 
that cell cultures do not mimic the biological environment and in vivo tumors are more resistant 
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to drugs than 2D cell cultures, with drug diffusion being around 5- to 10-fold faster in cell 
cultures than in solid tumors.66–68 For example, in the work of Sayes et al. on silica toxicity in 
vitro and in vivo, demonstrated that the toxicity of silica is different in vitro and in vivo.69 The 
extracellular matrix (ECM) present in in vivo tumors supports cancer cells and affects cellular 
functions, being involved in the tumor cell response to different stimuli.68 The presence of ECM 
in 3D tumors could influence the effect of drug treatment since it can prevent the diffusion of 
the drug into cancer cells.70 The lack of effect of DDS in RKO tumors in the CAM model could 
be due to the tumor microenvironment and by preventing the capacity of DDS to penetrate 
deeper into the tumors. It might also be related with the tested concentrations, zeolite structure 
and cell line used. In a previous study from our group, the effect of DDS based on NaMOR 
zeolite structure was assessed in glioblastoma cells and the results showed a reduction in 
tumor size.35 In the study here reported, were NaY and LTL were used in colorectal and breast 
cancer cells, which could explain the different results. Thus, results show that the cell type and 
zeolitic structure influence the effect of the DDS in vivo. Thus, the in vivo experiments require 
optimization to ensure that the DDS is able to penetrate the tumor mass. 
 
2.3.4.  CONCLUSIONS 
In this work, we confirmed that zeolite structures are good carriers for DDS. The obtained 
DDS show very promising results in vitro, with 5-FU potentiation when loaded into zeolites. 
Additionally, we found that DDS efficacy was lower in CAM model compared to the in vitro 
studies, showing the innate differences between in vitro and in vivo models. The CAM model 
revealed to be a good in vivo system to be used as a transition between in vitro experiments 
and a more complex in vivo model, since it can be used to evaluate of both effect of DDS on 
tumor growth and angiogenesis. However, there was no significant effect of the DDS in the in 
vivo model, which requires further optimization of the DDS for in vivo studies which reflects the 
complexity of the physiological environment. 
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SYNTHESIS, CHARACTERIZATION AND IN VITRO VALIDATION OF 
MAGNETIC NaY ZEOLITE WITH T2-MRI PROPERTIES4  
Magnetic nanoparticles (MNPs) have been gaining a significant importance as building 
blocks to form more complex nanostructures due to the multifunctional performance enabled 
by their magnetic character, i.e. magnetic resonance imaging (MRI) and magnetic 
hyperthermia (MH). This study focusses on the development of a magnetic zeolite 
nanocomposite (MZNC) as a suitable platform towards the design of a theranostic system. In 
addition to the well-known drug encapsulation properties of the zeolite structures, in this work 
we explored their ability to act as T2-MRI contrast agents in magnetic resonance imaging (MRI) 
when magnetic nanoparticles are incorporated in their structure. MZNC was prepared by a 
simple one-pot colloidal chemistry route based on the co-precipitation of Fe(II) and Fe(III) salts 




The as-synthesized samples were carefully characterized in terms of morphological, 
structural and magnetic properties. Results confirm the formation of magnetic assemblies with 
microporous structure and superparamagnetic behavior, based on the combination of the 
structural properties from the zeolite and the magnetic performance of the magnetite 
                                               
4 N. Vilaça, J. Gallo, R. Fernandes, F. Figueiredo, A. M. Fonseca, F. Baltazar, I. C. Neves, M. 
Bañobre-López, Synthesis, characterization and in vitro validation of magnetic NaY zeolite with T2-MRI 
properties, submitted. 




nanoparticles. TEM analysis evidenced the cell internalization of MZNC particles by human 
breast cancer cells and their accumulation in the cytoplasm, whereas cytotoxicity assays in 
both tumoral breast and non-tumoral mammary cell lines showed that MZNC was non-toxic at 
the highest concentration tested. Finally, the capability of MZNC to act as imaging probe in 
MRI was confirmed and validated in vitro at a clinical field of 3T, resulting in an enhanced dark 
contrast compared to control cells. The combination of the well-known high load encapsulation 
efficiency of NaY zeolite structures and the additional MRI contrast enhancement provided by 
their innovative assembly with biocompatible magnetite nanoparticles constitutes a step 
forward towards the design of inorganic hybrids as image-drug delivery systems combining 
thermo- and chemotherapeutic effects. 





The application of nanotechnology to medicine, nanomedicine, is expected to bring many 
advances to health by improving diagnostics and therapeutics of cancer.1–3 Nanomaterials can 
be used in many applications such as bioimaging, diagnostic technology, and drug delivery.4–
8 So far, numerous nanomaterials have been exploited in cancer nanomedicine including, 
polymers,9,10 lipids,11,12 mesoporous silica nanoparticles,13–16, zeolite nanoparticles17–19 and 
magnetic nanoparticles (MNPs).20–23 In particular, superparamagnetic iron oxide nanoparticles 
(SPIONs) are especially interesting in biomedicine due to their unique properties, such as 
biocompatibility and non-toxicity, tunable particle sizes and morphologies, ability to be 
functionalized with biological ligands and excellent magnetic properties that enable multiple 
diagnosis and therapy applications, such as magnetic resonance imaging (MRI), targeted drug 
delivery and alternating magnetic field (AMF)-based hyperthermia treatments.24,25 
The combination of MNPs with other materials to obtain hybrid composites that possess the 
advantages of both materials counterparts has been recently explored. In this sense, magnetic 
hybrid nanocomposites and inorganic assemblies have been found to open new perspectives 
for biomedical and environmental applications.26 For example, iron oxides nanoparticles were 
combined with polymeric or lipidic structures to obtain multifiunctional materials with 
therapeutic and/or imaging properties. Bañobre-López and co-workers27 incorporated 
magnetite nanoparticles into different biocompatible and bioresorbable materials to fabricate 
magnetic scaffolds for magnetic hyperthermia-based bone tissue engineering, whereas Grillo 
et al28 fabricated polycaprolactone nanocapsules containing SPIONs that provided the final 
sub-micrometer nanocomposites with both MRI and magnetic hyperthermia (MH) 
performance. On the other hand, zeolite-type structures (crystalline microporous 
aluminosilicates) have been widely studied as adsorbents and catalyst carriers due to their 
unique adsorption properties and their ion exchange capacity. Several synthesis procedures 
have been proposed to incorporate an extra iron framework into zeolites, i.e. liquid/solid ion 
exchange or chemical vapor deposition, which led to the coexistence of several ion species 
inside the pores or on the surface (i.e. Fe ions, FexOy clusters, Fe2O3 nanoparticles).29,30 Iron-
containing zeolites have been extensively studied for their outstanding catalytic activity 
(selective reduction of nitrogen oxides by NH3,30 low-temperature methane hydroxylation,31 
and chemical oxidation of methyl tert-butyl ether (MTBE) in water with H2O2.32,33). This 
excellent catalytic activity is mainly attributed to the activation of the extra Fe-lattice attached 
to the ion-exchange sites derived from a constrained coordination geometry enforced by the 
zeolite lattice.31,33 The extrapolation of zeolites structures to the biomedical field has been 
recently arisen from their ability to physically adsorb hydrophobic molecules and their stability 
in biological environments. Zeolites present high surface areas and regular channels or cages, 




forming a network of pores.  In this framework, a high variety of biomolecules can be 
entrapped, such as fluorescent dyes or drugs, making zeolites good candidates as drug 
encapsulation and delivery carriers.34–37 As an example, hydrophobic chemotherapeutic drugs 
like 5-fluorouracil, temozolomide and alpha-cyano-4-hydroxy-cinnamic acid have been 
successfully encapsulated in different zeolite structures in previous works from Vilaça et 
al.18,19,38 The incorporation of MNPs in zeolites has been already explored to develop 
magnetically controllable composites with optical properties.39 Also, the effect of this magnetic 
functionalization on the catalytic activity of zeolites has been also explored in environmental 
applications.40–42 However, the translation of these achievements and the applicability of 
magnetic zeolites in the biomedical field is still in a very early stage. To the best of our 
knowledge, there are only a few recent works dealing with the incorporation of MNPs in zeolites 
for biomedical application, mainly focused on the drug encapsulation properties of the zeolite 
structures36 and the capability of the MNPs to act as magnetic actuators and trigger a drug 
release by MH.43 
In this work we intend to provide the NaY zeolite with extra biomedical capabilities by 
assembling in situ synthesized magnetite nanoparticles, thus profiting from the drug 
encapsulation properties of the microporous zeolite structure and the magnetic properties of 
the superparamagnetic iron oxide nanoparticles (SPIONs). The inorganic assembly of these 
two materials in one single hybrid nanocomposite constitutes a step forward towards the 
design of suitable novel biomaterials with theranostic properties, enabling diagnosis and 
therapy technologies such as MRI, MH and drug delivery. Special focus was particularly paid 
on the ability of the final magnetic assemblies to generate a MRI contrast enhancement. 
SPIONs emerged as a safer alternative to the Gd chelates, which still exclusively constitute 
the contrast agents (CAs) used in the clinic nowadays. Unlike Gd-based CAs that offer a bright 
contrast (T1-CAs), SPIONs induce a dark contrast (T2-CAs) and are the gold star materials in 
nanoparticulated T2-CAs development for clinical MRI. With this purpose, we developed a 
simple wet-chemistry approach for the magnetization of NaY zeolite. The resultant magnetic 
zeolite nanocomposite (MZNCs) were thoroughly characterized, and their effect on breast 
cancer (MCF-7 and Hs 578T) and normal (MCF-10) cells was studied. On the one hand, the 
physiochemical characterization results showed that the magnetization of the zeolite structure 
was successfully achieved, whereas cell viability assays indicated that the as-synthesized 
MZNCs were non-toxic to the cells. Most of these nanoparticles were observed to be 
internalized by cells and accumulate in the cytoplasm. On the other hand, the capability of 
MZNCs to act as T2-MRI probes and generate a dark contrast enhancement was validated in 
vitro. These results are highly promising and invite to the design and optimization of this new 
generation of theranostic materials as an approach towards image-guided therapy and 
monitoring of the response to treatment. 





3.2.1.  CHEMICAL AND BIOLOGICAL REAGENTS 
The reagents used in this work were analytical grade and used as received without further 
purification. NaY zeolite (CBV100, faujasite structure, Si/Al = 2.83 and 700 nm)) in powder 
form was acquired from Zeolyst International. Iron(III) chloride hexahydrate (FeCl3.6H2O), 
iron(II) chloride tetrahydrate (FeCl2.4H2O) and ammonium hydroxide (NH4OH, 28%) were 
obtained from Sigma Aldrich. 
Dulbecco’s Modified Eagle’s Medium (DMEM (1x)), Dulbecco’s Modified Eagle’s Medium 
F12 (DMEM/F12 (1:1)), Fetal Bovine Serum (FBS), Penicillin-Streptomycin (P/S) were 
purchased from Gibco. Human insulin solution, cholera toxin and hydrocortisone were 
acquired from Sigma Aldrich and epidermal growth factor (EGF) from Peprotech. The human 
breast cancer cell lines MCF-7 and Hs 578T were obtained from ATCC (American Type Culture 
Collection) and the MCF-10 epithelial mammary cell line was kindly provided by Dra. Lígia 
Rodrigues (CEB, University of Minho, Portugal).  
 
3.2.2.  PREPARATION OF MZNCS 
MZNCs were synthetized by basic co-precipitation of Fe(II) and Fe(III) ions in the presence 
of commercial NaY zeolite nanoparticles. First, magnetite (Fe3O4) nanoparticles were prepared 
by slight modification of an elsewhere reported procedure.44 Briefly, water (20 mL, milliQ, 18 
MΩ cm) was purged by bubbling nitrogen (N2) gas for 30 min. Then, aqueous solutions of 
FeCl3.6H2O (1.74 g) and FeCl2.4H2O (0.64 g) were prepared and mixed. Next, NaY zeolite 
(0.50 g) was added to the resulting ferrous solution and mixed vigorously under mechanical 
stirring for 10 min. Then, 40 mL of NH4OH was added to the dispersion, which immediately 
turned into brown-black, and magnetic stirring was kept overnight. After, the dispersion was 
left to settle for 1 h, purified twice with water and three times with water/acetone (1:1) and 
recovered by magnetically separation and centrifugation. Finally, the sample was dried at 65 
°C for 24 h.  
 
3.2.3.  CHARACTERIZATION OF MZNCS  
The structural phase of the magnetic zeolite nanocomposite was analyzed by X-ray 
diffraction (XRD) using a PANanalytical X Pert PRO MRD diffractometer with a PIXcel 3D 
detector, set at accelerating voltage of 45 kV, and tube current of 40 mA at room temperature 
(RT). Fourier transform infrared (FTIR) analysis was performed using an ABB-FLTA 2000 




covering 4000-500 cm-1 range at RT. For each sample, 32 scans were collected with a 
wavenumber resolution of 8 cm-1. Morphological analysis of the samples was performed by 
transmission electron microscopy (TEM) using a JEOL 2100 working at 200 keV and scanning 
electron microscopy (SEM) using a Quanta FEG 650 (FEI). For TEM analysis, a drop of an 
aqueous dispersion of the nanocomposite was placed onto a 400-mesh copper grid coated 
with carbon film and dried under vacuum before being visualized into the microscope. For SEM 
analysis, a drop of material dispersion was placed onto a silicon wafer and left to dry under 
vacuum before being observed. Iron concentration in the sample was determined by 
inductively coupled plasma optical emission spectrometry (ICP-OES) (ICPE-9000, Shimadzu). 
For this, 7.4 µL of sample dispersion were digested with 1 mL of 37% HCl overnight. Then, the 
total volume was adjusted to 100 mL by adding MilliQ water prior to ICP analysis. The magnetic 
properties of MZNCs were characterized using a superconducting quantum interference 
device (SQUID) magnetometer (Quantum Design, USA). Surface areas and pore volumes of 
the samples were measured with an autosorb iQ2 equipment (Quantachrome) using N2 as the 
adsorbate at -196 °C. For each sample, approximately 60 mg of sample was degasified 
overnight at 120 °C. After this first step, an adsorption-desorption isotherm was measured, and 
values were used to calculate the surface area. 
 
3.2.4.  CELL CULTURE AND CELL VIABILITY ASSESSMENT 
MCF-7 breast cancer cells and MCF-10 epithelial mammary cells were cultivated at 37 °C 
with 5 % CO2 in DMEM (1x) supplemented with 10 % of FBS and 1 % of P/S, and in DMEM/F12 
(1:1) containing 5 % FBS, 1 % P/S and supplemented with 20 ng mL-1 of EGF, 100 ng mL-1 of 
cholera toxin, 0.01 mg mL-1 of insulin and 500 ng mL-1 of hydrocortisone, respectively. 
Cell toxicity of MZNCs was evaluated measuring the cellular protein content by the 
sulforhodamine B (SRB) assay.45,18 To this end, MCF-7 and Hs 578T cells (7000 cells per well) 
and MCF-10 cells (5000 cells per well) were plated in 96-well plates and allowed to adhere for 
24 h prior to use. The cells were incubated for 24 and 48 h with increasing concentrations of 
MZNCs solutions (25 – 100 µg mL-1), which were prepared in fresh medium without FBS. 
Statistical significance for each treatment compared to the control was done using one-way 
analysis of variance (ANOVA) followed by Dunnett’s test (GraphPad Prism 6® software) where 
p-value < 0.05 was considered as statistically significant. All results are expressed as mean ± 









3.2.5.  MZNCS INTERNALIZATION 
Hs 578T and MCF-10 cells were plated in 12-well plates at a density of 1.5 × 105 and 1.7 × 
105, respectively and allowed to adhere for 24 h. Then, the cells were exposed to 50 µg mL-1 
of MZNCs for 4 h. Cells were washed 3 times with PBS, harvested by trypsinization, 
centrifuged and resuspended in fresh medium. Subsequently, cells were fixed using 2.5% 
glutaraldehyde (Electron Microscopy sciences, Hatfield, USA) and 2% paraformaldehyde 
(Merck, Darmstadt, Germany) in cacodylate buffer 0.1 M (pH 7.4), dehydrated and then 
embedded in epon resin (TAAB, Berks, England). The resulting blocks were cut using a RMC 
Ultramicrotome (PowerTome, USA) in ultrathin sections and stained with uranyl acetate 
substitute and lead citrate and then observed with a JEOL JEM 1400 TEM (Tokyo, Japan), 
equipped with a CCD digital camera Orious 1100W. 
 
3.2.6.  MAGNETIC RESONANCE IMAGING 
Magnetic resonance imaging (MRI) was performed in a 3T horizontal bore MR Solutions 
Benchtop MRI system equipped with 48 G/cm actively-shielded gradients. To image the 
samples, a 56-mm diameter quadrature birdcage coil was used in transmit/receive mode. For 
the phantom imaging, different samples at a concentration of 50 µg mL-1 were incubated with 
Hs 578T cells for 4 h. After incubation, the cells were washed 3 times with PBS 1x, trypsinized 
and centrifuged to form a pellet. This pellet was resuspended in 50 µL of warm 2 % agar and 
pipetted into PCR microtubes. These microtubes were immediately immersed in ice/water for 
30 min to solidify the gel, and then were stored in the fridge until imaging analysis. MRI images 
of the phantoms were acquired with an image matrix 256 x 248, FOV 60 x 60 mm, 3 slices with 
a slice thickness of 1 mm and 0.1 mm slice gap. For T2-weighted imaging, fast spin echo (FSE) 
sequences with the following parameters were used: TE = 68 ms, TR = 4800 ms, NA = 5, AT = 
12m 24s. Image analysis was performed using ImageJ software (http://imagej.nih.gov/ij). 
 
3.3. RESULTS AND DISCUSSION 
3.3.1.  PREPARATION AND CHARACTERIZATION OF MZNCS 
The hybrid MZNCs were prepared through the chemical coprecipitation of an aqueous 
mixture of Fe(II) and Fe(III) chloride salts (Fe2+/Fe3+ molar ratio equal to 0.5) at basic pH 
containing commercial zeolite NaY nanoparticles. The faujasite structure choice was based on 
previous results that proved the biocompatibility and non-toxicity of the NaY zeolite against 
human cells, as well as on their excellent properties to encapsulate and deliver hydrophobic 




anti-cancer drugs.17,36,46 NaY zeolite was used in order to avoid batch-to-batch irreproducibility 
issues47 and guarantee the same physicochemical properties in all the materials replicas 
prepared. 
The in situ synthesized magnetic nanoparticles were characterized by powder XRD (Figure 
3.1A). The position and relative intensity of the reflections indicated the formation of a single 
phase of magnetite (Fe3O4) with inverse spinel structure (crystallographic open database –
COD–, pattern code 96-900-2318). The Dhkℓ was calculated by the Debye-Scherrer formula 
from the full width at half-maximum of the two most intense peaks in the whole measured range 
of 2indicating an average crystallite size of 6.6 ± 0.9 nm. This value was close to the particle 
size measured from TEM observations (d = 4.7 ± 0.2 nm, see Figure 3.2) and confirmed the 
magnetite nanoparticles as small single crystals. The inorganic assembly between the NaY 
zeolite structure and the in situ synthesized magnetite nanoparticles relies on the electrostatic 
attraction mediated by intermolecular hydrogen-bond formation between the hydroxyl groups 
at the surface of the iron oxide nanoparticles and those in the NaY zeolite particles. The 




Figure 3.1: A) Powder XRD patterns of magnetite nanoparticles (red), NaY zeolite crystals (black) and MZNC 
particles (blue); B) TEM images of a MZNC particles; C) Energy-dispersive X-ray spectroscopy (EDS) microanalysis 
on the MZNC particle shown in B; D) EDS compositional maps of a MZNC crystal. 
 
 






























Figure 3.1A also shows the XRD patterns from the NaY zeolite and the magnetic zeolite, 
MZNC. The diffraction pattern of the NaY zeolite showed the main characteristic peaks at 2 
angles in the range from 11 to 35o typical of the Miller peaks of the faujasite crystal structure.48 
After co-precipitation of the iron salts in presence of the NaY zeolite and the subsequent 
assembly between the in situ formed magnetite nanoparticles and the NaY zeolite particles, 
the XRD pattern of the resulting magnetic nanocomposite showed the main characteristic 
peaks at exactly the same position and with the same intensity as those observed in the parent 
zeolite pattern. This discards the presence of secondary phases as impurities and confirms 
the preservation of the faujasite crystal structure of the NaY zeolite during the magnetic 
nanocomposite formation. However, the presence of magnetite nanoparticles in the final 
magnetic zeolite is not clearly evidenced by XRD, as the diffraction intensity coming from the 
relative amount of the magnetite phase is too low compared to that of the zeolite and the 
corresponding reflections were not distinguished. This has been also observed in magnetic 
imidazolate frameworks and was attributed to the stronger XRD intensity of the hetero-
nanostructures than that of nanocrystals by several orders of magnitude.42 Additionally, in this 
particular nanocomposite the main reflections of NaY zeolite overlap the most intense 
diffractions peaks of magnetite, which coincide at the same 2 positions.   
 
 
Figure 3.2: (Upper) TEM micrograph of the as-synthesized magnetite nanoparticles; (lower) Particle size 
distribution obtained from the TEM picture above and fitted to a Gaussian function. 




The presence of magnetite nanoparticles in the final magnetic zeolite nanocomposite was 
evidenced by TEM analysis (Figure 3.1B). TEM images clearly show the presence of magnetic 
nanoparticles as dark spots grafted to the zeolite nanoparticles’ surface. Both morphology and 
average particle size of the magnetite nanoparticles remained unchanged after their assembly 
with the zeolite structure. Despite the number of washings carried out during the sample 
purification protocol, still some small amount of isolated magnetite nanoparticles can be 
observed. Images also evidence a homogenous and significant coverage of the zeolite 
nanoparticles’ surface with magnetite nanoparticles. However, although the porous structure 
of the zeolite particles is clearly distinguished (mainly close to the surface, see Figures 3.1B 
and 3.3A) and the presence of some dark spots could presumably be attributed to the internal 
rather than superficial localization of magnetite nanoparticles, the presence of magnetite 
nanoparticles inside the porous is not conclusive from the images.  
 
 
Figure 3.3: A) TEM image of a MZNC particle in which the porous structure is clearly observed. Fe3O4 NPs are 
also observed to be grafted to the zeolite particle surface B) SEM image of MZNC particles. C) SEM image of non-
magnetic NaY zeolite particles. 




SEM images also confirmed a homogenous distribution of magnetite nanoparticles around 
the zeolite particles, as deduced by the overall observed rough particle surface of the magnetic 
nanocomposite crystals, which is very likely indicative of the grafting of magnetic nanoparticles 
on the zeolite surface and which is not appreciated in the SEM image corresponding to the 
parent NaY zeolite (see Figures 3.3B and 3.3C). Energy-dispersive X-ray spectroscopy (EDS) 
microanalysis unequivocally detected the presence or Fe on the NaY zeolite particles’ surface 
and the compositional elemental maps further proved a random distribution of Fe around the 
NaY zeolite particles (Figures 3.1C and 3.1D, respectively), evidencing a homogeneous 
coating with magnetite nanoparticles. A high density of Al and Si is also observed, as they 
constitute the main compositional elements in the zeolite structure.  
The FTIR spectra of magnetite, NaY zeolite and MZNCs were recorded between 4000 and 
500 cm-1 (Figure 3.4). The formation of magnetite nanoparticles and their anchoring to the NaY 
zeolite structure was mainly evidenced by the band appearing at 600 cm-1 in the MZNCs 
spectrum, observed in the region where the zeolite does not absorb and that is ascribed to the 
intrinsic stretching vibration of the characteristic Fe-O bond of magnetite. In the magnetite 
spectrum this absorption band is slightly shifted to lower wavenumbers 580 cm-1, thereby 
confirming the presence of magnetite nanoparticles and their interaction with the zeolite 
structure.36,49 The additional bands at 1633 and 3400 cm-1 in the magnetite spectrum were 
assigned to the stretching vibration of the O-H hydroxyl groups.50 MZNCs spectrum presents 
characteristic bands of the zeolite structure at 547 cm-1  and 970 cm-1, which are related to the 
double ring and TO4 asymmetric stretch (T= Si, Al).36 In the same MZNCs spectrum, the (O–
H) stretching vibration at 3410 cm-1 and the δ(O–H) deformation band at 1650 cm-1 are 
attributed to the surface hydroxyl groups (terminal silanol groups) and the physisorbed water, 
while bands in the spectral region between 1250 and 500 cm-1 correspond to the lattice 
vibrations.45 Importantly, new bands at 3200 and 1400 cm-1 are observed in the MZNCs (not 
visible in the NaY zeolite spectrum) that could be attributed to inter and intramolecular 
hydrogen bonding, pointing to the formation of hydrogen bonds as the main driving force that 
governs the interaction between the in situ formed magnetite nanoparticles and the zeolite 
particles.36 Figure 3.5 show a scheme of the MZNCs preparation and the mechanism of 
interaction proposed between the in situ formed MNPs and zeolite nanoparticles’ surface.   
 





Figure 3.4: FTIR spectrum of Fe3O4 nanoparticles (C - black), NaY zeolite (A - red) and MZNC (B - blue). The 
IR-active chemical groups attributed to the main bands are indicated. 
 
 
Figure 3.5: Scheme of the MZNCs preparation and the mechanism of interaction proposed between the in situ 
formed MNPs and zeolite particles. 
 
Hysteresis loops of the MZNCs were measured with a SQUID magnetometer in the applied 
magnetic field range from ‒20 kOe to +20 kOe at 2 and 300 K (Figure 3.6C). The M vs H 
curves at 300 K showed the typical superparamagnetic (SPM) behaviour for small magnetite 
nanoparticles of around 5 nm (Figure 3.6D). No coercive forces or remanence were observed 
due to the small average nanoparticle size, which was well below the single-to-multi domain 




limit (around 20 nm for magnetite nanoparticles). The high surface-to-volume contribution in 
small magnetite nanoparticles is responsible of the observed non-saturated magnetization at 
the maximum field tested (20 kOe), as consequence of the atomic disorder and spin frustration 
at the surface (spin-glass like behaviour) and opposite to the spin-ordered magnetic core. In 
fact, a linear paramagnetic (PM) component is clearly over imposed to the classic SPM 
behaviour due to the small particle size of the magnetite nanoparticles. In an attempt to 
compare the saturation magnetization (Ms) of our MZNCs with data from other magnetized 
zeolites from the literature, the Ms was calculated by the extrapolation of the M vs H-1 curve 
for H-1 0. The Ms value obtained was 2.8 emu g-1 and contrasts with the 65 emu g-1 of 10-
20 nm magnetite nanoparticles and with the 92 emu g-1 of bulk magnetite.51,52 A low value of 
Ms is expected, as the amount of magnetite nanoparticles in the final hybrid is very low. 
Previously reported Ms data in zeolites magnetized with similar magnetite nanoparticles 
oscillate between 2.1 and 8.35 emu g-1 at room temperature.36,39,43 According to the value of 
Ms found for our MZNCs compared to that measured for our 5 nm SPM magnetite 
nanoparticles (Ms  60 emu g-1, Figure 3.6A), the mass of magnetite nanoparticles only took 
up about 1/23 in the MZNC. However, even though the total magnetic moment in the sample 
was apparently low, the powder sample was still attracted by the magnetic field generated by 
a portable external magnet (see inset in Figure 3.6C). At low temperature (2 K), the hysteresis 
loop showed a ferromagnetic (FM)-like behaviour as consequence of the magnetite 
nanoparticles to be in a magnetically blocked state, showing hysteresis, remanence and higher 
Ms than that observed at room temperature (Figure 3.6C), as predicted by the Bloch’s law.53 
For a further magnetic analysis, the temperature dependent zero-field-cooled (ZFC) and field-
cooled (FC) magnetization curves of MZNCs were measured from the 2 to 300 K under an 
applied magnetic field of 100 Oe (Figure 3.6D). As the temperature decreases from room 
temperature the magnetization increases until a maximum in the ZFC curve at 70 K, which 
represents the blocking temperature (TB), at which the thermal energy becomes comparable 
to the anisotropy energy barrier.54 TB is strongly dependent on the surface state, interparticle 
interactions, particle size and particle size distribution of the grafted magnetite nanoparticles. 
A wide range of TB in the range 20 - 170 K has been reported as a function of different surface 
coatings and particle sizes for magnetite nanoparticles in the 5 - 11 nm size range.55–57  The 
observed value of TB for MZNCs is in agreement with that of uncoated magnetite nanoparticles 
between 4 and 11 nm prepared by the co-precipitation method, what supports the XRD and 
TEM data that indicated a particle size for the as-synthesized magnetite nanoparticles around 
5 nm. It is also worth mentioning the thermal irreversibility feature observed in the ZFC-FC 
bifurcation temperature region below Tirr = 250 K. Large differences between the TB and Tirr 
are ascribed to a distribution of magnetic anisotropy in the sample, most likely due to the 




polydispersity in the particle size.58 This is also in agreement with the broad peak observed at 
TB in the ZFC curve. Furthermore, the gap T = TB - Tirr is on the order of 180 K, indicating 
strong magnetic couplings between the NPs. In a more detailed inspection of the shape of the 
FC curve we can observe that the magnetization monotonically increases as the temperature 
decreases until TB, below which it keeps increasing down to 2 K, with a small plateu between 
35 and 20 K. This feature points to a strong interacting magnetite nanoparticles system and 
highlights the presence of significant dipolar magnetic interactions. This magnetically strong 
interacting-like behaviour differs from the collective behaviour observed in other MNPs-based 
magnetic systems, such as magnetite nanoparticles arrays and magnetic zeolites,39,59 where 
both ZFC and FC magnetization decrease below TB. In the case of previous reported MNPs-
based magnetized zeolites, both the higher weight ratio of the nanoparticles to the zeolite and 
the degree of coverage of the zeolite crystals were higher than that of this work, meaning 
shorter inter-particle distances and higher dipolar magnetic interactions. On the other hand, if 
we compare the temperature dependence of the magnetization M(T) under ZFC and FC 
conditions of MZNCs and magnetite nanoparticles separately, we observe a significant 
decrease from 160 to 40 K once the magnetite nanoparticles are grafted and homogenously 
distributed on the zeolite nanoparticles’ surface (see Figures 3.6B and 3.6D). This hydrogen 
bonds-mediated interaction between magnetite nanoparticles and zeolites can decrease the 
interparticle aggregation and lead to the formation of smaller, but still interacting, magnetic 
aggregates. An opposite effect was found in magnetite nanoparticles coated with 3-
aminopropyl-triethoxysilane (APTES), where an increase of TB was observed when compared 
to that of uncoated nanoparticles. In this case,  the effect was ascribed to the alkosylanes 
condensation, which increases the interparticle aggregation, leading to the formation of larger 
aggregates particles.60 
In our case, magnetic results are consistent with the morphological characterization of 
MZNCs by TEM, where a coverage of the zeolite nanoparticles’ surface is observed, resulting 
in short-particle distances and presence of small particle aggregates. 
 





Figure 3.6: A) Hysteresis loops of the Fe3O4 nanoparticles at 300 and 2 K; B) Temperature dependence of the 
magnetization under ZFC and FC conditions at an applied field of H=100 Oe; C) Hysteresis loops of the MZNCs at 
300 and 2 K; D) Temperature dependence of the magnetization of MZNCs under ZFC and FC conditions at an 
applied field of H=100 Oe. 
 
N2 absorption analysis were performed in both NaY zeolite and MZNCs samples (Figure 
3.7). From the shape of the curves obtained, we verified that both samples showed a I-type 
isotherm according to the IUPAC classification, as they did not exhibit the hysteresis loop 
characteristic from microporous solids.61 Moreover, MZNCs retained the same isotherm profile 
as that of the parent NaY zeolite, although a significant reduction of the surface area from 792 
to 527 m2 g-1 was observed after the inorganic assembly between the magnetite nanoparticles 
and the zeolite particles. This reduction of the surface area strongly suggests the partial 
occlusion of the microporous network of the zeolite structure. On the one hand, this could be 
provoked by the incorporation of magnetic nanoparticles into the micropores and it has been 
already observed by different authors.62–64 The Fe2+ and Fe3+ metal ion precursors in the 
original solution could penetrate into the open pores of the zeolite particles, giving rise to the 
formation of magnetite nanoparticles inside the micropores once the coprecipitation is induced 
by the base addition. However, by comparing the NaY zeolite microporous channels diameter 
(0.73 nm) and the particle size distribution calculated from TEM data, seems unlikely that the 











































































































































formation of magnetite nanoparticles takes place inside the pores. On the other hand, it is well 
known that the zeolite structure present also a degree of the mesoporosity.18 However, 
although the incorporation of magnetite nanoparticles in the mesoporous channels (< 2 nm) 
cannot be completely discarded, since the particle size distribution of the magnetite 
nanoparticles determined by TEM shows the presence of very small magnetite nanoparticles 
of similar size, the observed magnetite nanoparticles distribution on the zeolite surface rather 
points to a blockage of the micro/meso porous by particle accumulation at the pore entrance 
as the main reason for the surface area reduction. This effect was also observed in bimetallic 
catalysts by Freitas et al, where this obstruction was caused by the incorporation of Cu and Pd 
metal species affected the amount of available acid sites and therefore the catalytic activity of 
the designed catalysts.65 










































Figure 3.7: N2 adsorption-desorption isotherms of NaY zeolite (open symbols) and MZNC (closed symbols) 
particles. 
 
3.3.2.  IN VITRO STUDIES 
3.3.2.1.  MZNCS CYTOTOXICITY AND INTERNALIZATION STUDIES. 
The in vitro effect of MZNCs was evaluated on three different human cell lines: Hs 578T and 
MCF-7 breast cancer cells, and MCF-10 normal breast epithelial cells. Different concentration 
of MZNCs from 0.025 to 0.100 mg mL-1 were incubated with the cells in serum-free medium. 
The effect of this incubation on the cell viability was studied after 24 and 48 h by means of the 




SRB assay for cytotoxicity screening. From the analysis of the results showed in the Figure 
3.8, we can deduce that there is not a cytotoxicity effect after 24 h of incubation induced either 
by NaY or MZNCs in any of the cell lines and concentrations tested. However, from the results 
obtained after 48 h of cell-samples exposure time, a slight reduction on the cell viability was 
observed for both Hs 578T and MCF-7 cells at high concentrations of NaY zeolite. This reveals 
a dose- and time-dependent toxicity in the case of NaY, which interestingly disappears when 
magnetite nanoparticles attach to NaY zeolite nanoparticles’ surface to yield the MZNC 
sample. For MCF-10 cells treated with these samples, no decrease in cell viability was 
observed both for NaY and MZNCs, which may be explained by the fact that normal cells 
display lower endocytosis activity than cancer cells.66 
 
 
Figure 3.8: Hs 578T, MCF-7 and MCF-10 cell viability after incubation with NaY and MZNCs at 24 and 48 h of 
incubation. The data are given as mean ± SD (n=3). 




In order to study the cell internalization of the MZNC particles, 50 µg mL-1 of this sample 
were incubated with Hs 578T breast cancer cells and MCF-10 epithelial mammary cells for 4 
h. After the incubation, the resulting cells were washed several times with fresh medium and 
processed as described in the experimental section to obtain a thin enough cross section of 
the cells for TEM analysis. A set of TEM images are shown in Figure 3.9 that confirm the 
internalization of MZNC particles by both cellular types, clearly distinguishable as dark stains 
within the cellular compartments (Figures 3.9B and 3.9D). Both cell lines incubated with MZNC 
particles showed filopodia, with nanoparticles located in cytoplasmic vesicles, without any 
apparent localization in the cellular organelles. A safe and efficient localization of MNPs into 
the cytosol is of utmost importance in applications such as phototherapy, intracellular 
imaging, cell tracking or targeting or in gene or intracellular drug delivery.67 
 
 
Figure 3.9: TEM images of Hs 578T and MCF-10 cells incubated with 50 µg mL-1 of MZNC particles for 4 h: A) 




Given the excellent cell internalization of MZNC particles by tumor cells, their capability as 
T2-CA for MRI was assessed in vitro at a clinical field of 3 T and 37 ºC. An agarose-gel cell 
phantom was prepared containing purified Hs 578T breast cells after 4 h incubation with both 
non-magnetic and magnetic zeolite samples (Figure 3.10A). The rational choice of agarose as 
supporting medium of the cells was based on an attempt to mimic as much as possible the 




solid morphology and structure of a human tissue, so that the results would better approach a 
relevant clinical application. The tissue-equivalent MRI phantom including a control (only cells) 
was imaged under T2-weighted conditions. As expected, the magnetite nanoparticles present 
in the MZNC act as T2 effectors and induce a darker contrast in the MRI image of the Hs 578T 
cancer cells, compared to that provided by non-incubated control cells or cells incubated with 
non-magnetic NaY zeolite. The quantitative analysis of the MRI image shows a clear reduction 
of the T2 signal intensity for those cells containing MZNC particles (Figure 3.10B). This 
observed T2-MRI contrast enhancement confirms their cell internalization and render these 
magnetic zeolites suitable T2-imaging probes in MRI applications, enabling new opportunities 
such as cell labeling and tracking and image-guided drug delivery. 
The development of zeolite structures for applications in the biomedical field is still in its 
early stage. The attachment of MNPs on the zeolite surface adds an interesting imaging 
functionality to the system. This is especially interesting in NaY zeolite, since in addition to 
their proved drug encapsulation ability, the herein demonstrated T2-MRI enhancement 
suggests their further optimization towards the design of more efficient theranostic agents, 
enabling new opportunities for these inorganic hybrids in the biomedical field.  
 
 
Figure 3.10: A) T2-weighted MRI images of an agarose cell phantom of MZNC and NaY particles internalized 
by Hs 578T cells. T2-weighted fast spin echo (FSE): TE = 68 ms; TR = 4800 ms; FOV = 60 x 60 mm; NA = 4; At = 
9’55’’; NS = 6; SG = 0.1 mm; ST = 1 mm. Agarose gel only with cells was taken as a control. B) Quantitative analysis 
of the MRI signal measured in the T2-weighted image shown in (A). 





Biocompatible and non-toxic magnetic NaY zeolite have been achieved by simple basic 
coprecipitation of Fe(II) and Fe(III) salts in an aqueous solution containing zeolite 
nanoparticles. The formation of small 5 nm magnetite nanoparticles and their grafting to the 
zeolite nanoparticles’ surface have been confirmed by XRD, SQUID, EDS, IR and TEM. MZNC 
particles showed a non-saturated superparamagnetic behavior and presence of dipolar 
magnetic interactions, in agreement with a fully coverage of the zeolites’ surface and formation 
of small aggregates (short interparticle distances). Also, the N2 adsorption-desorption profile 
of the MZNC particles pointed to an obstruction of the porous network, which was attributed to 
the magnetite nanoparticles accumulation at the zeolite surface rather than inside the pores. 
In vitro studies evidenced an excellent cell internalization of MZNCs by human breast tumor 
cells. The MRI properties of MZNC-labeled cells were studied in a tissue-equivalent agarose 
gel and rendered magnetic zeolites suitable T2-MRI contrast enhancers at a clinical field of 3 
T. These results constitute a step forward towards the design and optimization of zeolite 
structures as multifunctional systems for theranostic applications in biomedicine. The 
demonstrated cell labeling efficiency and capability to enhance the T2-MRI contrast, together 
with the previously proved drug encapsulation efficacy, make magnetic zeolites promising 
candidates for further development, which currently is in an early stage.  
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CHARACTERIZATION OF THE MECHANISMS INVOLVED IN THE 
UPTAKE OF ZEOLITE NANOCARRIERS BY HUMAN CELLS 
This chapter will focus on the work about the internalization and uptake of zeolite 
nanoparticles by human cells, as well as on the effect of the outer surface functionalization on 
the uptake of zeolite nanoparticles uptake. Since this type of studies are scarce, this work 
represents an important endorsement to the understanding of the endocytic mechanisms 
involved in zeolite nanoparticle internalization. 
Subchapter 4.1, describes the results of the study on the internalization of zeolite NaY and 
L nanoparticles by breast cancer cells and epithelial mammary cells. This study enabled the 
understanding how human cells interact with zeolite nanoparticles. The endocytic pathway for 
the internalization of these materials was also identified. 
In turn, subchapter 4.2 includes the results of the endorsement of the endocytic pathways, 
using six pharmacological inhibitors and also the uptake of positively and negatively charged 










INTERNALIZATION STUDIES ON ZEOLITE NANOPARTICLES BY HUMAN CELLS5 
Zeolites are crystalline porous materials with a regular framework which have non-toxic 
effects on a variety of human cell lines and have been explored for cell imaging and drug 
delivery. Understanding the interaction between zeolite nanoparticles and cells is imperative 
for improving their potentialities, since the process of internalization of these particles is still 
poorly understood. In this study, the intracellular trafficking and internalization kinetics of 
zeolite L into breast cancer cells and normal epithelial mammary cells were analysed using 
scanning electron microscopy (SEM), confocal microscopy and transmission electron 
microscopy (TEM) (see graphical abstract below). We also studied the involvement of 
endocytic pathways using two pharmacological inhibitors, chlorpromazine and dynasore. 
Zeolite nanoparticles were taken up by both cell types and the cellular uptake was fast and 
started immediately after 5 min of incubation. Interestingly, the uptake was dependent on the 
cell type since in breast cancer cells it was faster and more efficient, with a higher number of 
nanoparticles being internalized by cancer cells over time, compared to that in the epithelial 
mammary cells. TEM results showed that the internalized nanoparticles were mainly localized 
in the cell vacuoles. The data obtained upon using endocytic pharmacological inhibitors 
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4.1.1.  INTRODUCTION 
Cancer is currently the leading cause of death worldwide, with 14.1 million new cases, 32.6 
million people fighting against cancer (within 5 years of diagnosis) and 8.2 million deaths 
worldwide, as reported in 2012.1 Among different types of cancer, breast cancer, just after lung 
cancer, is the second most common and the most deadly malignancy in women2–5 with 1.7 
million cases diagnosed in 2012 worldwide and about 522 000 deaths.6 Breast cancer 
incidence is higher in developed countries but it is increasing in developing countries and is 
expected to rise in the next few years.7 Bearing these facts in mind, scientists have been 
focusing their efforts towards a better understanding of cancer origin and progression and have 
also been looking for novel nanomaterials for the development of more efficient and less toxic 
anticancer therapeutic strategies.8–11 One of these strategies explores drug delivery systems 
(DDS), which can deliver drugs to the desirable location, reduce side effects and control drug 
release rates. Furthermore, the use of carriers could improve the bioavailability of the drugs 
and protect them from degradation in harsh body environments.11,12 A number of different 
materials are used to prepare DDS such as metal nanoparticles, metal–organic frameworks 
(MOF), polymers, liposomes, dendrimers, carbon nanotubes and porous materials.13 
Amongst porous nanomaterials silica based systems have recently received a lot of 
attention. Zeolites are microporous crystalline aluminosilicates with three-dimensional 
frameworks, comprising silicon, aluminum and oxygen, and water molecules featuring a 
uniform network of channels and pores with regular dimensions.14–16 The channel size and 
shape define the structural parameters of a given type of zeolite.17 Zeolites have been 
successfully used as hosts for DDS,15,18–20 but a deep understanding of the uptake 
mechanisms associated with these structures, in order to design safe and efficient applications 
for therapeutic purposes, is still lacking. When nanoparticles are in contact with cells, they can 
be internalized by endocytosis, a mechanism in which a particle is engulfed by the cell 
membrane, originating intracellular vesicles.8,21 There are two different types of endocytosis: 
phagocytosis and pinocytosis. Phagocytosis occurs predominantly in special cells called 
phagocytes, such as macrophages, neutrophils and monocytes, and pinocytosis refers to the 
uptake of fluids and solutes.22,23 The endocytic pathways involved in the internalization of 
nanoparticles can be studied using endocytic markers to track the location of the nanoparticles, 
or using pharmacological inhibitors to identify the endocytic mechanism involved in the cellular 
uptake.21,23 
The aim of this work is to investigate the internalization mechanism and intracellular 
localization of zeolite nanoparticles in breast cancer cells and normal epithelial mammary cells. 
Zeolite L was chosen due to its ordered porous structure where the channels are 
unidimensional and parallel to each other. Such configuration allows molecules to diffuse in 





and out, and the channels can be closed with appropriate stopper molecules. In addition, small 
sized disc-shaped particles can be prepared, which decrease the tendency to form aggregates 
compared to zeolite Y. To achieve visualization of biologically related problems, we have used 
confocal imaging, scanning electron microscopy (SEM) and transmission electron microscopy 
(TEM). We have examined the cellular uptake of fluorescent labeled zeolite L in Hs 578T breast 
cancer cells, HMEC and MCF-10 epithelial mammary cells. In addition, pharmacological 
inhibitors were used to study the internalization mechanism. The results indicate that the 
internalization of zeolite L is faster in breast cancer cells than in normal cells and the 
internalization process is aided by a caveolin-mediated process. Our study gives a valuable 
contribution to the characterization of biological mechanisms involved in the uptake of zeolite 
nanoparticles by human cells. 
 
4.1.2.  EXPERIMENTAL  
4.1.2.1.  MATERIALS AND CELLS  
Sodium hydroxide, aluminum hydroxide, potassium hydroxide and Ludox® HS-40 colloidal 
silica, were purchased from Merck, Acros Organics and Sigma Aldrich (St. Louis, MO), 
respectively. NaY zeolite (CBV100) was acquired from Zeolyst International. N,N'-Bis(2,6-
dimethylphenyl)perylene-3,4,9,10-tetracarboxylic diimide (DXP) dye was acquired from Fluka.  
Dulbecco’s Modified Eagle’s Medium (DMEM (1x)), Dulbecco’s Modified Eagle’s Medium 
F12 (DMEM/F12 (1:1)), HuMEC Ready Medium (HuMEC), Fetal Bovine Serum (FBS), 
Penicillin-Streptomycin (P/S) were purchased from Gibco. Human insulin solution, cholera 
toxin and hydrocortisone were acquired from Sigma Aldrich and epidermal growth factor (EGF) 
from Peprotech. The human breast cancer cell line Hs 587T was obtained from ATCC 
(American Type Culture Collection), the human mammary epithelial cells (HMEC) were 
obtained from Gibco™ and the MCF-10 epithelial mammary cells were kindly provided by Dra. 
Lígia Rodrigues (CEB, University of Minho, Portugal). The pharmacological inhibitors, 
chlorpromazine and dynasore, were obtained from Sigma Aldrich. α-Tubulin antibody 
(SC23948) was from Santa Cruz Biotechnology and Alexa Fluor 594 goat anti-mouse 
(A11032) was purchased from Life Technologies. 
 
4.1.2.2.  SYNTHESIS AND CHARACTERIZATION OF ZEOLITE L 
Zeolite L was synthetized as previously described with some alterations.24–26 Briefly, 1.74 g 
of sodium hydroxide, 2.70 g of potassium hydroxide and 0.65 g of aluminum hydroxide were 
added to a round-bottom flask containing 17.3 g of distilled water, and refluxed for 3 h at 120 
°C until a clear solution was obtained. This solution was allowed to cool down to room 




temperature and then the amount of lost water was added. Under mechanic stirring, the 
solution was added to 17.67 g of Ludox® HS-40 and then the obtained gel was transferred to 
a PTFE vessel and left at room temperature for 18 h. After that, the PTFE vessel was rotated 
at 40 rpm, 160 °C, for 48 h. After cooling, the zeolite was recovered by centrifugation (7000 
rpm, 5 min) and washed five times with distilled water to obtain neutral pH. Finally, 1 g of zeolite 
L was dried under vacuum overnight. 
The morphology and the particle size of zeolite L was assessed by scanning electron 
microscopy (SEM) (Quanta Feg 250, FEI Company, USA). The X-ray diffraction (XRD) pattern 
was studied with a Bruker D2 Phaser (Bruker, USA). Nitrogen adsorption isotherms were 
obtained with a Micromeritics porosimeter (model ASAP-2020). Fourier transform infrared 
analysis (FTIR) was performed using ABB-FLTA 2000 covering 4000-500 cm-1 range and 
recorded with a resolution of 8 cm-1. Zeta potential was measured on a DelsaNano C Particle 
Analyzer, Beckman Coulter. 
 
4.1.2.3.  CELL CULTURE  
Hs 587T breast cancer cells were cultured in DMEM (1x) with 10% of FBS and 1% of P/S. 
HMEC cells were cultured in HuMEC Basal Serum Media supplemented with 1% of HuMEC 
supplement and 70 mg mL-1 of bovine pituitary extract and 1% P/S. MCF-10 epithelial 
mammary cells were cultured in DMEM/F12 (1:1) containing 5% FBS, 1% P/S and 
supplemented with 20 ng mL-1 of EGF, 100 ng mL-1 of cholera toxin, 0.01 mg mL-1 of insulin 
and 500 ng mL-1 of hydrocortisone. Both cell lines were maintained in a humidified atmosphere 
of 5% CO2 at 37 °C. 
 
4.1.2.4.  CELL VIABILITY ASSAYS  
Sulforhodamine B (SRB) colorimetric assay was used to assess the effect of zeolite L and 
inhibitors, chlorpromazine and dynasore, on cell viability. For this purpose, Hs 578T (7000 cells 
per cm2) and MCF-10 cells (5000 cells per cm2) were seeded onto 96-well plates and incubated 
overnight at 37 °C under 5% CO2 atmosphere. Then the medium was replaced by increasing 
concentrations of zeolite (10 - 125 µg mL-1), chlorpromazine (2 - 10 µg mL-1) and dynasore 
(100 - 400 µM) in medium with no FBS and incubated for 48 h with the zeolite solutions and 1 
h with the inhibitor solutions. Then, the cells were fixed with cold 10% (w/v) trichloroacetic acid 
(TCA) for 1 h and washed three times with distilled water. After the fixation step, the cells were 
stained with SRB for 30 min and washed three times with 1% (v/v) acetic acid and left to dry. 
Then the dye was solubilized with 10 mM Tris base solution and the absorbance was read at 
490 nm in a microplate reader. 
 





4.1.2.5.  INTERNALIZATION STUDIES OF ZEOLITE L  BY MICROSCOPIC TECHNIQUES  
In order to study the cell internalization of zeolites we have used and combined different 
techniques based on electron and optical microscopies.  
 
SEM microscopy analysis: SEM analysis was performed to assess the surface 
interactions between zeolite L with Hs 578T breast cancer cells and HMEC human mammary 
epithelial cells. In addition to the studies with zeolite L, we also performed assays with zeolite 
Y, to evaluate the influence of particle size and shape in cellular internalization. 
For these studies, cells were cultured onto 12 mm coverslips and incubated at 37 °C 
overnight. Then the culture medium was removed, and the cells were incubated with 50 µg 
mL-1 solution of the zeolites for 5, 10, 15, 20, 30 and 60 min. Afterwards, the used media was 
removed, and the cells were washed 3 times with PBS. Then the cells were fixed with 2.5% 
glutaraldehyde in PBS for 45 min at RT and for 1 h at 4 °C, and the fixed cells were also 
washed 3 times with PBS. After the fixation step, cells were dehydrated with increasing 
concentration of ethanol from 10% to 100%, for 20 min each. The coverslips were then dried 
at room temperature overnight. After this procedure, the coverslips were sputter-coated with 
gold and SEM images were then obtained with a FEI Quanta FEG 250 scanning electron 
microscope (FEI Company, USA). 
 
Confocal microscopy analysis: The cell uptake of zeolite L into Hs 578T and MCF-10 cells 
was investigated by confocal microscopy. For this purpose, Hs 578T and MCF-10 cell lines 
were seeded onto coverslips in 24-well plates with the density of 2.5 × 104 cells per well and 
incubated at 37 °C in 5% CO2 atmosphere overnight. Afterwards, 50 µg mL-1 zeolite L 
dispersion was added and incubated for 4 and 24 h. At the end of the incubation period, the 
cells were rinsed twice with PBS and fixed with cold methanol for 15 min, washed once with 
PBS Glycine 10 mM, washed again twice with PBS and permeabilized with triton x-100 0.1% 
for 10 min. Next, after two washes with PBS, the cells were blocked with BSA 5% in PBS 
during 30 min and then incubated with α-tubulin antibody (SC23948, Santacruz) diluted in 5% 
BSA in PBS (1:100) during 2 h at room temperature (RT). In the next step, cells were washed 
twice with PBS (5 min each) and incubated with the secondary antibody Alexa Fluor 594 goat 
anti-mouse (A11032, Life Technologies) diluted in 5% BSA in PBS (1:250) during 1 h at RT in 
the dark. Then, the cells were washed twice with PBS and the nuclei were stained with DAPI 
for 10 min. Finally, after two washes with PBS (5 min each) and one wash with sterile water 
(very quickly), the cells were mounted in Permafluor (Thermo Scientific). 
Confocal images were obtained with an Olympus FV1000 confocal microscope (Olympus). 
Images were acquired with an LSM UPLSAPO 60.0 × 1.35 N.A. oil immersion objective. The 




cells stained with DAPI (excitation/emission wavelength: 405/461 nm), and Alexa Fluor® 594 
dye (excitation/emission wavelength: 559/618 nm) were excited independently at 405, and 559 
nm, respectively. DXP dye was excited at 488 nm. Images were processed by Fluoview 
FV1000 software (Olympus). ImageJ software (National Institutes of Health) was used for 
quantification of the mean intracellular fluorescence. 
 
TEM microscopy analysis: For TEM, Hs 578T and MCF-10 cells were seeded at the 
density of 1.5 × 105 and 1.8 × 105 cells per well, respectively, and incubated at 37 °C in 5% 
CO2 atmosphere for 24 h. Then, the culture medium was removed, and the cells were 
incubated with 50 µg mL-1 dispersion zeolite L for 4 h and 24 h. After incubation, the spent 
media was removed, and the cells were washed three times with PBS 1x, trypsinized, 
centrifuged for 5 min at 900 rpm and resuspend in 1 mL of media. Then samples were fixed in 
2.5% glutaraldehyde (Electron Microscopy sciences, Hatfield, USA) and 2% paraformaldehyde 
(Merck, Darmstadt, Germany) in cacodylate buffer 0.1 M (pH 7.4), dehydrated and embedded 
in Epon resin (TAAB, Berks, England). After that, ultrathin sections (40 - 60 nm thickness) were 
prepared on a RMC Ultramicrotome (PowerTome, USA) using diamond knives (DDK, 
Wilmington, DE, USA).  The sections were mounted on 200 mesh copper or nickel grids, 
stained with uranyl acetate substitute and lead citrate for 5 min each, and examined under a 
JEOL JEM 1400 TEM (Tokyo, Japan). The images were digitally recorded using a CCD digital 
camera Orious 1100W Tokyo, Japan at the HEMS/i3S (IBMC) of the University of Porto. 
Recorded images were analysed using ImageJ Software. For quantification of the percentage 
of zeolite L nanoparticles internalized by cell lines, the images were thresholded leaving only 
the defined zeolite L nanoparticles and the area occupied by nanoparticles was calculated.27 
 
Investigation of endocytosis mechanisms using pharmacological inhibitors: To 
explore the mechanism of zeolite L uptake, we used two pharmacological inhibitors, 
chlorpromazine (CPZ) which interferes with clathrin-mediated endocytosis by a translocation 
of clathrin and adaptor proteins from the plasma membrane to intracellular vesicles blocking 
the formation of clathrin-coated pit,28–30 and dynasore which acts on clathrin and caveolin-
mediated processes.31,32 We used two approaches to investigate the effect of these inhibitors: 
flow cytometry and TEM. 
For flow cytometry analysis (FACS), Hs 578T and MCF-10 cells were seeded in 6-well plates 
at density of 1.25 × 105 for both cell lines and treated with chlorpromazine (10 µg mL-1) and 
dynasore (400 µM) in free-serum culture medium for 1 h at 37 °C, and incubated for 4 h with 
50 µg mL-1 of zeolite L. After the incubation time, the cells were washed, detached by 
trypsinization, centrifuged, resuspended in PBS and analysed by FACS. For TEM analysis, the 





cells were also treated with the inhibitors for 1 h and incubated with zeolite L for 4 h. After the 
incubation time, cells were prepared as described above. 
 
4.1.2.6.  STATISTICAL ANALYSIS  
Statistically significant differences of the results from cytotoxicity studies were determined 
by Student’s t test, and one-way analysis of variance (ANOVA) with the Dunnett’s test. 
Differences between groups of the confocal and TEM results were evaluated by two-way 
ANOVA followed by Bonferroni post-test. A p value lower than 0.05 was considered statistically 
significant. All statistical analyses were performed with GraphPad Prism 6® software. 
 
4.1.3. RESULTS AND DISCUSSION 
4.1.3.1.  PREPARATION AND CHARACTERIZATION OF ZEOLITE L 
The characterization results of synthesized zeolite L are shown in Figure. 4.1.1. The size 
and morphology of zeolite particles were obtained by scanning electron microscopy (SEM) 
(Figure. 4.1.1A). SEM images revealed homogenous disc-shaped particles with an average 
diameter of 432 ± 7 nm determined by ImageJ. The powder XRD pattern of zeolite L (Figure. 
4.1.1B) indicated the crystallinity of the synthesized material and revealed the characteristic 
XRD peaks of zeolite L at 2θ of 5.5, 19.4, 22.7, 28.0, 29.1 and 30.7.33 Nitrogen adsorption 
analysis (Figure 4.1.1C) showed a Langmuir adsorption which is the typical adsorption pattern 
of microporous materials, with a pore size of 0.7 nm. From FTIR spectrum (Figure 4.1.1D), it 
is possible to see the characteristic bands of zeolite L. The band in the region between 1098 
and 1020 cm-1 was assigned to the asymmetric stretch of the structure sensitive vibrations.34 
The bands at 3480-3410 cm-1 and 1641-1637 cm-1 are attributed to the O-H stretching vibration 
and O-H deformation, respectively. The bands at 642, 606 and 580 cm-1 are the vibrations of 
the tetrahedron due to the external linkages of the double rings in the framework structure and 
the bands between 767-721 cm-1 are due to the symmetric stretching of the internal 
tetrahedron of the zeolite structure.35,36 
The zeta potential of the zeolite particles was measured in water at neutral pH and presented 
a value of -44 mV, confirming the negatively charged surface of zeolites. 
 





Figure 4.1.1: Characterization of the synthesized zeolite L. A) SEM micrographs of zeolite L dispersed in ethanol. 
Inset: Histogram representing statistical size distribution of zeolite L nanoparticles. B) XRD pattern of zeolite L. C) 
Nitrogen adsorption of zeolite L. Inset: pore size distribution. D) FTIR spectrum of zeolite L. 
 
4.1.3.2.  CYTOTOXICITY STUDIES  
Viability tests were performed to evaluate the toxicity of zeolite L on Hs 578T breast cancer 
cells and MCF-10 epithelial mammary cells, using SRB assay. This assay is based on the 
binding of SRB to protein components of cells, allowing determination of cell density.37 
Six test solutions of zeolite L were prepared according to our previously established 
procedure.14,38,39 A stock solution (0.5 mg mL-1) was diluted using culture medium in order to 
obtain the test concentrations (0.01, 0.025, 0.05, 0.075, 0.1 and 0.125 mg mL-1). As described 
in our previous study, all suspensions were sonicated for 2 min for homogenization.38,39 
The effect of zeolite L on Hs 578T breast cancer growth and MCF-10 epithelial cells after 48 
h of incubation is shown in Figure 4.1.2. In the range of the tested concentrations, zeolite L did 
not exhibit any toxicity to normal cells, whereas the viability curve decreases for breast cancer 
cells from 0.05 mg mL-1. However, reduction in Hs 578T cell growth is only significant at 0.125 
mg mL-1 compared to the control, as calculated by Dunnett’s test. 
It was also important to evaluate the in vitro cytotoxicity of the endocytic inhibitors to know if 
the effect of the inhibitors comes from their endocytic inhibition capacity or toxicity to cells. So 
we investigated the effect of chlorpromazine and dynasore at three different concentrations: 2, 
5 and 10 µg mL-1 for chlorpromazine and 100, 200 and 400 µM for dynasore. The inhibitors 





were diluted in serum-free medium and incubated with the cells for 1 h. Both cell lines were 
quite insensitive to the tested concentration of chlorpromazine and dynasore, with viability 
values above 90% (data not shown). 
 
 
Figure 4.1.2: Cell viability of Hs 578T and MCF-10 cells, evaluated with SRB assay after 48 h incubation time 
with increasing concentrations of zeolite. Results are expressed in relation to the control (0% of zeolite, considered 
100% of viability) as mean ± SD of three independent experiments, each performed in triplicate. Differences with a 
p < 0.05 were considered statistically significant (*). 
 
4.1.3.3.  KINETIC STUDIES OF ZEOLITE UPTAKE INTO HS 578T  BREAST CANCER CELLS AND 
MCF-10  EPITHELIAL MAMMARY CELLS  
To exploit the potential of zeolite L as drug delivery system, it is important to understand the 
interactions and internalization of this type of zeolite in living cells. For this purpose, SEM, TEM 
and confocal microscopy were used in breast cancer cells and epithelial mammary cells. SEM 
experiments were performed on Hs 578T and HMEC cells. In these assays, the cells were 
incubated for 60 min with 50 mg mL-1 of zeolite solutions. Different studies have demonstrated 
that the shape and size of particles can influence the uptake process by the cells.40–42 For 
instance, Xie X. et al.43 demonstrated that shape can modulate the uptake of nanoparticles 
into RAW264.7 cells and Liu X. et al.44 have shown that the aspect ratio of bionanorods 
influences the internalization pathways in different cells. Thus, in the present study, besides 
SEM studies with zeolite L, we also performed SEM analysis with zeolite NaY which has a 
different morphology. Both materials have been tested in Hs 578T and HMEC cell lines in order 
to compare their rate of internalization and evaluate if the size and shape of zeolite 
nanoparticles have some effect on the kinetic or internalization process. The zeolite NaY used 




in this work shows cubic geometry with an average diameter of 700 nm,14 while zeolite L has 
disc-shaped particles around 400 nm.  
SEM results for zeolite NaY (Figure 4.1.3) show that after 5 min of incubation the cells start 
to engulf the zeolite particles with their filopodia, but only few of them are inside the cell maybe 
also due to the formation of aggregates. 
This result shows that the uptake of the zeolite particles is very fast, which is consistent with 
other published studies.45 Upon increasing the incubation time, it is noteworthy that the 
particles start to cross the cell membrane and the number of particles that are internalized 
increased with time. After 1 h of incubation, a large number of particles are completely 
internalized by the cell membrane. In the case of zeolite L (Figure 4.1.4), it is possible to see 
that after 5 min of incubation more particles, compared with zeolite NaY, are already 
internalized. These results could be explained by the fact that this zeolite is smaller and thinner 
than zeolite NaY, which makes their uptake easier. Once again for zeolite L, the number of 
internalized particles increases upon increasing the incubation time. These results are in 
agreement with other studies in which 50 nm and 120 nm nanoparticles are internalized faster, 
compared to 250 nm particles.46 
 
 
Figure 4.1.3: SEM micrographs showing the uptake of the zeolite NaY by Hs 578T breast cancer cells. (A) 
Control (without zeolite); cellular uptake observed after: (B) 5 min, (C) 10 min, (D) 15 min, (E) 30 min and (F) 60 
min. Scale bar: (A, B and F) 5 µm and (C, D and E) 3 µm. 
 
 






Figure 4.1.4: SEM micrographs showing the uptake of the zeolite L by Hs 578T breast cancer cells. (A) Control 
(without zeolite); cellular uptake observed after: (B) 5 min, (C) 10 min, (D) 15 min, (E) 30 min and (F) 60 min. Scale 
bar: (A) 5 µm and (B - F) 2 µm. 
 
The results for HMEC epithelial mammary cells (Figure 4.1.5) show that the internalization 
of zeolite L is much slower than that for the breast cancer cells. Moreover, even after increasing 
the incubation time, just a small amount of zeolite nanoparticles is internalized. 
 
 
Figure 4.1.5: SEM micrographs showing the uptake of the zeolite L by HMEC epithelial mammary cells. (A) 
Control (without zeolite); cellular uptake observed after: (B) 5 min, (C) 10 min, (D) 15 min, (E) 30 min and (F) 60 
min. Scale bar: (A) 5 µm and (B - F) 2 µm. 
 
The obtained results show that the shape and the size of the particles have an important 
role in their internalization and that this process is also dependent on the cell type. Cancer 
cells are able to uptake zeolites at a faster rate due to their higher permeability. Since SEM 




only allows the visualization of the cell surface, we also performed confocal microscopy and 
TEM to support these results. Therefore, zeolite L was loaded with a fluorescent dye, DXP, 
which is insoluble in aqueous media, and therefore it is not released from the zeolite pores.47 
Intracellular localization of zeolite L was carried out by Hs 578T and MCF-10 cells, incubated 
with 50 µg mL-1 of zeolite nanoparticles during 4 and 24 h. The uptake of the particles was 
analysed by confocal microscopy upon excitation of the dye at 488 nm and z-stacking analysis 
confirmed the internalization.  
Figure 4.1.6 shows the confocal images and z-stack for Hs 578T cells taken after 4 and 24 
h incubation. After 4 h, it is clear that a significant amount of zeolite nanoparticles is already 
inside the cells and after 24 h the amount of zeolite particles becomes higher, with the particles 
being predominantly localized in the cytoplasm. This is in line with other studies which have 
demonstrated that the cellular uptake of nanoparticles is time-dependent.48 
 
 
Figure 4.1.6: Confocal images of Hs 578T cells incubated with 50 µg mL-1 of zeolite L. Z-stack proving the uptake 
of zeolite L at 4 and 24 h incubation times. Cells nuclei were stained with DAPI (blue), α-tubulin was immunolabeled 
with a specific Alexa Fluor 594-coupled antibody (red) and zeolite L nanoparticles were labeled with DXP (yellow). 
Scale bar: 50 µm. 
 
But unlike, what was observed for Hs 578T cells, the uptake of zeolite L in MCF-10 cells, 
after the same times of incubation (Figure 4.1.7), is lower. At 4 h of incubation, the fluorescence 
intensity measured using ImageJ, for Hs 578T cell line was 18.3 (± 0.3) while for MCF-10 cells 
was 16.1 (± 0.4). For 24 h of incubation the fluorescence intensity was higher in both cell lines, 
22.2 (± 1.7) for Hs 578T and 18.2 (± 0.7) for MCF-10 (Figure 4.1.8). Commonly, the attractive 
forces such as van der Waals and electrostatic forces are responsible for the interaction 
between the particles and cell membranes and these interactions become more intense with 
time.49 Zeolites are negatively charged and it seems that for the MCF-10 cell line, there is some 





repulsion between zeolite nanoparticles and cells (Figure 4.1.7, white arrows). This repulsion 
suggests that the zeolite nanoparticles have low impact on these healthy cells. 
 
 
Figure 4.1.7: Confocal images of MCF-10 cells incubated with 50 µg mL-1 of zeolite L. Z-stack proves the uptake 
of zeolite L at 4 and 24 h incubation times. Cells nuclei were stained with DAPI (blue), α-tubulin was immunolabeled 
with a specific Alexa Fluor 594-coupled antibody (red) and zeolite L nanoparticles were labeled with DXP (yellow). 
Scale bar: 50 µm. 
 
 
Figure 4.1.8: Percentage of zeolite L nanoparticles internalized by Hs 578T and MCF-10 cells. Cells were 
incubated with 50 µg mL-1 of zeolite L at 4 and 24 h incubation times. Results were analyzed by ImageJ Software. 
Difference between groups were evaluated by Two-way ANOVA followed by Bonferroni post-test. ***p < 0.001. 
Mean ± SD. n=4 for Hs 578T experiments and n=5 for MCF-10 experiments. 
 
Confocal results confirm the SEM results in which we also observed more internalization in 
breast cancer cells than in epithelial mammary cells and once again confirm that the 
internalization of zeolite L nanoparticles is time-dependent. The higher internalization rates of 




zeolite L in breast cancer cells than in epithelial mammary cells, due to a higher permeability 
of the membrane, might explain the lower toxicity of zeolite L on epithelial mammary cells 
obtained by the cell viability test.  
TEM results for Hs 578T cell line for 4 and 24 h of incubation (Figure 4.1.9) clearly shows 
that the zeolite is internalized by the cells and it is localized mostly in vacuoles. By comparing 
these results with those for MCF-10 cell line (Figure 4.1.10) for the same incubation time, we 
observe again that the number of the internalized particles is lower than for Hs 578T cells 
(Figure 4.1.11). These results also corroborate the confocal data. Our results are not the only 
ones which show that the internalization of nanoparticles is higher in cancer cells. Other studies 
showed that ZnAl-HTlc nanoparticles were internalized faster by HeLa cervical cancer cells 




Figure 4.1.9: TEM micrographs of Hs 578T cells incubated with 50 µg mL-1 of zeolite L. (A) Control (cells only); 
(B) the uptake of zeolite L at 4 h of incubation time; (C) the uptake of zeolite L at 24 h of incubation time. The arrows 




Figure 4.1.10: TEM micrographs of MCF-10 cells incubated with 50 µg mL-1 of zeolite L. (A) Control (cells only); 
(B) the uptake of zeolite L at 4 h of incubation time; (C) the uptake of zeolite L at 24 h of incubation time. The arrows 
indicate the presence of zeolite L. Scale bar: 1 µm. 
 






Figure 4.1.11: Percentage of zeolite L nanoparticles internalized by Hs 578T and MCF-10 cells. Cells were 
incubated with 50 µg mL-1 of zeolite L at 4 and 24 h incubation times. Results were analyzed by ImageJ Software. 
Difference between groups were evaluated by Two-way ANOVA followed by Bonferroni post-test. ***p < 0.001. 
Mean ± SD. n=4 for Hs 578T experiments and n=5 for MCF-10 experiments. 
 
4.1.3.4.  THE EFFECTS OF ENDOCYTIC INHIBITORS ON CELLULAR UPTAKE  
In order to clarify the mechanism of internalization of zeolite L, we studied the zeolite uptake 
by Hs 578T and MCF-10 cells in the presence of two inhibitors, chlorpromazine (CPZ) and 
dynasore, which inhibit clathrin-dependent endocytosis and block GTPase activity of dynamin 
on clathrin and caveolin-mediated processes, respectively.51,52 For this propose we used flow 
cytometry and TEM analyses. The internalization of zeolite L by Hs 578T and MCF-10 cells 
without any pharmacological inhibitor and in the presence of CPZ or dynasore is shown in 
Figure 4.1.12. The literature data suggest that the internalization of zeolite L is affected by CPZ 
and dynasore.53 However, our results show that the pre-treatment of Hs 578T cells with CPZ, 
prior to incubation with the zeolite L had no effect on its uptake. In contrast, dynasore caused 
a significant decrease in the uptake of the zeolite L.  
The same behaviour was observed for MCF-10 cells, with no effect of CPZ and with 
dynasore exerting some inhibition on the internalization of zeolite L. The findings that CPZ had 
no effect on zeolite L internalization, could be related to the cell lines used in this work, since 
the internalization of particles is cell type- dependent.54,55 
Since CPZ inhibits clathrin-dependent endocytosis and dynasore inhibits clathrin and 
caveolin-mediated processes, the internalization of the zeolite L appears to be mediated by 
caveolin. These results also show that without any pharmacological inhibitor, Hs 578T cells 
internalize a bigger amount of zeolite L nanoparticles than MCF-10 cells, which is in 
accordance with the microscopy results. 





Figure 4.1.12: Effects of the pharmacological inhibitors on the uptake of zeolite L in Hs 578T and MCF-10 cells. 
Cells were treated with chlorpromazine (10 µg mL-1) and dynasore (400 µM) for 1 h before incubation with 50 µg 
mL-1 of zeolite L for 4 h. After incubation cells were collected and analyzed by flow cytometry. 
 
Flow cytometry results were also confirmed by TEM (Figure 4.1.13), where it is possible to 
observe the particles inside Hs 578T and MCF-10 cells when CPZ is used (Figure 4.1.13B and 
E), as opposed to dynasore, where there are no particles inside Hs 578T (Figure 4.1.13C) and 
only a small amount of zeolites are observed in MCF-10 cells (Figure 4.1.13F). 
 
 
Figure 4.1.13: TEM images of the effect of the pharmacological inhibitors on the uptake of zeolite L in Hs 578T 
and MCF-10 cells incubated with 50 µg mL-1 of zeolite L for 4 h. (A) Hs 578T without inhibitor; (B) Hs 578T treated 
with 10 µg mL-1 of chlorpromazine; (C) Hs 578T treated with 400 µM of dynasore; (D) MCF-10 without inhibitor; (E) 
MCF-10 treated with 10 µg mL-1 of chlorpromazine and (F) MCF-10 treated with 400 µM of dynasore. The arrows 
indicate the localization of zeolite L. Scale bar: 1 µm. 
 
 





4.1.4.  CONCLUSIONS 
In this work, we proved by SEM analysis that cell internalization of the zeolite L was faster 
in breast cancer cells when compared to normal breast cells, with some particles already 
internalized after 5 min of incubation. Internalization of zeolite L by the normal epithelial 
mammary cells was slower and, even after 60 min of incubation, only a small number of 
nanoparticles were internalized. The same behaviour was observed by confocal and TEM 
analyses, that evidenced that breast cancer cells internalize a higher number of zeolite 
nanoparticles than epithelial mammary cells, with the particles mainly localized in the vacuoles 
in both of the cell lines. The use of endocytic pharmacological inhibitors suggests that zeolite 
L is internalized by the cells by means of a caveolin-mediated process since dynasore inhibited 
significantly the uptake. These results may contribute to optimize the uptake of these systems 
by cancer cells. 
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ENDORSEMENT OF ENDOCYTIC PATHWAY INVOLVED IN THE 
INTERNALIZATION OF ZEOLITE NANOPARTICLES BY HUMAN CELLS6 
Due to an increasing interest in the biomedical applications of nanocarriers, it becomes more 
important to better understand their interaction with human cells. To gain further insight in this 
direction, in this work, studies of internalization of the parent zeolite L, using six 
pharmacological inhibitors, were performed to unveil the endocytic pathway involved. The 
results show that the zeolite L nanoparticles were internalized by a caveolin-mediated process, 
in breast cancer and epithelial mammary human cells. Also, the outer surface of disc-shaped 
zeolite L was functionalized using different compounds, amino (NH2) or carboxylic acid 
(COOH) groups and coated with poly-L-lysine (PLL) in order to assess if the surface charges 
of the nanoparticles have influence on the cellular uptake and endorse the internalization 
mechanism. Thus, we investigated the biocompatibility of these modified nanomaterials 
towards human cells. Subsequently, the uptake of these modified nanomaterials was 
examined, using confocal microscopy, scanning electron microscopy (SEM) and transmission 
electron microscopy (TEM) at different temperatures (37 °C and 4 °C). The obtained results 
show that functionalized nanomaterials are non-toxic to the human cells and that their 
internalization is fast, being faster for the nanomaterial modified with PLL (see graphical 
abstract below).  
 
 
                                               
6 N. Vilaça, E. A. Prasetyanto, R. Fernandes, F. Figueiredo, A. M. Fonseca, L. De Cola, F. Baltazar, 
I. C. Neves, Endorsement of endocytic pathway involved in the internalization of zeolite nanoparticles 














4.2.1.  INTRODUCTION 
The application of nanotechnology in medicine is a new and exciting field which can bring 
powerful progresses in the prevention, diagnosis and treatment of diseases by developing 
more efficient strategies.1 Nanocarriers display characteristics that make them interesting for 
the delivery of drugs, such as, high surface area per unit volume ratio, their small size and 
easy surface functionalization.2,3 There are numerous advantages related with drug delivery 
systems (DDS) using nanocarriers, including transport of the drugs to target tissues, protection 
of the drug from degradation and increase in drug concentration in the intended local of action, 
requiring lower doses of drug.4,5 Thus, it is essential to develop systems with more efficient 
drug delivery.6 For that, it is crucial to know the internalization mechanism of the DDS. This 
mechanism can occur by endocytosis. Endocytosis can be divided into phagocytosis, which 
refers to the uptake of large particles and is specific of phagocytic cells and pinocytosis, which 
refers to the uptake of fluids and solutes and are present in all types of cells.7,8 In turn, 
pinocytosis can be divided into clathrin-dependent endocytosis (CDE) and clathrin-
independent endocytosis (CIE).9,10 CDE pathway is associated with the internalization of 
nanoparticles up to 200 nm11 and in this process there is formation of a partially invaginated 
membrane structure by the action of the assembly proteins AP-2 and AP180 and then 
dynamin, a multidomain GTPase, which promotes scission of the invaginated clathrin-coated 
vesicles (CCV) which, in turn, are then released into the cytosol under cytoskeleton 
regulation.7,12 CIE can be divided into caveolin-mediated, caveolin- and clathrin-independent 
and macropinocytosis, according to the proteins involved in the pathways. In caveolae-
mediated endocytosis, caveolin is the main protein involved.13 In this process, nanoparticles 
are involved into flask-shaped vesicles and cut off from the membrane by the action of 
dynamin.13 Caveolin- and clathrin-independent pathways can be classified in Arf6-dependent, 
Cdc42-dependent and Rhoa-dependent, depending the type of GTPases involved.7,13,14 In 
turn, macropinocytosis can internalize nanoparticles without receptor mediation, but mediated 
by actin. This route is normally used to internalize particles with an average size below 2 mm.15 
To investigate the endocytic mechanisms involved in the internalization of nanoparticles, 
specific endocytic pharmacological inhibitors are used.14 
During the recent years, our research group has focused on the development of DDS based 
on zeolite nanostructures, for colorectal cancer treatment and more recently for breast cancer 
treatment.16–19 However, an important point of the work is elucidating how zeolite nanoparticles 
enter inside the cells to optimize the design of DDS. Recently, we showed that the zeolite L 
nanoparticles were internalized faster by breast cancer cells than epithelial mammary cells, 
with the nanoparticles mainly localized in the vacuoles by means of a caveolin-mediated 
process.20 Following these studies, in this work, the internalization mechanism of the parent 





zeolite L nanoparticles was investigated using six pharmacological inhibitors unveil the 
endocytic pathway involved. 
One of the strategies to enhance cellular uptake, internalization and avoid aggregation is to 
modify the outer surface of nanocarriers. Surface modification can be carried out by using 
functional groups, such as amino (-NH2), carboxylic (-COOH), sulfhydryl (-SH) groups, by 
PEGylation or other coatings and targeting ligands, such as antibodies, peptides and 
aptamers.5,21 These modifications will enable to increase the cellular uptake, the specificity and 
the efficiency of the intracellular delivery and endorse the internalization mechanism.22,23 
Positively-charged nanoparticles can interact with negative cellular membrane proteins, 
therefore are more efficiently internalized than negatively charged or neutral particles.24–26 
However, in order to design more efficient surface modifications, the endocytic mechanisms 
used by nanoparticles to entry into cells need to be known. When living cells are exposed to 
nanoparticles, these latter can enter the cells by endocytosis or through the phospholipid 
bilayer by a process of direct translocation.27–29 This latter is an energy-independent 
process.27,30 In the endocytosis process, the nanoparticles are firstly engulfed by membrane 
invaginations, originating endosomes or phagosomes depending on the type of cells. Then, 
the endosomes deliver the nanoparticles to various specialized vesicular structures and finally 
they are delivered to various intracellular compartments and recycled to the extracellular milieu 
or delivered across cells.79 
Motivated by that, we functionalized the outer surface of disc-shaped zeolite L nanoparticles 
with different groups, amino or carboxylic acid groups and coated with poly-L-lysine and we 
assessed the toxicity of these modified nanomaterials toward breast cancer and epithelial 
mammary cells. Then, the uptake of these modified nanomaterials was studied in the same 
human cell lines, using confocal microscopy, scanning electron microscopy (SEM) and 
transmission electron microscopy (TEM) at 37 °C and 4 °C, in order to evaluate if the uptake 
of these modified nanomaterials is energy-dependent.  
 
4.2.2.  EXPERIMENTAL  
4.2.2.1.  MATERIALS  
Dry toluene and (3-Aminopropyl)triethoxysilane (APTES) were acquired from Acros 
Organics and triethylamine (TEA) from Merck. Succinic anhydride and poly-L-lysine were 
purchased from Sigma Aldrich and dimethyl sulfoxide (DMSO) from Roth. N,N'-Bis(2,6-
dimethylphenyl)perylene-3,4,9,10-tetracarboxylic diimide (DXP) dye was acquired from Fluka.  
Dulbecco’s Modified Eagle’s Medium (DMEM), Dulbecco’s Modified Eagle’s Medium F12 
(DMEM/F12 (1:1)), Fetal Bovine Serum (FBS) and Penicillin-Streptomycin (P/S) were 




purchased from Gibco. Human insulin solution, cholera toxin and hydrocortisone were 
acquired from Sigma Aldrich and epidermal growth factor (EGF) from Peprotech. The human 
breast cancer cell line, Hs 587T, was obtained from ATCC (American Type Culture Collection) 
and the epithelial mammary cells, MCF-10, were kindly provided by Dra. Lígia Rodrigues (CEB, 
University of Minho, Portugal). The pharmacological inhibitors, chlorpromazine, dynasore, 
LY294002, nystatin, genistein and nocodazole were obtained from Sigma-Aldrich. 4′,6-
Diamidine-2′-phenylindole dihydrochloride (DAPI) was purchased from Sigma-Aldrich, α-
Tubulin antibody (SC23948) was from Santa Cruz Biotechnology and Alexa Fluor 594 goat 
anti-mouse (A11032) was purchased from Life Technologies. 
 
4.2.2.2.  INHIBITION OF THE ENDOCYTIC PATHWAYS  
To identify the endocytic pathways responsible for cellular uptake of zeolite L nanoparticles, 
were used six pharmacological inhibitors: chlorpromazine, dynasore, nystatin, LY294002, 
genistein and nocodazole. The cells treated with the inhibitors were observed by TEM to 
investigate the presence or absence of nanoparticles inside the cells. To achieve this purpose, 
1.5 × 105 Hs 578T and 1.8 × 105 MCF-10 cells were cultured on 24-well plates with zeolite L 
(50 µg mL-1) for 4 h. After the incubation time, the cells were fixed with 2.5% glutaraldehyde 
(Electron Microscopy sciences, Hatfield, USA) and 2% paraformaldehyde in cacodylate buffer 
0.10 M (pH 7.4). Then, the cells were dehydrated and included in Epon resin and ultrathin 
sections were stained with uranyl acetate. The samples were analyzed in a JEOL JEM 1400 
TEM. Images were digitally recorded using a CCD digital camera Orious 1100W Tokyo, Japan 
at the HEMS/i3S (IBMC) of the University of Porto. 
 
4.2.2.3.  ZEOLITE L  SURFACE FUNCTIONALIZATION 
In this study, we modified the outer surface of synthetized zeolite L obtained by method 
previously described,31,32 via attachment of various groups onto the zeolite surface: NH2 
groups, COOH groups and also coated with PLL in order to study if charge surface modification 
enhances cellular uptake. To functionalize the nanoparticles, we followed previous reported 
procedures.33  First, zeolite L was modified with amino groups. For this purpose, the zeolite L 
was suspended in toluene, followed by addition of (3-Aminopropyl)triethoxysilane (APTES), 
and triethylamine (TEA) and the mixture was sonicated for 5 min and then refluxed at 120 °C 
for 2 h. Then, it was left to cool down, centrifuged and washed once with toluene and twice 
with ethanol and dried under vacuum. 
To obtained carboxylic acid-functionalized zeolite L nanoparticles, an amount of amino-
modified zeolite L was dispersed in a succinic anhydride solution in DMSO and, after 10 min 





of sonication, the mixture was stirred overnight at room temperature (RT). The modified zeolite 
was then centrifuged and washed three times with water and dried under vacuum. 
For coating with poly-L-lysine (PLL), the zeolite L was dispersed in a 1 mg mL-1 solution of 
poly-L-lysine hydrobromide in water and the mixture was stirred overnight at room temperature 
and then washed three times with water. The obtained modified nanomaterials were dried 
under vacuum and characterized by zeta potential using a Delsa Nano C Particle Analyzer 
(Beckman Coulter, Brea, CA, USA) and SEM. The zeta potential values represent a mean of 
three measurements. 
From now on, the obtained modified nanomaterials will be designated as “L-NH2” for the 
zeolite L functionalized with amino groups, “L-COOH” for the zeolite L functionalized with 
carboxylic acid groups and “L-PLL” for the zeolite L coated with poly-L-lysine. 
 
4.2.2.4.  DXP  DYE LOADING  
To perform confocal microscopy studies is necessary to have an emitting fluorescence 
material; DXP dye was chosen to achieve this purpose. DXP dye loading was performed 
following a previously reported protocol.33 Briefly, zeolite L was mixed with 2 mL of DXP in 
dichloromethane in a glass ampoule. After that, DXP was dehydrated in a vacuum line at 1.0 
× 10-5 mbar for 6 h and sealed, and the mixture was left at 300 °C overnight in order to obtain 
dye insertion. The ampoule was then opened and the zeolite with the dye was washed with n-
butanol until the supernatant did not show any fluorescence. L-NH2, L-COOH and L-PLL were 
also loaded with DXP dye using the method described above. 
 
4.2.2.5.  CULTURE OF HUMAN CELL LINES  
Hs 578T cells were purchased from ATCC (ATCC® HTB126™). This cell line was cultured 
in DMEM medium supplemented with 10% FBS and 1% Pen/Strep and keep at 37 °C in 5% 
CO2 atmosphere. Cells were exposed to 50 µg mL-1 of the nanomaterials for 4 and 24 h. MCF-
10 epithelial mammary cells were cultured in DMEM/F12 (1:1) containing 5 % FBS, 1 % P/S 
and supplemented with 20 ng mL-1 of EGF, 100 ng mL-1 of cholera toxin, 0.01 mg mL-1 of insulin 
and 500 ng mL-1 of hydrocortisone. Both cell lines were maintained in a humidified atmosphere 
of 5 % CO2 at 37 °C. 
 
4.2.2.6.  SULFORHODAMINE B  ASSAY  
The toxicity of L-NH2, L-COOH and L-PLL was assessed using sulforhodamine B (SRB) 
assay as previously described.18 Briefly, Hs 578T and MCF-10 were seeded at density of 7000 
cells per cm2 and 5000 cells per cm2, respectively, and left to grow overnight at 37 °C under 5 




% CO2 atmosphere. After that, the medium was replaced by the solutions of the modified 
nanomaterials (0.01 - 0.125 mg mL-1) in medium FBS-free and incubated for 48 h. Then, cells 
were fixed for 1 h with cold 10 % (w/v) trichloroacetic acid (TCA), stained with sulforhodamine 
B for 30 min and the dye was solubilized with 10 mM Tris base solution and the absorbance 
was read at 490 nm. 
 
4.2.2.7.  CELLULAR UPTAKE OF FUNCTIONALIZED ZEOLITE L 
Confocal microscopy, transmission electron microscopy (TEM) and scanning electron 
microscopy (SEM) were used to analyze the internalization and uptake of modified zeolite L in 
Hs 578T breast cancer cells and epithelial mammary cells.  
For the confocal microscopy, 2.5 × 104 cells were seeded in coverslips on 24-well plates 
overnight. Then the cells were treated with 50 µg mL-1 of the nanomaterials and incubated for 
4 and 24 h. After the incubation time, cells were washed twice with PBS and fixed with cold 
methanol during 15 min and the immunoreaction was carried out. After fixation, cells were 
washed with PBS with 10 mM glycine, washed with PBS 1x, permeabilized with triton X-100 
0.1%, washed again and blocked with 5% BSA in PBS. Next, the cells were incubated with α-
tubulin antibody (SC23948, Santacruz) diluted in 5% BSA in PBS (1:100) for 30 min, washed 
with PBS 1x and incubated with secondary antibody Alexa Fluor 594 goat anti-mouse (A11032, 
Life Technologies) diluted in 5% BSA in PBS (1:250) during 1 h at RT. After washing, cell 
nuclei were stained with DAPI and mounted in Permafluor. Confocal images were acquired 
with an Olympus FV1000 confocal microscope (Olympus). Emission profiles were acquired 
with an LSM UPLSAPO 60.0 × 1.35 N.A. oil immersion objective. Cells stained with DAPI 
(excitation/emission wavelength: 405/461 nm), and Alexa Fluor® 594 dye (excitation/emission 
wavelength: 559/618 nm) were excited independently at 405, and 559 nm, respectively. DXP 
dye was excited at 488 nm. Image processing was done using a Fluoview FV1000 software 
(Olympus). 
For TEM analysis, Hs 578T and MCF-10 cells were plated at the density of 1.5 × 105 and 
1.8 × 105 cells per wells, respectively, and incubated at 37 °C in 5% CO2 atmosphere for 24 h. 
Then, the cells were incubated with 50 µg mL-1 suspension of the modified nanomaterials for 
4 h at 4 and 37 °C and 24 h at 37 °C. Afterwards, the cells were washed three times with PBS 
1x, trypsinized, centrifuged for 5 min at 900 rpm and resuspended in 1 mL of media. 2.5% 
glutaraldehyde (Electron Microscopy sciences, Hatfield, USA) and 2% paraformaldehyde 
(Merck, Darmstadt, Germany) in cacodylate buffer 0.1 M (pH 7.4) were used to fix the cells. 
After dehydration, the cells were embedded in Epon resin (TAAB, Berks, England), and 
ultrathin sections (40-60 nm) were prepared on a RMC Ultramicrotome (PowerTome, USA) 
using diamond knives (DDK, Wilmington, DE, USA). The sections were mounted on 200 mesh 





copper or nickel grids, stained with uranyl acetate substitute and lead citrate for 5 min each, 
and examined under a JEOL JEM 1400 TEM (Tokyo, Japan). Images were digitally recorded 
using a CCD digital camera Orious 1100W Tokyo, Japan at the HEMS/i3S (IBMC) of the 
University of Porto. 
To performed SEM experiments at 37 °C, Hs 578T cells were seeded at density of 5.0 × 104 
on 12-mm coverslips and to experiments at 4 °C both cells, Hs 578T and MCF-10, were seeded 
at the density of 5.0 × 104. After growing overnight, cells were incubated with 50 µg mL-1 
solution of the nanomaterials for 5, 10, 15, 20, 30, 60 min and 4 h at 37 °C and 10, 60 min and 
4 h at 4 °C. Then, the cells were washed 3 times with PBS 1x and fixed with 2.5% 
glutaraldehyde in PBS for 45 min at RT and for 60 min at 4 °C, and again washed 3 times with 
PBS 1x. After these steps, the cells were dehydrated with series graded of ethanol from 10% 
until 90% for 20 min each and twice with 100% for 20 min. Coverslips were then dried at RT 
overnight. For visualization, the coverslips were sputter-coated with gold and images were 
then recorded with a JEOL JSM-6010LV scanning electron microscope (JEOL, Tokyo, Japan). 
 
4.2.2.8.  STATISTICAL ANALYSIS  
The tests were performed in at least three independent experiments. Results of viability 
studies are expressed as means ± standard deviation (SD) and the results were analyzed 
using one-way ANOVA with GraphPad Prism 6® software. A p-value of < 0.05 was considered 
statistically significant. 
 
4.2.2.9.  IMAGING DATA ANALYSIS  
The images were analyzed by ImageJ software. For TEM quantification, the threshold tool 
was used, the zeolite L highlighted in red and the area occupied by particles was measured. 
For fluorescence quantification, was used the freehand-selection tool to select each cell and 
circularity, area, mean fluorescence measured, along with several adjacent background 
readings, and the total corrected cellular fluorescence (TCCF) was calculated.34 
 
4.2.3.  RESULTS AND DISCUSSION 
Among the different types of porous materials that can be used to prepare DDS, zeolites are 
good drug carriers due to their structures that can efficiently load drugs, their biological stability 
and lack of cell toxicity.35–37 Thus, as a continuation of our previous work,20 herein we have 
gone deeper into the understanding of the internalization mechanisms of the zeolite L 
nanoparticles, using for this purpose six pharmacological inhibitors: chlorpromazine (CPZ), 
dynasore, nystatin, LY294002, genistein and nocodazole. Two of them, CPZ and dynasore 




inhibitors, were already explored in our previous work.20 However, our goal here is to further 
characterize the endocytic pathways involved in the internalization of zeolite L nanoparticles, 
using different inhibitors. Additionally, we explored the surface functionalization of the zeolite 
L nanoparticles, in vitro biocompatibility and the differences in the cellular uptake.  
 
4.2.3.1.  ZEOLITE L  ENDOCYTIC PATHWAYS DETERMINATION USING PHARMACOLOGICAL 
INHIBITORS  
We already provided evidences for the internalization of the zeolite L nanoparticles by 
means of a caveolin-mediated process both in Hs 578T and MCF-10 cells.20 Thus, in order to 
further characterize the pathways involved in the zeolite L nanoparticles uptake, we used six 
pharmacological inhibitors: CPZ that inhibits clathrin-mediated endocytosis;38,39 dynasore 
which is a dynamin inhibitor by preventing the closure of the membrane invagination to form 
free vesicles interfering with both clathrin-mediated and caveolin-mediated endocytosis;40,41 
nystatin that is used to inhibit caveolin-mediated endocytosis by interaction with cholesterol 
and enhances cell membrane permeability;42,43 LY294002 which inhibits micropinocytosis;44 
genistein that is a caveolar inhibitor exerting its effect on the receptor-associated tyrosine-
specific protein kinase,6,45 and nocodazole which is a microtubule-depolymerizing agent which 
binds to β-tubulin and averts the formation of one of the two interchain disulfide linkages, which 
leads to inhibition of microtubule dynamics and consequently, blocks endocytic vesicle 
trafficking.46,47  
For these studies, Hs 578T breast cancer cells and MCF-10 epithelial mammary cells were 
treated with CPZ (10 µg mL-1), dynasore (400 µM), nystatin (5 µg mL-1), LY294002 (50 µM), 
genistein (200 µM) and nocodazole (41 µM) in culture media without FBS that were previously 
tested in terms of cytotoxicity. The effect of these inhibitors was investigated by TEM and 
Figure 4.2.1 displays the results obtained with Hs 578T breast cancer cells and the parent 
zeolite L nanoparticles.  
In Hs 578T cells, the zeolite L cellular uptake was strongly inhibited by dynasore since in 
Figure 4.2.1A-d nanoparticles are not observed inside the cell, which was already previously 
reported in our work.20 Also, nocodazole displayed an inhibitor effect since only few cells 
showed internalization of the nanoparticles (Figure 4.2.1A-h). Figure 4.2.1B demonstrates the 
percentage of zeolite L nanoparticles that are internalized by cells after their treatment with 
pharmacological inhibitors compared with cells not exposed to any inhibitor. We can see that 
when cells are not exposed to any inhibitor, a higher percentage of zeolite L nanoparticles 
(1.25% ± 1.04) is internalized while the presence of inhibitors seems to lower this percentage. 
In this respect, only dynasore and nocodazole exert significant inhibition in the internalization 
of zeolite L nanoparticles (ANOVA, p < 0.0001 and p < 0.001, respectively). The effect of 





nocodazole (0.25% ± 0.13) is lower than the effect of dynasore (0.03% ± 0.03) (Figure 4.2.1B). 
Cells treatment with dynasore inhibited almost completely the internalization of zeolite L 
nanoparticles. The treatment with nocodazole is not as effective as dynasore, however as 
already denoted, a lower percentage of nanoparticles is internalized and some zeolite L 
nanoparticles were located near the cellular membrane, demonstrating the difficulty of 
nanoparticles to enter into the cells when they were treated with nocodazole (Figure 4.2.1A-g, 
red arrow).  
 
 
Figure 4.2.1: A) Effect of the endocytic inhibitors on the internalization of zeolite L nanoparticles by Hs 578T 
breast cancer cells analyzed by TEM. Control (cells were not exposed to pharmacological inhibitors neither to zeolite 
L nanoparticles) (a); cells exposed only to zeolite L nanoparticles (b); cells were treated with 10 µg mL-1 of CPZ (c), 
400 µM of dynasore (d), 5 µg mL-1 of nystatin (e), 50 µM of LY294002 (f), 200 µM of genistein (g) and 41 µM of 
nocodazole (h) for 60 min before being exposed to 50 µg mL-1 of the zeolite L nanoparticles for 4 h. Images of cells 
are showed at a magnification of 8.000x (b), 12.000x (a, c, d, e, f) and 15.000× (g and h). Yellow and red arrows 
point toward some nanoparticles. Scale bar: 1 µm (a, c, d, e, f, g, and h); 2 µm (b).  B) Quantification of the 
percentage of zeolite L nanoparticles internalized by Hs 578T cells after their incubation with pharmacological 
inhibitors (n=10) related with zeolite L condition (cells not treated with inhibitor). 
 




For the remaining four inhibitors, there was no significant reduction in the zeolite L 
nanoparticles internalization since in all TEM images it is possible to observe their presence 
inside cells (Figure 4.2.1A, yellow arrows). By the findings of these experiments, it is possible 
to conclude that the uptake of the zeolite L nanoparticles by Hs 578T cells is mediated by a 




Figure 4.2.2: A) Effect of the endocytic inhibitors on the internalization of zeolite L nanoparticles by MCF-10 
cells. Control (cells were not exposed to pharmacological inhibitors neither to zeolite L nanoparticles) (a); cells 
exposed only to zeolite L nanoparticles (b); cells were treated with 10 µg mL-1 of CPZ (c), 400 µM of dynasore (d), 
5 µg mL-1 of nystatin (e), 50 µM of LY294002 (f), 200 µM of genistein (g) and 41 µM of nocodazole (h) for 60 min 
before being exposed to 50 µg mL-1 of the zeolite L nanoparticles for 4 h. Images of cells are showed at a 
magnification of 12.000× (a, b, c, d, g and f) and 15.000× (e, h). Yellow arrows point toward some particles. Scale 
bar: 1 µm. B) Quantification of the percentage of zeolite L nanoparticles internalized by Hs 578T cells after their 
incubation with pharmacological inhibitors (n=10) related with zeolite L condition (cells not treated with inhibitor). 
 
In the case of MCF-10 cell line (Figure 4.2.2), dynasore and nocodazole also strongly 
inhibited zeolite L uptake since in the TEM images corresponding to these two inhibitors, no or 
very few zeolite L nanoparticles were observed inside the cells (Figure 4.2.2A-d and 4.2.2A-





h). Once again in this cell line, using CPZ, nystatin, LY294002 and genistein we observed 
nanoparticles inside the cells (Figure 4.2,2, yellow arrows), which demonstrates no inhibition 
of cellular uptake by these inhibitors. In Figure 4.2.2B, it is possible to see a significant 
reduction in the percentage of internalized zeolite L nanoparticles when the cells were treated 
with dynasore (ANOVA, p < 0.001; 0.03% ± 0.02) and also a significant reduction when the 
cells were treated with nocodazole (ANOVA, p < 0.001; 0.05 % ± 0.03). Ricardo Marega et al. 
showed that the internalization of Zeo-NHCO-Ctxb is affected by CPZ, amiloride and genistein 
and Zeo-NH2 was influenced by dynasore.47 Only dynasore effect is in line with our findings. 
The differences between Ricardo Marega’s results and the results presented in this work might 
be explained by the different cell lines used and the different functionalization of zeolite surface 
since these characteristics could influence the endocytic pathway.48 
Overall, the results of these experiments demonstrate that the pathways involved in the 
internalization of zeolite L are the same for both Hs 578T and MCF-10 cells despite the lower 
amount of internalized nanoparticles by the latter cell line. 
 
4.2.3.2. SURFACE FUNCTIONALIZATION OF ZEOLITE L  NANOPARTICLES  
The typical disc-shaped zeolite L nanoparticles were functionalized using different 
compounds (Figure 4.2.3) in order to verify if the surface charges of the nanoparticles affect 
the cellular uptake and endorse the internalization mechanism.  
Amino-functionalization of zeolite L (L-NH2) was obtained by silanization with 3-
aminopropyltriethoxysilane (APTES, H2N(CH2)3Si(OC2H5)3) molecules and carboxyl-
functionalization was obtained by ring opening linker elongation reaction of the amine 
group49,50 (Figure 4.2.3, reactions 1 and 2); poly-L-lysine coating was obtained by mixing the 
zeolite L with a solution of poly-l-lysine (Figure 4.2.3, reaction 3).  
 
 
Figure 4.2.3: Schematic representation of the functionalization procedures. 1) Amino-functionalization of zeolite 
L; 2) Carboxyl-functionalization of zeolite L; 3) Coating of zeolite L with poly-L-lysine (PLL). 
 




After these procedures, it was necessary to confirm if the zeolite L was successfully 
functionalized. The first approach to investigate that was to measure the zeta potential of the 
samples. For that, a very diluted solution of the modified nanomaterials was prepared and the 
zeta potential was measured. The zeta potential of the parent zeolite L was -44 mV, confirming 
the stability of the surface of the zeolite. After the functionalization with amino groups, the zeta 
potential value changed to +35 mV, confirming the amino functionalization of the outer surface 
of zeolite L. Then the amino-groups reacted with succinic anhydride to convert the primary NH2 
to COOH groups (Figure 4.2.3, reaction 2), forming a sample (L-COOH) with -28 mV zeta 
potential as a result of the formation of carboxylic groups on the outer surface of zeolite L. In 
turn, poly-L-lysine (PLL), a positively charged polymer, with no toxicity and with good 
biocompatibility,51 was used to coat zeolite L surface, originating a positively charged sample 
with +32 mV zeta potential (Figure 4.2.4). 
 
 
Figure 4.2.4: Zeta potential of unmodified and modified zeolite L in water. The error bars represent the standard 
deviation for three measurements. 
 
SEM micrographs of the zeolite L (Zeo L) and the modified nanomaterials, L-NH2, L-COOH 
and L-PLL (Figure 4.2.5), show that the functionalized samples present the same morphology 
and similar size of the particles comparing with the parent zeolite L.  
 






Figure 4.2.5: SEM micrographs of functionalized zeolite L dispersed in ethanol. A) Zeolite L unmodified, scale 
bar: 4 µm. B) L-NH2, scale bar: 5 µm; C) L-COOH, scale bar: 4 µm; and D) L-PLL, scale bar: 4 µm.  
 
4.2.3.3.  IN VITRO TOXICITY STUDIES  
The effect of the modified nanomaterials and the parent zeolite L on the viability of Hs 578T 
and MCF-10 cells was determined by the sulforhodamine B assay. Comparing the materials 
with control (only cells), the parent zeolite L induced some toxicity on Hs 578T cells for 0.075, 
0.100 and 0.125 mg mL-1, reducing cell viability in 15, 14 and 24%, respectively (Figure 4.2.6). 
In contrast, when cells were treated with L-NH2, L-COOH and L-PLL nanomaterials, a 
decrease in cell viability was not evident compared to the control even at higher concentrations, 
within the tested concentration range (0.010 - 0.125 mg mL-1). Furthermore, there were no 
significant differences between the amino-functionalized, carboxylic-functionalized and PLL 
coated zeolites. These results show that the functional groups used on the zeolite L do not 
increase material cytotoxicity and it even appears to decrease the toxicity observed for the 
parent zeolite L. 
 





Figure 4.2.6: Cell viability, measured by SRB assay, of Hs 578T cells incubated with different concentrations of 
Zeo L, L-NH2, L-COOH e L-PLL after 48 h incubation. Data are expressed in relation to the control (0% of zeolite, 
considered 100 % of viability) as mean ± SD of five independent experiments, each performed in triplicate. Asterisk 
represents statistically significant differences from unexposed control, *p < 0.05, **p < 0.01, ***p < 0.001 and ****p 
< 0.0001. 
 
Contrarily to what happened in Hs 578T cells, treatment of the MCF-10 cells with zeolite L, 
L-NH2, L-COOH and L-PLL, did not decrease cell viability after 48 h of incubation (Figure 
4.2.7). These results demonstrate that functionalization of zeolite L with amino and carboxylic 
groups and coating with PLL is non-toxic for both studied cell lines, whereas zeolite L presents 
some toxicity for Hs 578T cells for higher concentrations. 
 
 
Figure 4.2.7: Cell viability, measured by SRB assay, of MCF-10 cells incubated with different concentrations of 
Zeo L, L-NH2, L-COOH e L-PLL after 48 h incubation. Data are expressed in relation to the control (0% of zeolite, 
considered 100% of viability) as mean ± SD of five independent experiments, each performed in triplicate. Asterisk 
represents statistically significant differences from unexposed control, *p < 0.05, **p < 0.01, ***p < 0.001 and ****p 
< 0.0001. 





4.2.3.4. CELL INTERNALIZATION OF THE FUNCTIONALIZED ZEOLITE L  NANOPARTICLES  
Hs 578T and MCF-10 cells were incubated with the parent zeolite L (negatively charged) 
and the modified nanomaterials, L-NH2 (positively charged), L-COOH (negatively charged) and 
L-PLL (positively charged) and confocal microscopy imaging was performed. Figure 4.2.8 
illustrates the confocal results for Hs 578T cell line for 4 and 24 h of incubation time at 37 °C. 
From analysis of Figure 4.2.8A, it is possible to observe a yellow fluorescent signal which 
corresponds to the nanoparticles accumulated into Hs 578T cells after 4 h of incubation time. 
This signal is stronger in Figure 4.2.8A-b and Figure 4.2.8A-d, which corresponds to L-NH2 (34 
± 22) × 103 and L-PLL (39 ± 26) × 103 nanomaterials. Figure 4.2.8B also shows a yellow 
fluorescent signal, however this signal is stronger than the images shown in Figure 4.2.8A, 
which is expected since these results correspond to 24 h of incubation and the uptake of the 
nanoparticles increased with the time of incubation as has shown by Rosa et al.52 Also in Figure 
4.2.8B, it is possible to observe a stronger signal in images corresponding to L-NH2 (46 ± 19) 
× 103 and L-PLL (64 ± 45) × 103. These results show that the cellular internalization of positively 
charged nanoparticles (L-NH2 and L-PLL) is higher compared to that of negatively charged 
nanoparticles (Zeo L and L-COOH), which are in line with the reported in literature.53 
 





Figure 4.2.8: Confocal microscopy of Hs 578T cells incubated with samples (0.5 mg mL-1) for 4 h (A) and 24 h 
(B) at 37 °C: a) Zeo L; b) L-NH2; c) L-COOH; d) L-PLL. Scale bar: 50 µm. Quantitative calculation of total 
fluorescence intensity per cell (C). Error bar denote standard deviations. 
 
In Figure 4.2.9A and Figure 4.2.9B, it is possible to observe the obtained results for MCF-
10 cells after 4 and 24 h of incubation time. The results show the yellow fluorescence signal, 
however this signal is weaker than in Figure 4.2.8, related to Hs 578T cells, which demonstrate 
that only a small amount of zeolite nanoparticles, both positively and negatively charged, is 
internalized. This finding could be explained by the different growth rates of cancer and normal 
cells. Cancer cells grow faster and have higher metabolic rates than normal ones, which may 
explain the faster uptake of the nanoparticles by cancer than normal cells whose growth is 
slower.54 Another possible explanation for the fact that Hs 578T cells internalize more zeolite 
nanoparticles than MCF-10 overtime could be related to the fact that cancer cell are more 
permeable than normal cells, which can enhance the permeability of tumoral cells to particles. 
Since this effect is not present in normal cells, it is expected that normal cells internalize less 
particles than tumoral ones.55–57 
Despite the lower number of accumulated particles in normal cells, once again, the number 
of internalized nanoparticles is higher for positively charged than for negatively charged ones, 
as it is demonstrated in Figure 4.2.9C. These results are in accordance with other studies in 





the literature, where it is reported that positively charged nanoparticles have higher rates of 
internalization by cells than those negatively charged, because the cellular membrane is 
negatively charged and positively charged nanoparticles will allow electrostatic interactions 
with the cell membrane, favoring cellular uptake.58–60 
 
 
Figure 4.2.9: Confocal microscopy of MCF-10 cells incubated with samples (0.5 mg mL-1) for 4 h (A) and 24 h 
(B) at 37 °C: a) Zeo L; b) L-NH2; c) L-COOH; d) L-PLL. Scale bar: 50 µm. Quantitative calculation of total 
fluorescence intensity per cell (C). Error bar denote standard deviations, *p <0.05. 
 
Confocal results show that Hs 578T and MCF-10 cells are able to internalize the zeolite L 
nanoparticles. To corroborate the cellular uptake by the nanomaterials, we also performed 
TEM analysis. To do this, cells were incubated with the zeolite nanoparticles during 4 h. The 
obtained results are displayed in Figure 4.2.10 for Hs 578T cell line and Figure 4.2.11 for MCF-
10 cell line. These are consistent with those results obtained by confocal microscopy; 
nanoparticles with positively charged surface have a higher rate of internalization by both cells 
lines than nanoparticles with negatively charged surface. Once again, it is obvious that Hs 
578T cells internalize a higher amount of nanoparticles than MCF-10 cells overtime, 
independently on the surface charge. From the TEM results it is also possible to observe that 
the nanomaterials were in vesicles inside the cells, likely vacuoles, for both cell lines. 





Figure 4.2.10: Internalization of materials by Hs 578T cells evaluated using TEM. The cells were incubated with 
50 µg mL-1 of each nanomaterial for 4 h at 37 °C. a) Control (only cells); b) Zeo L; c) L-NH2; d) L-COOH; e) L-PLL. 
Yellow arrows point toward some particles. 
 
 
Figure 4.2.11: Internalization of materials by MCF-10 cells evaluated using TEM. The cells were incubated with 
50 µg mL-1 of each nanomaterial for 4 h at 37 °C. a) Control (only cells); b) Zeo L; c) L-NH2; d) L-COOH; e) L-PLL. 
Yellow arrows point toward some particles. 
 
SEM is a superficial technique which demonstrates what is happening on the surface of the 
cells when they are incubated with the nanomaterials. For SEM analysis, Hs 578T cells where 
incubated with the parent zeolite L and the modified nanomaterials for different times. Herein, 
we just present the micrographs corresponding to 4 h of incubation (Figure 4.2.12). The results 
show that the internalization of the zeolite nanoparticles is fast for both negatively and 





positively charged nanoparticles, with internalized particles already at 20 min of incubation. 
However, the number of internalized nanoparticles is higher for positively charged ones (L-NH2 
and L-PLL). As it was observed by TEM and confocal analyses, also in SEM results it is 
possible to observe that the number of internalized nanoparticles is time-dependent, with a 
higher number of internalized particles after 4 h of incubation. 
From TEM and SEM results, it is possible to observe the presence of filopodia that engulfed 
zeolite L nanoparticles and are responsible for the beginning of the internalization process. In 
TEM images, the formation of vesicles with the particles inside can also be observed, which 
support the internalization of the zeolite L nanoparticles by endocytosis. 
 
 
Figure 4.2.12: SEM micrographs of Hs 578T cells incubated with 50 µg mL-1 of nanomaterials for 4 h at 37 °C. 
A) Control (only cells), B) Zeo L, C) L-NH2, D) L-COOH and E) L-PLL.  
 
4.2.3.4. ENERGY-DEPENDENCE OF THE UPTAKE OF THE MODIFIED NANOMATERIALS  
To assess if the uptake of the modified nanomaterials and the parent zeolite L is dependent 
on energy, we also performed experiments at 4 °C, since this approach inhibits all energy-
dependent pathways.30 When cells are incubated at 4 °C, many proteins and enzymes are 
inactivated61 and the membrane become more rigid, which hampers the internalization of 
particles.62 Hs 578T and MCF-10 cells were pre-incubated at 4 °C during 1 h with DMEM FBS-
free and then incubated with the nanomaterial suspensions for 4 h at 4 °C and then the 
samples were analyzed by TEM. 
From the results, it is possible to observe that when the cells are exposed to the temperature 
of 4 °C their filopodia is reduced. Filopodia are plasma-membrane filaments rich in actin which 
have an important role in several processes, including endocytosis63 and these protrusions are 




reduced at 4 °C, it is expected that the rates of internalization decrease. This decrease was 
observed (Figure 4.2.13 and 4.2.14) especially in cancer cells. Figure 4.2.13 shows a 
significant decrease on cell filopodia of cancer cells, which is translated in a strong reduction 
in cell internalization. In normal cells (Figure 4.2.14), a decrease on cellular filopodia formation 
was also observed, however this is less obvious than in the cancer ones. This observation 
could be explained by the fact of cancer cells have more abundant filopodia63,64 than normal 
ones and the temperature has a more significant effect on cancer cells filopodia formation than 
in normal cells. 
Comparing the obtained results at 37 °C (Figures 4.2.10 and 4.2.11) with the results at 4 °C 
(Figures 4.2.13 and 4.2.14), a reduction in the number of internalized nanoparticles was 
observed, which proves that the uptake of the zeolite L is an energy-dependent process. This 
reduction is proved by the quantification of the percentage of zeolite L nanoparticles which are 
internalized by both cell lines at 37 and 4 °C (Figure 4.2.13B and 4.2.14B). In Hs 578T cell line 
(Figure 4.2.13B), comparing the results at 37 and 4 °C it is clearly observed that at 37 °C a 
higher percentage of nanoparticles is internalized than at 4 °C. For MCF-10 cell line (Figure 
4.2.14B), it is observed the same trend than in Hs 578T, with the internalization of zeolite 
nanoparticles being reduced at 4 °C. A close look on the literature confirmed the effect of the 
temperature on the nanoparticles internalization. For example, Sandra Vranic et al., showed 
in their work that the internalized of SiO2 nanoparticles by pulmonary epithelial cell line (NCI-
H292) is reduced at 4 °C.62 Also, Azzah M. Bannunah et al. demonstrated that the trafficking 
of both positively and negatively charged nanoparticles by intestinal Caco-2 cells is 
temperature-dependent.65 
 






Figure 4.2.13: Effect of temperature on the internalization of materials by Hs 578T cells. Cells were pre-
incubated at 4°C for 1 h and then treated with 50 µg mL-1 of Zeo L (b), L-NH2 (c), L-COOH (d) and L-PLL (e) for 4 
h. Unexposed cells were used as control (a). Images of cells are showed at a magnification of 12.000× (a, c, d and 
e) and 15.000× (b). Yellow arrows point toward some particles. Scale bar = 1 µm. B) Quantification of the percentage 









Figure 4.2.14: A) Effect of temperature on the internalization of materials by MCF-10 cells. Cells were pre-
incubated at 4 °C for 1 h and then treated with 50 µg mL-1 of Zeo L (b), L-NH2 (c), L-COOH (d) and L-PLL (e) for 4 
h. Unexposed cells were used as control (a). Images of cells are showed at a magnification of 12.000× (a, c, d and 
e) and 15.000× (b). Yellow arrows point toward some particles. Scale bar = 1 µm. B) Quantification of the percentage 
of zeolite L nanoparticles internalized by MCF-10 cells at 37 and 4 °C. *p < 0.05 (n=10). 
 
In SEM results (Figure 4.2.15 and 4.2.16) it is also possible to observe a reduction on cellular 
filopodia in both cell lines. Some nanoparticles seem to be internalized, however most of them 
are located around the cellular membrane. 
From this study, it is possible to conclude that for the internalization of the parent and the 
modified zeolite L by Hs 578T and MCF-10 cells, the presence of filopodia and protein activity 
is needed since at low temperature the internalization is significantly reduced. 
 






Figure 4.2.15: SEM images of Hs 578T cells incubated for 4 h at 4 °C with 50 µg mL-1 of b) Zeo L, c) L-NH2, d) 
L-COOH and e) L-PLL. Unexposed cells were used as control (a). 
 
 
Figure 4.2.16: SEM micrographs of MCF-10 cells incubated for 4 h at 4 °C with 50 µg mL-1 of b) Zeo L, c) L-
NH2, d) L-COOH and e) L-PLL. Unexposed cells were used as control (a). 
 
These results are in agreement with the results obtained using the different pharmacological 
inhibitors for zeolite L internalization which showed that the internalization of zeolite L by both 
studied cell lines is dependent on caveolin and microtubule polymerization since it was 
demonstrated that when the cells are exposed to low temperature conditions and the activity 
of proteins is reduced, the zeolite nanoparticles are less internalized. 
Figure 4.2.17 depict the different endocytic pathways. The results of this study are 
represented by the step 4 highlighted in red. 





Figure 4.2.17: Different endocytic pathways. 1) Phagocytosis; 2) Macropinocytosis; 3) Clathrin-mediated 
endocytosis; 4) Caveolin-mediated endocytosis and 5) Clathrin- and caveolin- independent endocytosis. 
 
Our results related to zeolite functionalization show that the different functional groups on 
zeolite L surface have an effect on the rate of internalization of nanoparticles, with positively 
charged nanoparticles being more internalized than those negatively charged. 
 
4.2.4.  CONCLUSIONS 
In the present work, the parent zeolite L was modified by binding different groups to its outer 
surface and the effect of this functionalization in cultured cancer and normal cells was 
evaluated. The results demonstrate that the groups chosen for the surface functionalization of 
the zeolite nanoparticles are quite biocompatible since the nanomaterials are non-toxic to the 
cells. The uptake efficiency and endocytic pathways of zeolite L were also evaluated. We have 
shown how the surface charge affects the uptake of zeolite L by cancer and normal cells. The 
main endocytic pathway involved in the internalization of zeolite L in Hs 578T cells is caveolin-
mediated, which confirms our previous results. Nevertheless, in this work we observed that 
microtubule polymerization also has some importance on zeolite L nanoparticle internalization 
into Hs 578T cells. From the studies with MCF-10 cells, we observed that there are two main 
endocytic pathways involved in zeolite L internalization, caveolin-mediated process and 
microtubule polymerization. Internalization of zeolite L by both Hs 578T and MCF-10 cells 
appears to be energy-dependent and the differences were more obvious for Hs 578T cancer 
cells than for MCF-10 cells, which proves that cellular uptake is cell type-dependent. 
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CONCLUSIONS AND FUTURE WORK 
In this final chapter, a general overview of the major findings of the work developed under 
the scope of the thesis is given, highlighting the relationship between the results presented in 
all chapters and subchapters and the most relevant conclusions. Finally, some ideas for the 




















5.1.  GENERAL OVERVIEW AND CONCLUDING REMARKS  
5.1.1  GENERAL OVERVIEW  
The increasing number of new cases of cancer encourages the search for new 
methodologies for cancer detection or treatment. Thus, different approaches have been 
developed to target therapy for specific human sites/tissues. One of them is the use of 
nanomaterials as carriers for drug delivery systems (DDS). These DDS have expanded rapidly 
with new advances in biomedical sciences and this is a field of vital importance in medicine 
and healthcare. An ideal DDS is a system that should prevent premature degradation of the 
therapeutic agents, improve their bioavailability, enhance the efficacy and increase the 
tolerability of the drugs. Also, the carrier must maintain drug concentrations within their 
therapeutic window, by controlling the drug release rates, and reach the specific target(s) – 
such as tumor cells and tumor tissue - to enhance their accumulation in the target environment 
and increase their penetration in cells, with low cytotoxicity.  
In this context, organic and inorganic nanomaterials, as polymeric nanoparticles, liposomes, 
dendrimers, magnetic nanoparticles, mesoporous nanoparticles and zeolite structures, have a 
range of structural and physical properties that are suitable for therapeutic delivery systems. 
The diverse and highly controlled structural properties of zeolites as nanostructures make them 
interesting candidates for a variety of medical and healthcare applications, so it is important to 
understand their effect in vitro and in vivo. Another important challenge is to understand the 
mechanisms related to the internalization of these zeolite nanoparticles by cells. During this 
work, different approaches were explored: i) how small drug molecules interact with zeolites 
and the interaction with mesoporous silica structures was also compared; ii) how DDS 
prepared with these porous structures act in vitro and in vivo iii) how zeolites act as magnetic 
resonance imaging agents; iv) how zeolite nanoparticles interact with living cells; and v) how 
the functionalization of zeolite surface could influence the uptake by human cells. 
 
5.1.2.  CONCLUDING REMARKS  
This work is a continuation of the line of research of our group, from which the potential of 
DDS based in zeolites for colorectal cancer treatment was already reported. Thus, in this work, 
in addition of the evaluation of the effect of DDS on colorectal cancer, their potential was also 
investigated in breast cancer treatment. 
In the last years, some literature data has been showing the correlation between the use of 
anti-inflammatory drugs and reduced incidence of cancer. Thus, this work started by the 
exploration of the use of salicylic acid (SA) for breast cancer treatment. For this purpose, 
salicylic acid was loaded into zeolite (NaY) and mesoporous structures (MCM-41 and SBA-




15), resulting in three different DDS, SA@NaY, SA@MCM-41, and SA@SBA-15. It was 
observed that mesoporous structures loaded more efficiently SA molecule than the zeolite 
structure. The found differences could be explained by the different pore size of the structures. 
NaY has smaller pores than mesoporous structures, being expected lower loading capacity. 
From the drug release studies performed in simulated body fluid at 7.4 and 37 °C, we 
demonstrated that in the first 15 min, there was an initial burst with around 50% of drug 
released. The kinetics of these studies demonstrated that the release of SA from NaY fits the 
Korsmeyer-Peppas model, while Higuchi model fits the release from mesoporous structures. 
The drug bioactivity studies, carried out in two breast cancer cell lines (Hs 578T and MDA-MB-
468), demonstrated that SA@MCM-41 and SA@SBA-15 were able to decrease cell growth of 
both cell lines, while SA@NaY did not ehibit any effect on cell viability. Mesoporous structures 
were the most promising among the porous structures tested, when both loading capacity and 
antitumor activity were considered. However, bearing in mind that the major objective of this 
work was to explore the potential of zeolites as DDS, NaY was chosen to be explored in further 
studies in order to select the best DDS, using a classical anticancer drug, 5-fluorouracil (5-FU).  
We further explored the use of zeolite NaY as host for DDS preparation with 5-FU for in vitro 
models of colorectal and breast cancer, comparing them with other zeolitic structures (NaA 
and ZSM5) and one titanosilicate (ETS-10). Compared to NaA and ZSM5, which have small 
and medium pores respectively, NaY presents large pores. Similarly, in the SA study, it was 
observed that the pore size has influence in the loading of 5-FU into the hosts. NaY and ETS-
10 (large pores) loaded higher amounts of 5-FU than the other zeolitic structures. Drug release 
studies, conducted at pH 7.4, 5.8 and 2.0 to mimic the pH of blood, intestine, and stomach, 
also demonstrated the effect of pore size on drug release. It was found that large pore 
structures have highest release rates due to the higher amount of adsorbed drug. The integrity 
of the molecular structure of 5-FU was maintained in all tested pH values, and the pH did not 
affect 5-FU release. These findings, show that silica structures could protect the drug from the 
body fluids. Parent zeolites are non-toxic for colon cancer and breast cancer cells, since they 
did not affect cell viability/growth. In the whole, the DDS used have proven to be effective on 
reduction of cell viability and potentiation of 5-FU. 
In the part of the thesis where we explored the use of zeolites as hosts for drug loading, 
were selected zeolite NaY and a synthetized disc-shaped zeolite L (LTL structure) for further 
studies. 5-FU was successfully loaded into these zeolites. In vitro studies revealed that both 
parent zeolites are non-toxic for cells, while DDS reduced cell viability of Hs 578T and RKO 
cells significantly. It is known that smaller particles (< 100 nm) could be used for systemic 
administration, while larger particles (> 100 nm) will have more potential for topical 
administration. Also, the colloidal stability is an important factor for intravenous administration. 





All zeolite structures used in this work, had particles higher than 100 nm and did not present a 
good colloidal stability.  
In addition to colorectal and breast cancer cells, we investigated the effect of DDS in vitro in 
melanoma cells in order to explore the potential of these materials for topical applications. The 
obtained results suggest that these materials are promising for topical applications since the 
DDS reduce cell viability of melanoma cancer cells in a significant way. The in vivo viability 
assays of the DDS was performed using the chick embryo chorioallantoic membrane as model 
(CAM) for breast and colon cancer cells implantation. Thus, the DDS induced a reduction in 
tumor perimeter for Hs 578T cells, while no reduction was detected for RKO tumors, under the 
concentration of DDS used. In addition to the concentration used, penetration of the DDS 
should also be more difficult in 3D tumor structures, which may explain the lack of effect in 
RKO tumors. 
The results obtained from these studies showed that beyond the type of zeolitic structure 
selected for DDS preparation, the efficacy of DDS is quite dependent on the cell type and the 
features of the tumors. Nevertheless, independently of these factors, overall, the results 
presented in this thesis demonstrated the potential of zeolites for DDS preparation. 
Consequently, we went deeper into the use of zeolites for biomedical applications, exploring 
the potential of these structures as hybrid materials to be used in magnetic resonance imaging 
(MRI) or hyperthermia treatments. Thus, the reaction between zeolite NaY and the magnetic 
nanoparticles led to attachment of the magnetic nanoparticles on the zeolite surface (MZNCs), 
which was confirmed through different characterization techniques. The possibility of zeolite 
NaY magnetization to be used as MRI contrast agent, was assessed by analyze of T2-weighted 
on Hs 578T cells. It was observed that T2 signal intensity decreases as iron concentration 
increases, being lower for MZNCs, exhibiting darker MRI images in the condition 
corresponding to cells incubated with MZNC. 
MZNCs have proved to be non-toxic to breast cancer and epithelial mammary cells, showing 
less cytotoxicity than the parent zeolite. It was also proved by TEM that MZNCs are able to be 
internalized by cells. These results confirm the potential of zeolite NaY to be used as MRI 
agent. Combining the potential of zeolites as DDS with the results obtained in this work, and 
after the optimization of colloidal properties of zeolites, it is expected that zeolites could be 
used in hyperthermia for cancer therapy enhancing the efficacy of the drugs. 
Another main purpose of this work was the assessment of the endocytic pathways involved 
in the zeolite internalization by cells. It was verified that MZNCs are able to be internalized by 
cells. So, we also studied how the parent zeolites interact with living cells. Zeolite L used in 
these studies was successfully synthesized, originating disc-shaped nano particles with 400 
nm. Thanks to its features, this zeolite has lower tendency to form aggregates than NaY. It 
was observed that after 5 min of incubation the cells started already to engulf NaY, while zeolite 




L have some nanoparticles already internalized for the same time period. These results 
demonstrate the importance of the shape of the particles in the internalization process. In 
addition to zeolite shape, another aspect which influences nanoparticles internalization, is the 
cell type. Comparing the internalization rate in different cell lines under the same incubation 
conditions, we observed that cancer cells are faster in zeolite nanoparticle internalization, 
compared to normal cells. The high internalization rate observed for the cancer cells, must be 
related not only to their higher permeability, but also to their faster growth and higher metabolic 
rates than normal cells, whose growth is slower. Six pharmacological inhibitors were used to 
determine the endocytic pathway involved in the zeolite nanoparticle internalization by the 
selected cell lines. From all the inhibitors used, only the inhibitors of caveolin-dependent 
endocytosis and microtubule dependent pathways affected cell internalization, which 
demonstrates that in the studied cell lines, zeolite nanoparticles are internalized via a caveolin-
mediated process and this internalization is also dependent on microtubule polymerization. 
The surface chemistry of the zeolites plays also an important role in their uptake by cells. 
Normally, positive charged materials are more internalized by cells due to the negative charge 
of the cell membrane. Our findings also support this trend, with positively-charged zeolites 
being higher internalized than negatively-charged zeolites. It was also found that the 
internalization is time-dependent with higher quantity of zeolite nanoparticles internalized after 
24 h of incubation than at 4 h. 
Summarily, the use of zeolite structures as carriers for DDS revealed to be a promising 
approach, however it is highly influenced by the surface chemistries, forms and sizes of zeolite 
nanoparticles and cell type. Also, this thesis highlights the importance to better understand the 
endocytic mechanisms underlying zeolite internalization to design more efficient targeted DDS 



















5.2. FUTURE WORK 
DDS preparation using zeolite structures as hosts has been denoted as a promising 
approach and this thesis contributed with important findings to understand how zeolite 
nanoparticles interacts with living cells. However, their in vivo application and toxicity remains 
challenging and more experimental work should be carried out to provide further insights on 
the use of these materials in cancer therapy. 
 
In the preliminary studies, it was observed that salicylic acid is suitable to be used in breast 
cancer treatment when loaded into mesoporous silica. In order to improve the effect of this 
drug into the zeolite DDS, additional zeolitic structures should be evaluated. 
Taking into account the achievements with 5-FU loaded into the zeolite structures and the 
good results obtained with salicylic acid loaded into mesoporous structures, the combination 
of the drugs loaded into the zeolite structures should be explored, as a combined therapy. For 
that purpose and considering the promising results obtained with 5-FU, it should be also 
combined with other chemotherapeutic drugs, such as paclitaxel or doxorubicin, to take 
advantage of the synergic effect of both drugs and improve the effect against cancer cells. 
 
In order confirm of the internalization mechanisms, the endocytic pathways should be 
studied in other cell lines to verify if the same pathways are used by zeolites to enter different 
cells. Also, the internalization pathways used by other zeolites should be studied, to verify if 
the internalization pathways are dependent of the zeolite structures. Specific details as to how 
the endocytic proteins might affect the internalization of zeolite nanoparticles warrant further 
studies. For this purpose it would also be relevant to confirm the effect of the pharmacological 
inhibitors through downregulation of specific endocytic proteins involved in zeolite 
internalization. 
 
Although zeolite functionalization with positive groups enhances its cellular uptake in vitro, 
in vivo tumor accumulation should be studied. Furthermore, zeolite surface should be 
functionalized with other ligands, such as antibodies, in order to target them to specific places. 
 
In vivo studies using the CAM model should be optimized and additional in vivo models such 
as the murine model (mice xenografts) should be used, to study the effect of zeolite and DDS 
in vivo. In these studies, in addition to the effect of the DDS in tumor reduction, cancer cell 
proliferation, invasion and angiogenesis, should be also evaluated. It would be also important 
to assess the formation of reactive oxygen species (ROS) to understand if these materials can 
induce formation of free-radicals and consequently induce oxidative stress. 




The possible bioaccumulation of zeolites as hosts is also still a challenge to be tackled to 
understand if these materials can be eliminated from the body or if they need to be modified 
to avoid bioaccumulation in the liver. 
 
Taking into account the promising results obtained with melanoma cells, topical applications 
of DDS based on zeolites should be further explored, since the skin cancer incidence has been 
increasing over the last years and it is estimated that the frequency of this type of cancer 
increases as a result of increased exposure to solar UV radiation. 
